Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
1 
Approved, Date: 5 September 2013   
 
 
Clinical Protocol  
 
A Multicenter Phase 1/2b Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibrutinib (PCI -32765), in 
Combination with Carfilzomib (Kyprolis™) in Subjects with relapsed or relapsed and refractory Multiple 
Myeloma   
 
 
Protocol  PCYC -1119 -CA; Phase 1/2b 
 
Ibrutinib (PCI -32765)  
 
 
EudraCT Number:  2013 -001681- 41 
 
IND Number:  102,688  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Status:  Approved  
Date:  5 September 2013  
Prepared by:  Pharmacyclics, Inc.   
 
GCP Compliance:  This study will be conducted in compliance with Good Clinical Practice and 
applicable regulatory requirements .  
Confidentiality Statement 
The information in this document contains trade secrets and commercial information that are privileged or 
confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any 
event, persons to whom the information is disclosed must be informed that the information is privileged or 
confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all 
future information supplied to you that is indicated as privileged or confidential. 

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
3 
Approved, Date: 5 September 2013  Proprietary and Confidential TABLE OF CONTENTS 
INVESTIGATOR AGREEME NT ................................................................ ............................... 2 
TABLE OF CONTENTS ................................ ................................................................ .............. 3 
STUDY SYNOPSIS ................................ ................................................................ ....................... 8 
ABBREVIATIONS ................................ ................................................................ ...................... 13 
1. INTRODUCTION ................................ ................................................................ ............... 15 
1.1. Multiple Myeloma ................................ ................................................................ ............. 15 
1.2. Ibrutinib (PCI-32765) Background ................................................................ .................... 16 
1.2.1.  Ibrutinib in Multiple Myeloma ................................................................ ....................... 17 
1.2.2.  Summary of Human Pharmacokinetics ................................................................ .......... 17 
1.2.3.  Summary of Clinical Safety of Ibrutinib ................................................................ ........ 18 
1.3. Carfilzomib ................................ ................................................................ ........................ 20 
1.3.1.  Summary of Nonclinical Data:  Carfilzomib ................................ ................................ ..20 
1.3.2.  Summary of Clinical Data in Multiple Myeloma:  Carfilzomib ................................ .....21 
1.4. Rationale for the Combination ................................................................ ........................... 22 
1.5. Study Rationale ................................ ................................................................ .................. 23 
2. OBJECTIVES AND HYPOTHESIS ................................................................ ................. 24 
2.1. Objectives ................................ ................................................................ .......................... 24 
2.1.1.  Primary Objective ................................ ................................................................ ........... 24 
2.1.2.  Secondary Objectives ................................ ................................................................ .....24 
2.1.3.  Exploratory Objectives ................................................................ ................................ ...24 
2.2. Hypothesis................................ ................................................................ .......................... 25 
3. STUDY DESIGN AND RATIONALE ................................................................ .............. 25 
3.1. Overview of Study Design ................................................................ ................................ .25 
3.2. Phase 1 Dose Escalation and Expansion Overview ................................ ........................... 27 
3.3. Phase 2b Double-blind, Placebo Controlled Efficacy Evaluation Overview .................... 27 
4. SUBJECT SELECTION ................................ ................................................................ .....28 
4.1. Inclusion Criteria ................................ ................................................................ ............... 28 
4.2. Exclusion Criteria ................................ ................................................................ .............. 29 
5. TREATMENT OF SUBJECTS ................................................................ .......................... 31 
5.1. Phase 1 Dose Escalation ................................................................ ................................ ....31 
5.2. Definition of Dose Limiting Toxicity ................................................................ ................ 32 
5.3. Randomization and Blinding ................................................................ ............................. 33 
5.4. Treatment Regimens ................................ ................................................................ .......... 33 
5.5. Ibrutinib or Ibrutinib/Placebo ................................................................ ............................ 34 
5.5.1.  Formulation, Packaging, and Storage of Ibrutinib or Ibrutinib/Placebo ......................... 34 
5.5.2.  Dosage and Administration of Ibrutinib ................................................................ ......... 35 
5.5.3.  Dose Delay of Ibrutinib ................................................................ ................................ ..36 
5.5.4. Dose Modification of Ibrutinib ................................................................ ....................... 36 
5.5.5.  Overdose Instructions ................................ ................................................................ .....37 
5.6. Carfilzomib ................................ ................................................................ ........................ 37 
5.6.1.  Formulation, Packaging, and Storage of Carfilzomib ................................ .................... 37 
5.6.2.  Dosage, Preparation and Administration of Carfilzomib ................................ ............... 37 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
4 
Approved, Date: 5 September 2013  Proprietary and Confidential 5.6.2.1.  Administration Precautions of Carfilzomib ................................ ................................ .37 
5.6.2.2.  Hydration and Fluid Monitoring  ................................................................ .................. 38 
5.6.2.3.  Dexamethasone Premedication ................................................................ .................... 38 
5.6.3.  Dose Modification of Carfilzomib ................................................................ .................. 38 
5.7. Criteria for Permanent Discontinuation of Study Drug ................................ ..................... 40 
6. CONCOMITANT THERAPY ................................................................ ........................... 40 
6.1. Permitted Concomitant Medications................................................................ .................. 40 
6.2. Prohibited Concomitant Medications ................................................................ ................ 40 
6.3. Medications to be Used With Caution ................................................................ ............... 41 
6.3.1.  CYP Inhibiting/Inducing Drugs ................................................................ ...................... 41 
6.3.2.  Concomitant Use of QT Prolonging Agents ................................ ................................ ...42 
6.3.3.  Concomitant Use of Antiplatelet Agents and Anticoagulants ................................ ........ 42 
6.4. Guidelines for Ibrutinib Management with Surgeries or Procedures ................................ 42 
7. STUDY EVALUATIONS ................................................................ ................................ ...43 
7.1. Screening / Administrative ................................................................ ................................ 43 
7.1.1.  Informed Consent ................................ ................................................................ ........... 43 
7.1.2.  Confirmation of Eligibility ................................................................ ............................. 43 
7.1.3.  Medical History and Demographics ................................................................ ............... 43 
7.1.4.  Prior and Concomitant Medications ................................................................ ............... 43 
7.1.5.  Adverse Even ts ................................ ................................................................ ............... 44 
7.2. Study Assessments ................................ ................................................................ ............. 44 
7.2.1.  Physical Examination, Height, and Weight ................................ ................................ ....44 
7.2.2.  Eastern Cooperative Oncology Group (ECOG) Performance Status ............................. 44 
7.2.3.  Vital Signs................................ ................................................................ ....................... 44 
7.2.4.  Electrocardiogram  ................................ ................................................................ ........... 44 
7.2.5.  Echocardiogram (ECHO) ................................................................ ............................... 44 
7.3. Efficacy Assessments ................................ ................................................................ ......... 45 
7.3.1.  Serum and Urine Protein Electrophoresis ................................................................ .......45 
7.3.2.  Serum Free Light Chain Assay ................................................................ ....................... 45 
7.3.3.  Serum and Urine Immunofixation ................................................................ .................. 45 
7.3.4.  Quantitative Serum Immunoglobulins (IgA, IgG and IgM) ................................ ........... 45 
7.3.5.  C-Reactive Protein and Serum β2 -microglobulin ................................ ........................... 45 
7.3.6.  Bone Radiological Assessment ................................................................ ....................... 46 
7.3.7.  Bone Marrow Aspirate/Biopsy ................................................................ ....................... 46 
7.3.8.  Survival and Subsequent Anticancer Therapies ................................ ............................. 46 
7.3.9.  Patient-Reported Outcome (PRO) Assessment (Phase 2b only) ................................ ....47 
7.4. Clinical Laboratory Assessments ................................................................ ....................... 47 
7.4.1.  Hematology ................................ ................................................................ ..................... 47 
7.4.2.  Serum Chemistry ................................ ................................................................ ............ 47 
7.4.3.  Coagulation Studies ................................ ................................................................ ........ 47 
7.4.4.  Pregnancy Test  ................................ ................................................................ ................ 48 
7.4.5.  Hepatitis Serologies ................................ ................................................................ ........ 48 
7.4.6.  Thyroid-stimulating Hormone (TSH) ................................................................ ............. 48 
7.5. Pharmacokinetics and Pharmacodynamics (Phase 1 and Selected Phase 2b Sites) ........... 48 
7.5.1.  Pharmacokinetics and Pharmacodynamics Sample Collection ................................ ......48 
7.5.2.  Pharmacokinetics Sample Collection for Subject Treated with Concomitant 
CYP3A4/5 Inhibitors on Ibrutinib Treatment ................................ ................................ .49 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
5 
Approved, Date: 5 September 2013  Proprietary and Confidential 7.5.3.  Pharmacokinetics Analytical Procedures ................................................................ ........ 49 
7.5.4.  Pharmacokinetics Parameters ................................................................ ......................... 49 
7.5.5.  Pharmacodynamics Analytical Procedures ................................................................ .....50 
7.5.6.  Pharmacodynamics Parameters ................................................................ ...................... 50 
7.6. Biomarkers (Phase 1 and Selected Phase 2b Sites) ................................ ........................... 50 
7.6.1.  Genetic and Molecular Prognostic Markers ................................ ................................ ...50 
7.7. Sample Collection and Handling ................................................................ ....................... 50 
8. STUDY PROCEDURES ................................ ................................................................ .....51 
8.1. Overview  ................................ ................................................................ ............................ 51 
8.2. Screening Phase  ................................ ................................................................ ................. 51 
8.3. Treatment Phase ................................ ................................................................ ................. 52 
8.3.1.  Cycle 1 ................................ ................................................................ ............................ 52 
8.3.1.1.  Cycle 1, Day 1 ................................ ................................................................ .............. 52 
8.3.1.2.  Cycle 1, Day 2................................ ................................................................ .............. 53 
8.3.1.3.  Cycle 1, Day 8................................ ................................................................ .............. 53 
8.3.1.4.  Cycle 1, Day 9................................ ................................................................ .............. 54 
8.3.1.5.  Cycle 1, Day 15................................ ................................................................ ............ 55 
8.3.1.6.  Cycle 1, Day 16................................ ................................................................ ............ 55 
8.3.2.  Cycles 2-3 ................................ ................................................................ ....................... 55 
8.3.2.1.  Cycles 2-3, Day 1 ................................ ................................................................ ......... 55 
8.3.2.2.  Cycles 2-3, Day 2 ................................ ................................................................ ......... 56 
8.3.2.3.  Cycles 2-3, Day 8 ................................ ................................................................ ......... 56 
8.3.2.4.  Cycles 2-3, Day 15 ................................ ................................................................ .......57 
8.3.2.5.  Cycles 2-3, Days 9 and 16 ................................................................ ........................... 57 
8.3.3.  Cycle 4 (and subsequent cycles) ................................................................ ..................... 57 
8.3.3.1. Cycle 4 (and subsequent cycles), Day 1 ................................................................ ......57 
8.3.3.2.  Cycle 4 (and subsequent cycles), Days 2, 8, 9 and 16 ................................ ................. 58 
8.3.3.3.  Cycle 4 (and subsequent cycles), Day 15 ................................ ................................ ....58 
8.3.4. Suspected Disease Progression Visit ................................................................ .............. 58 
8.3.5.  End of Treatment Visit ................................................................ ................................ ...59 
8.4. Follow- Up Phase ................................ ................................................................ ................ 59 
8.4.1.  Follow-up Procedures (Until Disease Progression) ................................ ........................ 59 
8.4.2.  Survival Follow-up  ................................ ................................................................ ......... 60 
9. SUBJECT COMPLETION/WITHDRAWAL ................................ ................................ ..60 
9.1. Discontinuation of Treatment ................................................................ ............................ 60 
9.2. Withdrawal From the Study ................................................................ ............................... 60 
10. STATISTICAL METHODS ................................................................ ............................... 61 
10.1.  Analysis Populations ................................ ................................................................ .......... 61 
10.1.1.  Intent- to-Treat Population ................................................................ ............................... 61 
10.1.2.  Response-evaluable Population ................................................................ ...................... 61 
10.1.3.  Safety Population ................................ ................................................................ ............ 61 
10.1.4.  Additional Analysis Populations ................................................................ .................... 61 
10.2.  Sample Size Determination ................................................................ ................................ 61 
10.3.  Subject Information ................................ ................................................................ ........... 62 
10.4.  Efficacy Analyses  ................................ ................................................................ .............. 62 
10.4.1.  Primary Endpoint ................................ ................................................................ ............ 62 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
6 
Approved, Date: 5 September 2013  Proprietary and Confidential 10.4.2.  Secondary Endpoints ................................ ................................................................ ......62 
10.4.3.  Exploratory Endpoints ................................................................ ................................ ....63 
10.5.  Analysis Methods................................ ................................................................ ............... 63 
10.5.1.  Analysis for Phase 1 ................................ ................................................................ .......63 
10.5.2.  Primary Efficacy Analyses ................................................................ ............................. 63 
10.5.3.  Secondary Efficacy Analysis ................................................................ .......................... 64 
10.5.4.  Exploratory Efficacy Analysis ................................................................ ........................ 64 
10.5.5.  Pharmacokinetic Analyses ................................................................ .............................. 65 
10.5.6.  Pharmacodynamics Analysis Plan ................................................................ .................. 65 
10.5.7.  Safety Analyses................................ ................................................................ ............... 66 
10.5.8.  Data Monitoring Committee ................................................................ ........................... 67 
11. ADVERSE EVENT REPORTING ................................................................ .................... 67 
11.1.  Adverse Event Definitions and Classifications ................................ ................................ ..67 
11.1.1.  Adverse Event ................................ ................................................................ ................. 67 
11.1.2.  Serious Adverse Event ................................................................ ................................ ....69 
11.1.3.  Unexpected Adverse Events  ................................................................ ........................... 69 
11.1.4.  Causality ................................ ................................................................ ......................... 70 
11.1.5.  Severity Criteria ................................ ................................................................ .............. 70 
11.2.  Documenting and Reporting of Adverse Events and Serious Adverse Events by 
Investigators  ................................ ................................................................ ....................... 71 
11.2.1.  Adverse Event Reporting Period ................................................................ .................... 71 
11.2.2.  Assessment of Adverse Events  ................................................................ ....................... 71 
11.2.3.  Expediting Reporting Requirements for Serious Adverse Events ................................ ..72 
11.2.4.  Other Malignancies ................................ ................................................................ ......... 72 
11.2.5.  Events of Special Interest  ................................................................ ............................... 72 
11.2.5.1.  Major Hemorrhage ................................ ................................................................ .......72 
11.2.5.2.  Intracranial Hemorrhage ................................................................ .............................. 73 
11.2.6.  Pregnancy................................ ................................................................ ........................ 73 
12. ETHICAL ASPECTS ................................ ................................................................ .......... 73 
12.1.  Study-Specific Design Considerations ................................................................ .............. 73 
12.2.  Regulatory Ethics Compliance ................................................................ .......................... 74 
12.2.1.  Investigator Responsibilities ................................................................ ........................... 74 
12.2.2.  Institutional Review Board, Research Ethics Board, and Independent Ethics 
Committee Approval................................ ................................................................ .......74 
12.2.3.  Informed Consent ................................ ................................................................ ........... 74 
12.2.4.  Protected Subject Health Information Authorization ................................ ..................... 75 
12.2.5.  Financial Disclosure ................................ ................................................................ .......75 
12.2.6.  Liability and Clinical Trial Insurance ................................................................ ............. 75 
13. ADMINISTRATIVE REQUIREMENTS ................................................................ ......... 76 
13.1.  Protocol Amendments ................................ ................................................................ ........ 76 
13.2.  Regulatory Documentation ................................................................ ................................ 76 
13.2.1.  Regulatory Approval/Notification ................................................................ .................. 76 
13.2.2.  Required Prestudy Documentation ................................................................ ................. 76 
13.3.  Subject Identification, Enrollment, and Screening Logs ................................ ................... 77 
13.4.  Treatment Compliance ................................ ................................................................ .......77 
13.5.  Drug Accountability................................ ................................................................ ........... 78 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
7 
Approved, Date: 5 September 2013  Proprietary and Confidential 13.6.  Source Documentation ................................ ................................................................ .......78 
13.7.  Case Report Form Completion ................................................................ .......................... 79 
13.8.  Data Quality Assurance/Quality Control  ................................................................ ........... 79 
13.9.  Record Retention ................................ ................................................................ ............... 79 
13.10.  Study Monitoring and Audits................................................................ ............................. 80 
13.11.  Study Completion/Termination ................................................................ ......................... 81 
13.11.1.  Study Completion ................................ ................................................................ ........... 81 
13.11.2.  Study Termination ................................ ................................................................ .......... 81 
13.12.  Use of Information and Publication ................................................................ ................... 81 
14. REFERENCES ................................ ................................................................ .................... 82 
15. APPENDICES ................................ ................................................................ ...................... 84 
 
LIST OF APPENDICES 
Appendix 1: Schedule of Assessments ................................................................ ....................... 85 
Appendix 2: Eastern Cooperative Oncology Group Performance Status Scale ......................... 89 
Appendix 3: Definitions of Response ................................................................ ......................... 90 
Appendix 4: International Staging System (ISS) for Myeloma Criteria ................................ ....93 
Appendix 5: Lines of Therapy ................................................................ ................................ ....94 
Appendix 6: Disease Classification (Study Population) ................................ ............................. 95 
Appendix 7: Inhibitors and Inducers of CYP3A4/5 ................................ ................................ ...96 
Appendix 8: EQ-5D ................................ ................................................................ .................... 97 
Appendix 9: EORTC QLQ -MY20 ................................................................ ........................... 101 
 
LIST OF TABLES 
Table 1: Dosing Schedule ................................................................ ................................ ....26 
Table 2: Phase 1 Dosing Levels ................................................................ ........................... 31 
Table 3: Dose Escalation Guidelines for Sequential Cohorts ................................ .............. 32 
Table 4: Ibrutinib Dose Modifications ................................................................ ................. 36 
Table 5: Dose Modification for Carfilzomib Toxicity ................................ ......................... 38 
Table 6: Dose Reduction of Carfilzomib ................................................................ ............. 39 
Table 7: Pharmacokinetics and Pharmacodynamics Sample Collection Schedule .............. 48 
 
LIST OF FIGURES 
Figure 1: Synergy between Carfilzomib and Ibrutinib in ABC-DLBCL Lines .................... 23 
Figure 2: Study Design Schematic ................................................................ ........................ 26 
 
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
8 
Approved, Date: 5 September 2013  Proprietary and Confidential STUDY SYNOPSIS 
A Multicenter Phase 1/2b Study of the Bruton’s Tyrosine Kinase Inhib itor, Ibrutinib (PCI-32765), 
in Combination with Carfilzomib (Kyprolis™) in Subjects with relapsed or relapsed and refractory 
Multiple Myeloma  
Protocol Number:  PCYC-1119-CA 
Phase:   1/2b 
Duration of Study:   4 years 
Indication:   Relapsed and/or Refractory Multiple Myeloma 
Ibrutinib (PCI-32765) is a first-in -class, potent, orally administered covalent inhibitor of Brut on’s 
tyrosine kinase (BTK) currently being co-developed by Pharmacyclics, Inc and Janssen Research & 
Development, LLC , for the treatment of B-cell malignancies.  
OBJECTIVES AND HYPOTHESIS 
Primary Objectives 
Phase 1:   
 To determine the maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of 
ibrutinib in combination with carfilzomib. 
 To describe the toxicities associated with the combination of ibrutinib and carfilzomib in subjects 
with relapsed or relapsed and refractory multiple myeloma ( MM). 
Phase 2b :  
 To evaluate the efficacy of carfilzomib in combination with ibrutinib compared to carfilzomib in 
combination with placebo on the duration of progression-free survival ( PFS) in subjects with relapsed 
or relapsed and refractory MM. 
Secondary Objectives 
Phase 1:   
 Overall response rate (ORR) (≥ partial response ( PR); according to the International Working  
Group (IMWG) criteria [ Rajkumar 2011 ])  
 Duration of response (DOR). 
Phase 2b:  
To compare the treatment groups in terms of the following:  
 ORR (≥ PR; according to the IMWG [ Rajkumar 2011 ]).  
 DOR .  
 Overall survival (OS). 
 Time to progression ( TTP) 
In addition,  
 To evaluate the safety and tolerability of ibrutinib in combination with carfilzomib.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
9 
Approved, Date: 5 September 2013  Proprietary and Confidential Exploratory Objectives 
 To evaluate duration of the clinical benefit rate including subjects with minimal response ( MR) or 
better according to the IMWG. 
 To evaluate prognostic and predictive biomarkers and genetics relative to treatment outcomes. 
Phase 1 : 
 To determine the pharmacokinetics (PK) and pharmacodynamics of ibrutinib ( eg, BTK  occupancy of 
drug, levels of secreted protein or bone biomarkers) i n subjects with MM. 
Phase 2b:  
 To evaluate time-to -next treatment (TTNT). 
 To evaluate patient-reported outcomes (PROs) and disease-related symptoms according to European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Multiple 
Myeloma (EORTC QLQ-MY20) and Euro QoL 5 dimension questionnaire (EQ -5D). 
Hypothesis 
The hypothesis of this study is that treatment of ibrutinib in combination with carfilzomib will lead to a 
prolonged PFS compared to carfilzomib monotherapy in subjects who have received at least two prior 
lines of therapy including bortezomib (BTZ) and an immunomodulatory drug (IMiD ). 
OVERVIEW OF STUDY DESIGN 
Approximately 176 subjects, inclusive of Phase 1 and Phase 2b, will be enrolled . The Treatment Phase 
will extend from first dose until disease progression, unacceptable toxicity or study closure (defined as 
2 years after the last subject is enrolled). During the Treatment Phase, efficacy evaluations will be 
performed at the beginning of each cycle and will include an overall disease assessment, complete blood 
count, physical examination, and assessment of PROs (Phase 2b only) .  
This study will be conducted in two Phases: 
Phase 1  will be an open-label, national, multicenter study in subjects with MM who have received at least 
two prior lines of therapy, including BTZ and an IMiD to establish the RP2D . Phase 1 will be conducted 
at approximately 12 clinical centers in the United States, with up to 42 total subjects enrolled.  
In the Dose Escalation portion of the study, up to three cohorts may be explored and dose escalation will 
follow the 3+3 principles . In the Dose Expansion portion of the study, a maximum of 2 cohorts will be 
expanded up to a total of 18 subjects per cohort in the absence of dose-limiting toxicity (DLT) . 
The decision to expand a cohort will be made after review of the dose escalation data, and enrollment to a 
particular cohort(s) may be stopped at any time .  
Ibrutinib will be administered orally daily at 560 or 840 mg and will be initiated on Day 8 of Cycle 1 . 
Treatment should be continuous (without interruption) and will be self -administered . Carfilzomib will be 
administered intravenously  (IV) over 30 (+10)  minutes, on two consecutive days each week for three 
weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12 -day rest period (Days 17 to 28) . The Cycle 1 
carfilzomib starting dose is 20 mg/m2 and if tolerated the dose will be increased to ≥27 mg/m2/day on 
Day 8 Cycle 1 and stay at that level for subsequent cycles.  
After enrollment completion of Phase 1, further enrollment into Phase 2b will commence after the RP2D 
is identified and the initial safety and efficacy data are evaluated as favorable by the Sponsor . The RP2D 
will be determined on the basis of PK, safety, and efficacy data obtained during Phase 1.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
10 
Approved, Date: 5 September 2013  Proprietary and Confidential Phase 2b  will be conducted as a randomized, double-blind, international, multicenter study in subjects 
with MM who have received at least two prior lines of therapy, including BTZ and an IMiD . 
Eligible subjects will be randomized in a 1:1 ratio to Treatment Arm A or B: 
 Treatment Arm A: carfilzomib in combination with ibrutinib 
 Treatment Arm B: carfilzomib in combination with matching placebo 
SUBJECT SELECTION 
Key Eligibility Inclusion Criteria: 
 Subjects with MM who have received at least two prior lines of therapy including BTZ and an 
IMiD and had either no response or documented disease progression  to the most recent line of 
therapy .  
 Measurable disease of MM as defined by at least ONE of the following: serum monoclonal 
protein (SPEP) 1 g/dL, >200 mg of monoclonal protein in the urine on 24 hour electrophoresis 
(UPEP), or serum free light chain (SFLC): involved FLC ≥10 mg/dL (≥100  mg/L) AND 
abnormal serum kappa to lambda serum free light chain ratio. 
 Adequate hematologic function independent of transfusions and growth factor support; absolute 
neutrophil count (ANC) 750/mm3, platelet counts 75,000/mm3 (or 50,000/mm3 if bone 
marrow involvement is ≥50%), he moglobin level 8 g/dL. 
 Adequate renal and hepatic function; Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) 3 x upper limit of normal (ULN), total bilirubin 1.5 x ULN , 
Estimated Creatinine Clearance  (Cockcroft-Gault) ≥30  mL/min . 
 Eastern Cooperative Oncology Group (ECOG) performance status of 0 –2. 
Key Eligibility Exclusion Criteria: 
 Primary refractory disease defined as nonresponsive in patients who have never achieved a 
minimal response or better with any therapy. 
 Plasma cell leukemia , primary amyloidosis, POEMS syndrome. 
 Radiotherapy within 21 days prior to first administration of study treatment .  
 Prior therapy with alkylators, anthracyclines, high dose corticosteroids, IMiDs, or proteasome 
inhibitors 21 days prior to first administration of study treatment or monoclonal antibody 
≤6 weeks prior to first administration of study treatment. 
 Peripheral neuropathy Grade ≥  2 at screening .  
 Prior treatment with ibrutinib or any other protein kinase inhibitory drug or drug targeting the 
BCR signal transduction pathway. 
 Prior treatment with carfilzomib if subjects were considered non-responsive to carfilzomib.  
 Unable to swallow capsules or disease significantly affecting gastrointestinal function. 
 Requires anticoagulation with warfarin or equivalent vitamin K antagonists. 
 Requires treatment with strong CYP3A4/5 inhibitors. 
 Left ventricular ejection fraction (LVEF) ≥40%.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
11 
Approved, Date: 5 September 2013  Proprietary and Confidential DOSAGE AND ADMINISTRATION 
Ibrutinib will be administered orally once daily on a 28-day cycle beginning on Day 8 of Cycle 1 of the 
Treatment Phase. Treatment will continue until disease progression or other reason for treatment 
discontinuation . In Phase 1, ibrutinib will be administered at 560 mg (4 capsules) or 840 mg (6 capsules) 
according to the designed treatment level. Subjects enrolled in the double-blind, placebo-controlled 
Phase 2b will receive the RP2D of ibrutinib or the matching amount of placebo capsules. 
All subjects will receive carfilzomib IV over 30 minutes with carfilzomib at 20 mg/m2 on Days 1 and 2 of 
Cycle 1 . Thereafter, subjects will receive carfilzomib IV over 30 minutes on Days 8, 9, 15, and 16 of 
Cycle 1, and thereafter (Cycle ≥2) on Days 1, 2, 8, 9, 15, and 16 according to the designed treatment level 
in Phase 1. Subjects enrolled in the double-blind, placebo-controlled Phase 2b will receive carfilzomib 
according to the established RP2D of either 20/27 or 20/36 mg/m2. Dexamethasone 4 mg premedication 
will be administered prior to each carfilzomib infusion during Cycle 1 only and re-initiated as clinically 
appropriate. 
 
28-day dosing cycle  Ibrutiniba Carfilzomibb 
Dose Level -1 420 mg once daily  20 / 27 mg/m2 
Dose Level 1  
(starting dose)  560 mg once daily  20 / 27 mg/m2 
Dose Level 2  560 mg once daily  20 / 36 mg/m2 
Dose Level 3  840 mg once daily  20 / 36 mg/m2 
a. Ibrutinib will be administered PO daily on Days 8 -28 in Cycle 1 and thereafter on  Days 1 -28 
b. Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 of each cycle . Prior to 
carfilzomib administration subject will be given 4  mg dexamethasone (oral or IV)  during 
Cycle 1 only and re -initiated as clinically appropriate.  
 
EFFICACY EVALUATIONS 
Response evaluations will be performed at the beginning of each cycle until disease progression or until 
study closure, whichever comes first . Response evaluations will include an overall disease assessment, 
complete blood count, physical examination, and assessment of PROs .  
If at any time complete response ( CR) is suspected, all assessments including serum and urine must be 
performed as per the IMWG response assessment guidelines. 
Radiologic skeletal survey will be performed at Screening and only be repeated as clinical ly indicated 
and/or to document response/progression status. 
SAFETY EVALUATIONS 
The study will be monitored in accordance with the Sponsor’s pharmacovigilance procedures . 
Adverse events and serious adverse events will be review ed.  
A Data Monitoring Committee (DMC) will be commissioned for this study. In Phase 1, the DMC will 
review safety and efficacy data and advise on the RP2D. In Phase 2b, the DMC will review the unblinded 
safety data on an ongoing basis. 
 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
12 
Approved, Date: 5 September 2013  Proprietary and Confidential STATISTICAL METHODS 
Phase 1  
Designed to determine the MTD and toxicity profile of ibrutinib and carfilzomib using the standard 
3+3 design . Up to 3 dose cohorts will be explored, in the absence of DLT within the initial first 
3 subjects, dose escalation will continue . The MTD will be defined as the lowest dose level below which 
drug-related DLT is observed in ≥33% (ie, ≥2 of 3 or ≥2 of 6) subjects in a cohort . Up to 2 tested dose 
cohorts will be expanded up to 18 subjects per cohort to confirm initial safety/tolerability findings . 
Phase 1 is not powered for comparisons of treatment cohorts . The Phase 1 efficacy endpoints are the ORR 
according to the IMWG response criteria. The point estimate of the rate and the corresponding exact 
binomial 95% confidence interval will be calculated . For DOR, the distribution of DOR as assessed by 
Investigator will be provided using Kaplan-Meier estimates for responders. 
Phase 2b 
The sample size is calculated based on the primary endpoint of PFS in subjects treated with carfilzomib in 
combination with ibrutinib compared to subjects treated with carfilzomib and placebo . The calculation is 
based on the assumption that the median PFS is 4 months for carfilzomib and placebo arm and the 
enrollment rate will be 10 subjects per month . Approximately 1 34 eligible subjects will be enrolled to 
observe 101 PFS events in this study . Assuming 75% improvement in median PFS of the carfilzomib in 
combination with ibrutinib arm over carfilzomib and placebo arm (hazard ratio of 0.57), the study has at 
least 80% power to achieve a statistical significance level of 2.5% (1-sided) under exponential 
distribution for PFS .  
Primary Efficacy Analysis: 
PFS will be assessed by a set of written rules and formulae developed based on IMWG response criteria 
and will be analyzed using Kaplan-Meier estimates and two treatment arms will be compared using 
stratified log-rank test, stratified by the refractory status to the most recent line of therapy and the number 
of prior lines of therapy (2-4 versus ≥5). A sensitivity analysis of PFS will be conducted without 
censoring at subsequent therapy if initiated prior to documented PD. 
Secondary Efficacy Analysis: 
Overall response rate (ORR) will be compared using the Cochran-Mantel-Haen szel chi-square test, 
stratified by the two stratification factors : the refractory status to the most recent line of therapy and the 
number of prior lines of therapy (2-4 versus ≥5) . The distribution of DOR will be estimated using the 
Kaplan-Meier method similar to PFS. 
Exploratory Efficacy Analysis: 
Descriptive statistics for change in scores from baseline to each assessment will be summarized for the 
PROs . Other time to event analysis will be analyzed by the same method as PFS. Categorical endpoints 
will be compared between two treatment arms using the Cochran-Mantel-Haen szel chi-square test, 
stratified by the two stratification factors used . Overall survival will be compared using stratified log rank 
test. Survival rate at landmark points will be summarized based on Kaplan-Meier point estimates. 
Safety Analysis:  
Detailed tabulations of safety data (adverse events, clinical laboratory tests and other safety endpoints) 
will be provided for all subjects receiving the study drug. Summary statistics will include means, standard 
deviations, and medians for continuous variables and proportions for categorical variables. 
The end of the study will occur 2 years after the last subject is randomized, or the Sponsor terminates the 
study, whichever comes first.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
13 
Approved, Date: 5 September 2013  Proprietary and Confidential ABBREVIATIONS 
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
aPTT  activated partial thromboplastin time  
ASC T autologous stem cell transplant  
AST  aspartate aminotransferase  
AUC  area under the curve  
-hCG  beta-human chorionic gonadotropin  
BCR  B-cell receptor  
BM bone marrow  
BSA  body surface area  
BTK  Bruton’s tyrosine kinase  
BTZ  Bortezemib  
CBC  complete blood count  
CBR  clinical benefit response rate  
CFR  Code of Federal Regulations  
CI confidence interval  
CLL  chronic lymphocytic leukemia  
Cmax maximum conc entration  
Cmin minimum concentration  
CR complete response  
CRF  case report form  
CT computed  tomography  
CYP  Cytochrome P  
DCB  duration of clinical benefit response  
DLBCL  diffuse large B cell lymphoma  
DLT  Dose limiting toxicity  
DMC  Data Monitoring Com mittee  
DOR  duration of objective response  
ECG  electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EDC  electronic data capture  
ELISA  enzyme -linked immunosorbent assay  
EMR  Electronic medical records  
EORTC QLQ -MY20  European O rganization for Research and Treatment of Cancer Quality of Life 
Questionnaire  for Multiple Myeloma  
EQ-5D Euro QoL 5 dimension questionnaire  
FDA  Food and Drug Administration  
FISH  fluorescence in situ hybridization  
FLC free light chain  
GCP  Good Clinic al Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
IEC Independent Ethics Committee  
IgA, IgG and IgM monoclonal immunoglobulin A, G and M antibod ies  
IL-6  interleukin -6 
IMiD   immunomodulatory drug  
IMWG  International Myeloma Working Group  
INR international normalized ratio  
IRB Institutional Review Board  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
14 
Approved, Date: 5 September 2013  Proprietary and Confidential ISS International Staging System  
ITT Intent -to-Treat (population)  
IV Intravenous  
LC-MS/MS  liquid chromatography/tandem mass spectrometry  
LDH  lactic  acid dehydrogenase  
MCL  Mantle Cell Lymphoma  
MedDRA  Medical Dictionary for Regulatory Activities  
MIP 1α  macrophage inhibitory protein -1α 
MM multiple myeloma  
M- protein  monoclonal paraprotein  
MR minimal response  
MRI  magnetic resonance imaging  
MTD  maximum tolerated dose  
MUGA  multiple gated acquisition scan  
NCI CTCAE  National Cancer Institute Comm on Terminology Criteria for Adverse Events  
ORR  overall response rate (ORR = sCR + CR + VGPR + PR)  
OS overall survival  
PBMC  peripheral blood mononuclear cells  
PD progressive disease  
PCR  polymerase chain reaction  
PET positron emission tomography  
PFS progression -free survival  
PK pharmacokinetic(s)  
POEMS  Polyneuropathy , Organomegaly , Endocrinopathy  or Edema , M-protein  and Skin 
abnormalities  
PR partial response  
PRO  patient -reported outcomes  
PT Prothrombin time  
RANKL  receptor activator of nuclear factor κB ligand  
REB  Research Ethics Board  
RP2D  Recommended Phase 2 Dose  
SAP Statistical Analysis Plan  
sCR stringent complete response  
SD  stable disease  
SEER  Surveillance Epidemiology and End Results  
SFLC  Serum Free Li ght Chain (Freelite®) 
SLL small lymphocytic lymphoma  
SPEP   serum protein electrophoresis  
study drug  ibrutinib or matching ibrutinib placebo  
study treatment  ibrutinib or matching ibrutinib placebo  plus carfilzomib  
Tmax time to maximum plasma concentrat ion 
t1/2 half life  
TSH  thyroid stimulating hormone  
TTNT  time-to-next treatment  
TTP time-to-progression  
ULN  upper limit of normal  
UPEP  urine protein electrophoresis  
US United States  
VGPR  very good partial response  
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
15 
Approved, Date: 5 September 2013  Proprietary and Confidential 1. INTRODUCTION 
1.1. Multiple Myeloma 
Multiple myeloma (MM) is a disseminated malignant proliferation of plasma cells and 
plasmacytoid cells ( Palumbo 2011 ). Its yearly United States (US) age-adjusted incidence of 
5.4/100,000 is comparable to that of chronic lymphocytic leukemia/small lymphocyti c 
lymphoma (CLL/SLL; 5.7/100,000), which in turn is second only to diffuse large B-cell 
lymphoma (DLBCL; 6.9/100,000) among lymphoid malignancy subtypes. Its most recently 
estimated (Surveillance Epidemiology and End Results [SEER]) population based 5-year 
survival of 37.7% is inferior to those of CLL/SLL (77.1%) and DLBCL (59%) ( SEER 2009 ). 
MM is thus one of the most significant areas of unmet medical need, in terms of survival and 
incidence, among lymphoid malignancies . Myeloma cell growth occurs within bones and 
specifically involves the bone marrow. Its clinical hallmarks include bone destruction, which 
may be manifested by lytic lesions, severe osteopenia, pathologic fractures and hypercalcemia, 
and impaired bone marrow function, which may result in anemia, thrombocytopenia, and 
neutropenia . Bone destruction in particular is a major cause of severe and disabling morbidity in 
myeloma. Bone lesions are present in the majority of patients at presentation and nearly all 
patients by the time the disease runs its course . Myeloma cells typically secrete 1 (or rarely 
more) monoclonal paraprotein (M-protein) molecule, which may be intact immunoglobulin 
(usually IgG or IgA; rarely IgD, E, or M) or free (κ or λ) light chains . Examples of completely 
nonsecretory myeloma are rare. Myeloma M-proteins can cause numerous complications 
including renal insufficiency, amyloidosis, hyperviscosity, and neuropathy. The various direct 
and indirect destructive effects of myeloma cells render MM patients highly symptomatic and 
challenging to manage. In addition, these patients are subject to greater morbidity and higher 
mortality compared to those with the more common subtypes of lymphoma.  
Myeloma cells are highly dependent upon the bone marrow microenvironment, including the 
presence of certain cytokines (eg, interleukin-6 [IL-6]), chemokines, macromolecules in the 
extracellular matrix, and supportive cells (stromal cells), for their growth and survival. Crucial 
cytokines and chemokines are secreted into the microenvironment by bone marrow (BM) stromal 
cells, and some by the MM cells themselves. Adhesion of MM cells to BM stromal cells triggers 
secretion of cytokines, which augment MM cell growth and survival and confers drug resistance 
(Roodman 2010b). Vascular endothelial growth factor, basic fibroblast growth factor –2, and 
other factors secreted by MM and/or BM stromal cells promote angiogenesis, and thereby further 
support tumor cell growth and survival. More recently, much progress has been made in 
elucidating the role of osteoclasts in the development of lytic lesions and in reciprocally 
contributing to a microenvironment supportive of myeloma cell growth and progression . 
Multiple myeloma cells stimulate osteoclastogenesis by secretion of factors including receptor 
activator of nuclear factor κB ligand (RANKL), IL -6, and macrophage inhibitory protein- 1α 
(MIP- 1α), while osteoclasts themselves may produce IL -6, as well as interact with stromal cells. 
These interactions contribute to a favorable microenvironment for myeloma cell adhesion and 
proliferation ( Kawano 1988, Roodman 2004, Aggarwal 2006, Roodman 2010a, Roodman 2010b, 
Roodman 2011 ).  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
16 
Approved, Date: 5 September 2013  Proprietary and Confidential Current treatments include combination chemotherapy with regimens using melphalan 
(Alkeran®), proteasome inhibitors (bortezomib [Velcade®], carfilzomib [Kyprolis®]), 
immunomodulatory drugs ( IMiDs) (thalidomide [Thalomid®], lenalidomide [REVLIMID®] and 
pomolidomide [Pomalyst®]) with and without corticosteroids. Younger patients are consolidated 
with high-dose therapy (ablative chemotherapy or radiation) with stem cell transplantation. 
Although improvements in progression-free survival (PFS) and overall survival (OS) have 
occurred in the past five years, even with the best available approved agents, 20 –40% of patients 
fail to respond to the primary therapy, and almost all subjects are known to eventually relapse.  
Therefore, novel rationally designed therapies, based on a thorough understanding of disease 
mechanisms; continue to be urgently required for MM patients 
1.2. Ibrutinib (PCI-32765) Background 
Ibrutinib (PCI-32765) is a first- in-class, potent, orally administered covalent inhibitor of 
Bruton’s tyrosine kinase (BTK) currently  being co-developed by Pharmacyclics, Inc and Janssen 
Research & Development, LLC , for the treatment of B-cell malignancies including CLL, 
the related SLL, Mantl e Cell Lymphoma (MCL), and Waldenstrom’s Macroglobulinemia . 
In vitro, ibrutinib inhibits purified BTK and selected members of the kinase family with 10-fold 
specificity compared with non-BTK kinases.  
The investigational product is formulated as a hard gelatin capsule for oral administration. At the 
present time there are no approved inhibitors targeting BTK.   
B cells are lymphocytes with multiple functions in the immune response, including antigen 
presentation, antibody production, and cytokine release. B-cells express cell surface 
immunoglobulins comprising the B-cell receptor (BCR), which is activated by binding to 
antigen . Antigen binding induces receptor aggregation and the clustering and activation of 
multiple tyrosine kinases, which in turn activate further downstream signaling pathways 
(Bishop 2003).  
The process of B-cell maturation, including immunoglobulin chain rearrangement and somatic 
mutation, is tightly regulated. It is thought that B-cell lymphomas and CLL result from mutations 
and translocations acquired during normal B-cell development ( Shaffer 2002 ). Several lines of 
evidence suggest that signaling through the BCR is necessary to sustain the viability of B-cell 
malignancies.  
The role of BTK in BCR signal transduction is demonstrated by the human genetic 
immunodeficiency disease X-linked agammaglobulinemia and the mouse genetic disease 
X-linked immunodeficiency, both caused by a mutation in the BTK gene. These genetic diseases 
are characterized by reduced BCR signaling and a failure to generate mature B-cells. The BTK 
protein is expressed in most hematopoietic cells with the exception of T-cells and natural killer 
cells, but the selective effect of BTK mutations suggests that its primary functional role is in 
antigen receptor signaling in B-cells ( Satterthwaite 2000 ).  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
17 
Approved, Date: 5 September 2013  Proprietary and Confidential Data from Study PCYC-04753 demonstrate that although ibrutinib is rapidly eliminated from the 
plasma after oral administration, once daily dosing with ibrutinib is adequate to sustain maximal 
pharmacodynamic activity for 24 hours postdose at d ose levels ≥2.5 mg/kg. 
In Study PCYC-0 4753, the BTK occupancies for the 2.5 mg/kg/day to 12.5 mg/kg/day cohorts 
and for the 560 mg continuous dosing cohort, were all above 90% at either 4 or 24 hours after 
drug administration. For the most comprehensive nonclinical and clinical information regarding 
ibrutinib background, safety, efficacy,  and in vitro and in vivo preclinical activity and toxicology 
of ibrutinib, refer to the latest version of the ibrutinib Investigator's Brochure. 
1.2.1. Ibrutinib in Multiple Myeloma 
Study PCYC-1111 -CA is a multicenter Phase 2 study in subjects with relapsed or relapsed and 
refractory MM. The primary objective of the study is to determine the efficacy of ibrutinib, both 
as a single agent and in combination with dexamethasone by the clinical benefit response rate 
(CBR). The secondary objectives are to evaluate the efficacy of ibrutinib in this population as 
assessed by the duration of clinical benefit response (DCB), overall response rate (ORR), 
duration of response (DOR). The exploratory objectives are PFS,  time to progression (TTP), 
and OS, hematologic improvement, and the safety and drug PK. 
Subjects are enrolled to one of four cohorts, with ibrutinib doses ranging from 420 mg/day 
(Cohort 1),  560 mg/day (Cohort 2), and 840 mg/day (Cohorts 3 and 4). Ibrutinib is given in 
combination with weekly dexamethasone in Cohorts 2 and 4; addition of dexamethasone is 
permitted upon disease progression in Cohorts 1 and 3. Cohort 1 and 2 have been fully enrolled, 
and accrual to cohorts 3 and 4 is ongoing. Three of 13 subjects in Cohort 1 had decreases of the 
monoclonal myeloma M-protein, one of whom had a partial response (PR) following the addition 
of dexamethasone. A total of 5 out of 13 subjects continued on treatment for more than 
4 months. As of April 2013, 2  subject s were continuing on treatment for more than 12 months, 
one with stable disease (SD) and one with a PR (in combination with dexamethasone) . 
There have been no new safety signals in this study . Decreases in multiple cytokines and 
chemokines that were elevated at baseline were noted among subject s with SD.  
1.2.2. Summary of Human Pharmacokinetics 
The results from extensive PK sampling and evaluation performed in approximately 250 subjects 
receiving ibrutinib across 3  clinical studies are sum marized below. 
Following oral administration of ibrutinib at doses ranging from 1.25 to 12.5 mg/kg/day as well 
as fixed dose levels of 420, 560 and 840 mg/day, exposure to ibrutinib increased as doses 
increased with substantial intersubject variability. The mean half life (t 1/2) of ibrutinib across 
3 clinical studies ranged from 4  to 9  hours, with a median time to maximum plasma 
concentration (T max) of 2  hours. Administration of 420 mg ibrutinib with a high-fat breakfast in 
subjects with chronic lymphocytic leukemia (CLL) approximately doubled the mean systemic 
exposure compared to intake after overnight fasting with median time to T max delayed from 2 to 
4 hours. Ibrutinib was extensively metabolized to the dihydrodiol metabolite PCI-45227 , 
a reversible inhibitor of B TK, with approximately 15 times lower inhibitory potency compared to 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
18 
Approved, Date: 5 September 2013  Proprietary and Confidential ibrutinib . The metabolite- to-parent AUC ratio ranged from 0.7 to 3.4 . Steady state exposure of 
ibrutinib and PCI-45227 was less than 2 -fold of first dose exposure.  
The results of human mass balance study of [14C]-ibrutinib conducted in six healthy male 
subjects demonstrated that less than 10% of the total dose of [14C]-ibrutinib is renally excreted, 
whereas approximately 80% is recovered in feces. Based on these findings, there is no plan to 
conduct a study of ibrutinib in renally impaired subjects. Subjects with mild and moderate renal 
insufficiency (creatinine clearance >30 mL/min) were eligible to enroll on 
Study PCYC-1102 -CA in which PK assessments were included. No dose adjustment is needed 
for mild or moderate renal impairment (greater than 30 mL/min creatinine clearance). There is 
no data in subjects  with severe renal impairment or subjects on dialysis . In vitro studies have 
indicated that ibrutinib is metabolized by cytochrome P450 (CYP) 3A4/5. The study of ibrutinib 
in hepatic impaired subjects (PCI-32765CLL1006) is in progress.  
1.2.3. Summary of Clinical Safety of Ibrutinib  
Safety data are available for 636  subjects treated in 5 monotherapy and 3  combination therapy 
studies, a s discussed below (Investigator’s Brochure Version 7, dated 31 July  2013 ). For a 
comprehensive summary of nonclinical and clinical information regarding the efficacy and 
safety of ibrutinib, refer to the latest version of the Investigator's Brochure for ibrutinib. 
Monotherapy Studies 
The integrated safety profile of ibrutinib administered as monotherapy to 506 subjects across 
several clinical studies ( PCYC-04753, PCYC-1102-CA, PCYC-1104 -CA, and PCYC-1106 -CA,  
PCI-32765MCL2001, PCYC-1111-CA, PCYC-1117-CA, and PCI-32765 -JPN-101) has been 
evaluated. The most common treatment-emergent adverse events as of 0 6 April 2013 were 
diarrhea (42.1%), fatigue (33.8%), nausea (26.1%), cough (20.2%), and peripheral edema 
(18.6%). Grade 3 or 4 adverse events were experienced by 60.7% of subjects, the most common 
(>2%) of which were hematologic in nature: neutropenia (9.7%), thrombocytopenia (6.5%), 
and anemia (4.9%). Pneumonia (7.7%) was the most frequent nonhematologic Grade 3/4 adverse 
event. Serious adverse events were experienced by 46.4% of treated subjects.  
The only serious events occurring in more than 1 % of subjects (excluding disease progression) 
were pneumonia (7.9%), atrial fibrillation (3.2%), and febrile neutropenia (2.8 %). 
Combination Therapy Studies 
The safety of ibrutinib administered as combination therapy to 130 subjects was evaluated in 
3 clinical studies: PCYC-1108 -CA, PCYC-1109 -CA, and PCI-32765DBL1002 . 
In Study PCYC-1108 -CA, ibrutinib is administered in combination with either the FCR 
(fludarabine, cyclophosphamide, and rituximab) or the BR (bendamustine and rituximab) 
regimen chemotherapy. In Study PCYC-1109-CA, ibrutinib is administered in combination 
with the monoclonal antibody ofatumumab in patients with relapsed and refractory CLL . 
In Study PCI-32765 DBL1002, ibrutinib is administered in combination with standard R-CHOP 
(rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone).  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
19 
Approved, Date: 5 September 2013  Proprietary and Confidential Across these combination studies, the most common adverse event has been diarrhea (47.7%), 
nausea (33.1%), infusion related reaction (29.2%), and fatigue (26.2%). Neutropenia (24.6%) has 
been the most common hematologic toxicity, followed by anemia (20.0%) and thrombocytopenia 
(19.2%).  
Adverse events that were Grades 3 or 4  or higher in severity were reported in 57.7% of subjects. 
The most common have been hematologic: neutropenia (21.5%), anemia and thrombocytopenia 
(7.7% each), and febrile neutropenia (6.2%). Pneumonia (7.7%) was the most frequently 
reported nonhematologic Grade 3 or higher adverse event.  
Overall, 36.2% of treated subjects have experienced at least 1 serious adverse event. The only 
event reported as related  occurring in more than 2 subjects has been pneumonia. The most 
commonly reported serious adverse events were febrile neutropenia and pneumonia (6.2% each), 
cellulitis (3.8%), atrial fibrillation (3.1%), and dehydration and dyspnea (2.3% each).  
Treatment Discontinuations 
As of 6 April 2013, 71/636 subjects discontinued treatment due to an adverse event, across the 
monotherapy and combination therapy ibrutinib studies (excluding Study PCYC-1103-CA); 
62 subjects receiving monotherapy population and 9 subjects receiving combination therapy. 
The most frequently reported adverse events that led to treatment discontinuations were 
pneumonia (13 subjects), respiratory failure (4 subjects), and cardiac arrest and Richter’s 
Syndrome (3 subjects each).  
Treatment-related Lymphocytosis 
Similar to other agents targeting B-cell receptor signaling, transient lymphocytosis is a 
pharmacodynamic effect of ibrutinib, in which the inhibition of BTK-mediated cellular homing 
and adhesion results in a mobilization of tumor cells to the peripheral blood ( Stevenson 2011 ). 
Upon initiation of treatment, a transient phase of increase in lymphocyte counts (ie, ≥50% 
increase from baseline and above absolute count 5,000/µL), often associated with reduction of 
lymphadenopathy has been observed in most subjects (75%) with relapsed/refractory CLL/SLL 
and some subjects (33%) with relapsed/refractory MCL treated with ibrutinib monotherapy. This 
observed transient lymphocytosis is usually not associated with an adverse event and should not 
be considered progressive disease in the absence of other clinical findings. Lymphocytosis in 
subjects with CLL/SLL on ibrutinib monotherapy typically occurs during the first few weeks 
(median time 1.1 weeks) of ibrutinib therapy and typically resolves within a median of 
18.7 weeks while on treatment.  
Available data in subjects with MM that have been treated with ibrutinib monotherapy in a 
Phase 1 study, there has been no evidence of treatment-related lymphocytosis. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
20 
Approved, Date: 5 September 2013  Proprietary and Confidential Hemorrhagic Events 
There are reports of hemorrhagic events in subjects treated with ibrutinib in both monotherapy 
and combination clinical studies . The majority of these hemorrhagic adverse events were of 
Grade 1 or 2 in severity, including minor hemorrhagic events like contusion, epistaxis and 
petechiae; and major hemorrhagic events including gastrointestinal bleeding, intracranial 
hemorrhage and hematuria. Hemorrhagic events of Grade 3 or higher, including central nervous 
system hemorrhage of any grade severity, occurred in 3.4% (17/506) of subjects treated in 
monotherapy studies and in 3.1% (4/130) of subjects treated in combination therapy studies. 
Subjects were excluded from participation in ibrutinib Phase 2 and 3 studies if they required 
warfarin or other vitamin K antagonists ( Section 6.3.3 ).  
Subjects in the current study will be monitored closely for hemorrhagic adverse events. Ibrutinib 
should be held at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and 
the risk of bleeding (Section 6.4). 
1.3. Carfilzomib 
The proteasome is a multi-catalytic proteinase complex that is responsible for degradation of a 
wide variety of protein substrates within normal and transformed cells. Intracellular proteins 
targeted for degradation by the proteasome are first ubiquitinated via the ubiquitin conjugation 
system. Ubiquitinated proteins are then cleaved within the proteasome by 1 or more of 3 separate 
N-terminal threonine protease activities: a chymotrypsin-like activity, a trypsin-like activity, 
and a caspase-like activity. 
Carfilzomib for injection is a tetrapeptide epoxyketone-based inhibitor of the chymotrypsin-like 
activity of the 20S proteasome. Carfilzomib, which is structurally and mechanistically different 
from the dipeptide boronic acid proteasome inhibitor bortezomib (BTZ), showed less off-target 
activity when measured against a broad panel of proteases including metallo-, aspartyl -, and 
serine proteases compared to BTZ; the latter showed off-target inhibitory activity in the 
nanomolar range against several serine proteases ( Arastu-Kapur 2011 ).  
Carfilzomib ( KYPROLIS™ ) is approved in the US for the treatment of patients with MM who 
have received at least two prior therapies including BTZ and an IMiD and have demonstrated 
progressive disease (PD) on or within 60 days of completion of the last therapy . In addition, 
carfilzomib has been studied in other cancers including Waldenstrom’ s Macroglobulinemia, 
non-Hodgkin’s lymphoma, mantle cell lymphoma, and a variety of solid tumors.  
1.3.1. Summary of Nonclinical Data:  Carfilzomib 
Based upon in vitro and in vivo studies, it is anticipated that more intense and sustained 
proteasome inhibition can be achieved with carfilzomib relative to BTZ, resulting in enhanced 
antitumor activity. Continuous 72 hour exposure to carfilzomib was associated with potent 
cytotoxic and pro-apoptotic activity across a broad panel of tumor-derived cell lines in culture 
(Demo 2007 ). Incubation of hematologic tumor cell lines with carfilzomib for as little as 1 hour 
led to rapid inhibition of proteasome activity followed by accumulation of polyubiquitinated 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
21 
Approved, Date: 5 September 2013  Proprietary and Confidential proteins and induction of apoptotic cell death. Carfilzomib was also cytotoxic in 
bortezomib-resistant tumor cell lines ( Suzuki 2011 , Kuhn 2007).  
Preclinical studies in rats and monkeys have been performed in which carfilzomib was 
administered intravenously (IV) for 5 consecutive days followed by 9 days of rest for 2 cycles . 
Proteasome inhibition of more than 80% was achieved, suggesting that high-level inhibition of 
the proteasome with the epoxyketone class is possible, affording new opportunities to escalate 
dose to optimize antitumor effects ( Yang 2011 ).  
1.3.2. Summary of Clinical Data in Multiple Myeloma:  Carfilzomib 
Carfilzomib clinical development in MM initially involved single agent testing at various doses, 
which served as the foundation for understanding the safety, tolerability and efficacy of 
carfilzomib ( Alsina 2012, Hájek 2012, Jagannath 2012, O'Connor 2009, Siegel 2012 ). 
Each treatment cycle was 4 weeks, and carfilzomib was administered as a 2 to 10 minute IV 
infusion on Days 1, 2, 8, 9, 15 and 16. The carfilzomib dose was 20 mg/m2 in Cycle 1, followed 
by 27 mg/m2 in Cycle 2 and for all subsequent administrations and resulted in ORR of 23.7% in 
a relapsed/refractory patient population ( Siegel 2012, Vij 2012a, Vij 2012b ).  
An ongoing trial, Study PX-171-007, has explored the single-agent safety and efficacy 
characteristics of carfilzomib at doses ranging from 20 mg/m2 to 36 mg/m2 by IV bolus  
(2-10 minute injections). Additional cohorts of MM subjects were subsequently investigated 
whereby carfilzomib doses from 36 mg/m2 to 70 mg/m2 were administered over a longer infusion 
time (30-minute infusions), and the maximum tolerated dose (MTD) in myeloma subjects was 
20/56 mg/m2. The 30-minute infusion of carfilzomib was better tolerated than the 2-10 minute 
bolus and enabled a higher MTD. The overall safety profile for a 30-minute infusion of 
carfilzomib at 20/56 mg/m2 is similar to that seen in previous Phase 2 studies of 27 mg/m2 
carfilzomib given over 2 –10 minutes and no new or unexpecte d adverse event s have been 
observed. The most common constitutional adverse events included fatigue, nausea, pyrexia, 
and headaches and were generally low grade. The most common hematologic adverse event s 
were thrombocytopenia and anemia ( Badros, 2012).  
The same study (Study PX-171-007) explored a combination of dexamethasone (20 mg on 
Days 1, 2, 8, 9, 15, and 16, and 40 mg on Day 22) with carfilzomib in MM subjects administered 
by 30-minute infusion at 20/45 mg/m2 and 20/56 mg/m2 and found it to be tolerable and safe 
(Badros 2012 ). The safety and efficacy of the 20/56 mg/m2 carfilzomib regimen in combination 
with dexamethasone is being examined in the ongoing Phase 3 ENDEAVOR study 
(Study 2011-003).  
An additional study demonstrated increased activity of carfilzomib as measured by ORR, in 
34 MM  subjects treated with single-agent carfilzomib at the MTD of 20/56 mg/m2. 
These relapsed MM subjects had an average of 5 prior lines of therapy with 78% of subjects 
refractory to BTZ at the time of study entry. The ORR was 50% for all subjects and 57% in BTZ 
refractory subjects. The median PFS is 4.6 months and the median OS has not been reached with 
a median follow-up of 9.6 months ( Lendvai 2012 ).  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
22 
Approved, Date: 5 September 2013  Proprietary and Confidential The results of the PX-171-007 safety analysis revealed no new or unexpected adverse events 
observed with escalated doses up to 56 mg/m2, with the safety and efficacy of doses above 
27mg/m2 alone and in combination being examined in multiple ongoing studies, including the 
Phase 3 CLARION study. There is also evidence of an improvement in efficacy based upon the 
ORR of 50% demonstrated in heavily pretreated patients treated at doses above the labeled 
indication. ( Lendvai 2012, Siegel 2012 ) Based upon these findings we will examine ibrutinib in 
combination with standard doses as well as escalated doses of carfilzomib to evaluate both safety 
and efficacy based on the trial design.  
1.4. Rationale for the Combination 
Clinically, ibrutinib is an attractive agent to combine with carfilzomib because of the excellent 
tolerance of ibrutinib, which is administered orally. More specifically, evidence has been 
presented of ibrutinib-BTZ supra-additivity or synergy in vitro with MM cells ( Rushworth 2013) 
and also with MCL and DLBCL cell lines ( Dasmahapatra 2013 ). Concentrations of ibrutinib that 
were applied were relatively high (≥1  μM) as compared to concentrations generally achieved 
clinically (100-400 nM). More recently Ou et al ( Proc. AACR, 2013 ) has noted similar ibrutinib-
carfilzomib synergy in MCL lines in vitro at high ibrutinib concentrations, as have researchers at 
Pharmacyclics testing activated B-cell like DLBCL cell lines at ibrutinib concentrations as low 
as 0.1 nM (unpublished data, see Figure 1). It is intriguing that supra-additivity was often noted 
in ibrutinib or BTZ resistant cell lines, suggesting the combination may overcome some 
resistance mechanisms. Although this data was with non-MM cell lines, the results are important 
in establishing a proof-of-principal for an underlying mechanism that may be generalizable . 
Recent results more directly applicable to MM were obtained in an in vitro screening study of 
combinations of other drugs with ibrutinib, conducted by Zalicus, Inc. (Commissioned by 
Janssen Pharmaceutical, unpublished data on file). In this study, evidence of supra-additive 
effects of ibrutinib and carfilzomib were noted with three MM cell lines: AMO-1, INA-6 and 
HuNS1, with Synergy Scores of 3.5, 2.9 and 3.7 respectively (with >1 indicating additivity). 
These MM cell lines are known to express BTK which supports the interpretation that this was 
an on-target effect. Evidence for supra-additivity with bortezomib was not as robust. As is the 
case for several B-lymphroliferative diseases, interactions of the malignant cells with the 
microenvironment may exert protective effects; such interactions may be disrupted by ibrutinib 
in vivo. There is also some potential for synergistic effects on bone metabolism in vivo, 
as ibrutinib has been noted to have osteoclast inhibitory effects ( Tai 2012 ), while proteosome 
inhibitors stimulate osteoblastic activity ( Zangari 2011, Zangari 2012).  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
23 
Approved, Date: 5 September 2013  Proprietary and Confidential Figure 1 : Synergy between Carfilzomib and Ibrutinib in ABC-DLBCL Lines  
 
    Carfilzomib potentiates ibrutinib activity in ibrutinib sensitive lines (top) and resistant lines (bottom) . 
The panels also show the synergistic inhibitory effect of carfilzomib with ibrutinib at 0.1 nM (left) and ibrutinib 
at 1 nM (right) (Pharmacyclics unpublished data). 
1.5. Study Rationale  
This multicenter study will be conducted in two separate Phases.  
The Phase 1 Dose Escalation portion of the study is designed to establish the MTD of ibrutinib in 
combination with carfilzomib following the classical 3+3 dose escalation schema.  In the Phase 1 
Dose Expansion portion of the study, up to two cohorts will be extended to a maximum of 
18 subjects to ensure a more accurate assessment of the initial toxicity and efficacy profile of this 
novel combination regimen.  
After a favorable evaluation of the obtained safety and efficacy profile at the recommended 
phase 2 dose (RP2D), Phase 2b  portion will be initiated and conducted as a randomized, placebo 
controlled, double-blinded, multicenter study. The study is designed to evaluate whether 
treatment with ibrutinib in combination with carfilzomib will result in a clinically meaningful 
improvement in PFS compared to carfilzomib and placebo in subject s who have received at least 
two prior lines of therapy including BTZ and an IMiD. 

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
24 
Approved, Date: 5 September 2013  Proprietary and Confidential 2. OBJECTIVES AND HYPOTHESIS 
2.1. Objectives 
2.1.1. Primary Objective 
Phase 1:  
 To determine the maximum tolerated dose (MTD ) and the recommended Phase 2 dose 
(RP2D) of ibrutinib in combination with carfilzomib. 
 To describe the toxicities associated with the combination of ibrutinib and carfilzomib in 
subjects with relapsed or relapsed and refractory multiple myeloma (MM). 
Phase 2b:  
 To evaluate the efficacy of carfilzomib in combination with ibrutinib compared to 
carfilzomib in combination with placebo as assessed by the PFS in subjects with relapsed or 
relapsed and refractory MM. 
2.1.2. Secondary Objectives 
Phase 1:  
 Overall response rate (ORR) (≥ PR; according to the International Myeloma Working Group 
(IMWG) criteria [ Rajkumar 2011 ]).  
 DOR . 
Phase 2b:  
To compare the treatment groups in terms of the following:  
 ORR (≥ PR; according to the IMWG [ Rajkumar 2011 ]).  
 DOR.  
 Overall survival (OS). 
 Time to progression (TTP ). 
 To evaluate the safety and tolerability of ibrutinib in combination with carfilzomib.  
2.1.3. Exploratory Objectives 
 To evaluate duration of the clinical benefit rate including subjects with minimal response 
(MR) or better according to the IMWG.  
 To evaluate prognostic and predictive biomarkers and genetics relative to treatment 
outcomes. 
Phase 1 : 
 To determine the PK and pharmacodynamics of ibrutinib (eg, B TK occupancy of drug, 
levels of secreted protein or bone biomarkers) in subjects with MM.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
25 
Approved, Date: 5 September 2013  Proprietary and Confidential Phase 2b : 
 To evaluate time- to-next treatment (TTNT ). 
 To evaluate patient-reported outcomes (PROs) and disease-related symptoms according to 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
for Multiple Myeloma (EORTC QLQ -MY20) and EuroQol dimension questionnaire (EQ -5D).  
2.2. Hypothesis  
The hypothesis of this study is that treatment of ibrutinib in combination with carfilzomib will 
lead to prolonged PFS compared to carfilzomib monotherapy in subjects who have received at 
least two prior lines of therapy including BTZ and an IMiD. 
3. STUDY DESIGN AND RATIONALE 
3.1. Overview of Study Design 
The study will be conducted in two Phases. 
Phase 1 will be an open-label study. The Dose Escalation portion of the study is designed to 
establish the MTD of ibrutinib in combination with carfilzomib. Up to three cohorts ( Table 2 ) 
may be explored and dose escalation will follow the 3+3 dose escalation schema. In Dose 
Expansion, a maximum of two cohorts will be expanded up to a total of 18 subjects per cohort in 
the absence of dose-limiting toxicity (DLT) to ensure a more accurate assessment of the initial 
toxicity and efficacy profile.  
Phase 2b will be randomized, placebo-controlled, double-blind study designed to evaluate 
whether treatment with ibrutinib in combination with carfilzomib will result in an  improvement 
in PFS compared to carfilzomib and placebo in subject s who have received at least two prior 
lines of therapy including BTZ and an IMiD. 
Approximately 17 6 subjects, inclusive of Phase 1 and Phase 2b, will be enrolled. Both Phases 
include a Screening Phase, Treatment Phase and a Follow-Up Phase ( Figure 2 ). The Screening 
Phase assessments will be performed within 28 days prior to study treatment. Eligible subjects 
must have diagnosis of MM that meets published diagnostic criteria, have received at least two 
prior lines of therapy including BTZ and an IMiD, and have documented relapse/refractory 
disease according to IMWG consensus criteria. The Treatment Phase will extend from first dose 
until criteria for permanent discontinuation of ibrutinib are met ( Section 5.7). During the 
Treatment Phase, efficacy evaluations will be performed at the beginning of each cycle and will 
include an overall disease assessment, complete blood count ( CBC) , physical examination, and 
assessment of PROs (Phase 2b only) .  
The Post-treatment Follow-up Phase will begin once a subject discontinues ibrutinib treatment 
and will continue until death, lost to follow up, consent withdrawal, or study end, whichever 
occurs first.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
26 
Approved, Date: 5 September 2013  Proprietary and Confidential  Subjects who discontinue for reasons other than disease progression (ie,  for adverse event 
or Investigator decision), will complete an End of Treatment Visit (30 ± 3 days from the 
last dose of ibrutinib or carfilzomib, whichever is later), and should continue to have 
disease evaluations (12 weeks ± 14 days).  
 Subjects who discontinue due to disease progression will complete an  End  of 
Treatment Visit and be followed for survival and subsequent anti-cancer therapy 
(12 weeks ± 14 days) until study ends.  
It is imperative that survival status be assessed and that the date of death is documented for each 
subject  that has died.  
A Data Monitoring Committee (DMC) will be commissioned for this study. In Phase 1, 
the DMC will review  safety and advise on the RP2D. In Phase 2b,  the DMC will review the 
unblinded safety data on an ongoing basis.  
Table 1 : Dosing Schedule 
 
Cycle  Cycle 1  Cycle ≥2  
Days  D1/2 D8/9 D15/16 D1/2 D8/9 D15/16 
Ibrutinib or  
Placebo  (Phase 2b only)  0 mg  560-840 mg (4 -6 capsules)  
continuously Days 8 - 28 560-840 mg (4 -6 capsules) continuously            
Days 1 – 28 
Carfilzomib  20 mg/m2 27-36 mg/m2 27-36 mg/m2 27-36 mg/m2 27-36 mg/m2 27-36 mg/m2 
 
 
 
Figure 2 : Study Design Schematic 
 
 

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
27 
Approved, Date: 5 September 2013  Proprietary and Confidential 3.2. Phase 1 Dose Escalation and Expansion Overview 
Phase  1 will be conducted at approximately 20 clinical centers in the US, with up to 42 total 
subjects enrolled.  In the Dose Escalation portion, up to three dose levels will be explored and 
dose escalation will follow the 3+3 principles. In the Dose Expansion portion, a maximum of 
2 cohorts will be expanded up to a total of 18 subjects per cohort (inclusive of subjects enrolled 
in the Dose Escalation portion) in the absence of DLT. The decision to expand a cohort will be 
made after review of the d ose escalation data, and enrollment to a particular cohort(s) may be 
stopped at any time.  
Ibrutinib will be administered orally daily at 560 or 840 mg and will be initiated on Day 8 of 
Cycle 1. Treatment should be continuous (without interruption) and will be self -administered  
(unless otherwise specified in this protocol) . Carfilzomib will be administered IV over 30 (+10) 
minutes, on two consecutive days each week for three weeks (Days 1, 2, 8, 9, 15, and 16), 
followed by a 12 -day rest period (Days 17 to 28).  The Cycle 1 carfilzomib starting dose is 
20 mg/m2 on Days 1 and 2, and if tolerated the dose will be increased to 27  or 36 mg/m2/day on 
Day 8 of Cycle 1 and stay at that level for subsequent cycles). See Section 5.4 for study 
treatment details.   
After enrollment completion of Phase 1 , further enrollment into Phase 2 b will commence after 
the RP 2D is identified and the initial safety and efficacy data are evaluated as favorable by the 
Sponsor. The RP2D will be determined on the basis of PK, safety, and efficacy data obtained 
during Phase 1.  
3.3. Phase 2b Double -blind, Placebo Controlled Efficacy Evaluation Overview 
Phase 2b  (efficacy evaluation) will be a randomized, placebo-controlled,  international, 
multicenter study. This portion of the study will be conducted at approximately 60 international 
clinical centers, with approximately 1 34 subjects enrolled. Subjects will be treated according to 
the identified RP2D. The final Phase 2b dose level will be selected  by the Sponsor. 
Eligible subjects will be randomized in a 1:1 ratio to Treatment Arm A or B: 
 Treatment Arm A: carfilzomib in combination with ibrutinib. 
 Treatment Arm B: carfilzomib in combination with matching placebo. 
Subjects randomized to the ‘placebo’ arm will receive matching number of placebo capsules. 
Subjects will be stratified at randomization by the refractory status to the most recent line of 
therapy and the number of prior line of therapy (2- 4 versus ≥5). Randomization will also be 
stratified by geographic region: US versus non-US. Geographic region will not be used as a 
factor in the statistical analysis except for the summary. Refractory to the most recent treatment 
is defined as a) nonresponsive or b) relapse while on therapy or relapse within 60 days of the last 
treatment. Nonresponsive is defined as either failure to achieve minimal response or 
development of PD while on therapy.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
28 
Approved, Date: 5 September 2013  Proprietary and Confidential Ibrutinib will be administered orally daily at the RP2D starting on Day 8 of Cycle 1. Treatment 
should be continuous (without interruption) and will be self-administered. Carfilzomib will be 
administered IV over 30 (+10) minutes, on two consecutive days each week for three weeks 
(Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). The Cycle 1 
carfilzomib starting dose is 20 mg/m2 and if tolerated the dose will be increased to the RP2D on 
Day 8 of Cycle 1 and stay at that level for subsequent cycles.  
4. SUBJECT SELECTION 
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, 
the Investigator should consult with the Medical Monitor before enrolling a subject in the study. 
Eligibility will be confirmed by the Sponsor ’s Medical Monitor prior to enrollment.  
4.1. Inclusion Criteria 
To be enrolled in the study, each potential subject must satisfy all of the following 
inclusion criteria. 
Disease Related  
1. Subjects with MM who have received at least two prior lines of therapy ( Appendix 5 ) 
including BTZ and an IMiD and had either no response or documented disease progression to 
the most recent treatment regimen.  
2. Measurable disease of MM as defined by at least ONE of the following: 
 Serum monoclonal protein (SPEP) 1 g/dL 
 >200 mg of monoclonal protein in the urine on 24 hour electrophoresis (UPEP) 
 Serum free light chain (SFLC) : involved FLC ≥10 mg/dL (≥100  mg/L) AND 
abnormal kappa to lambda serum free light chain ratio 
Laboratory 
3. Adequate hematologic function within 7 days prior to enrollment (Phase 1) or randomization 
(Phase 2b), defined as: 
 Absolute neutrophil count (ANC)  750/mm3  
 Platelet counts 75,000/mm3 (or 50,000/mm3 if bone marrow involvement is ≥50%)  
 Hemoglobin level 8 g/dL 
Results must be independent of transfusion and growth factor support for at least 7 days , 
with the exception of pegylated G-CSF (pegfilgrastim) and darbopoeitin which requires at 
least 14 days. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
29 
Approved, Date: 5 September 2013  Proprietary and Confidential 4. Adequate hepatic and renal function within 7 days prior to enrollment (Phase 1) or 
randomization (Phase 2b): 
 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 x upper 
limit of normal (ULN) 
 Total bilirubin 1.5 x ULN (unless bilirubin r ise is due to Gilbert’s syndrome or of 
non-hepatic origin) 
 Estimated Creatinine Clearance (Cockcroft-Gault) ≥30 mL/min  
Demographic 
5. Men and women ≥  18 years of age on the day of signing the informed consent. 
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 –2. 
Ethical/Other 
7. Female subject of childbearing potential must have a negative serum (human chorionic 
gonadotropin) or urine pregnancy test within 3 days prior to enrollment (Phase 1) or 
randomization (Phase 2b) and agree to use dual methods of contraception during the study 
and for 1 month following the last dose with ibrutinib . Post menopausal females (>45 years 
old and without menses for >1 year) and surgically sterilized females are exempt from this 
criterion. 
8. Male subject must use an effective barrier method of contraception during the study and for 
3 months following the last dose if sexually active with a female of childbearing potential. 
9. Sign (or their legally-acceptable representatives must sign) an informed consent document 
indicating that they understand the purpose of and procedures required for the study and are 
willing to participate in the study. 
10. Willing to provide blood and tissue samples for correlative research purposes (Phase 1 and 
selected Phase 2 sites). 
4.2. Exclusion Criteria 
Subjects must not meet any of the following exclusion criteria to be eligible to enroll in 
this study: 
Disease-Related 
1. Primary refractory disease defined as nonresponsive in patients who have never achieved a 
minimal response or better with any therapy. 
2. History of plasma cell leukemia, primary amyloidosis, POEMS syndrome. 
3. Radiotherapy within 21 days prior to f irst administration of study treatment. However, if the 
radiation portal was localized to single lesion or fracture site and covered by ≤5% of the 
bone marrow reserve (by investigator estimate), the subject may be enrolled irrespective of 
the end date of radiotherapy.   
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
30 
Approved, Date: 5 September 2013  Proprietary and Confidential 4. Recent prior chemotherapy  
 Alkylators (eg,  melphalan, cyclophosphamide) 21 days prior to first administration 
of study treatment  
 Anthracyclines 21 days prior to first administration of study treatment 
 High dose corticosteroids, IMiDs (thalidomide or lenalidomide), or proteasome 
inhibitors (eg, BTZ) 21 days prior to first administration of study treatment  
 Monoclonal antibody ≤6 weeks prior to first administration of study treatment.  
5. Peripheral neuropathy Grade ≥2 at screening. 
6. Prior treatment with ibrutinib (PCI-32765) or any other protein kinase inhibitory drug or 
drug targeting the BCR signal transduction pathway. 
7. Prior treatment with carfilzomib if subjects were considered non-responsive to carfilzomib.   
Concurrent Conditions 
8. Major surgery or a wound that has not fully healed within 4 weeks prior to first 
administration of study treatment.  
9. Infection requiring systemic treatment within 2 weeks prior to first administration of study 
treatment, or unexplained fever within 2 weeks prior to first administration of study 
treatment.  
10. Concomitant therapy with denosumab (bisphosphonate is allowed).  
11. Unable to swallow capsules or disease significantly affecting gastrointestinal function, 
such as malabsorption syndrome, resection of the stomach or small bowel, or complete 
bowel obstruction.  
12. Diagnosed or treated for malignancy other than MM, except: 
 Malignancy treated with curative intent and with no known active disease present 
for ≥3 years before the first dose of study treatment and felt to be at low risk for 
recurrence by the treating physician 
 Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of 
disease 
 Adequately treated carcinoma in situ without evidence of disease. 
13. Uncontrolled diabetes mellitus.  
14. History of stroke or intracranial hemorrhage within 6 months prior to first administration of 
study treatment. 
15. Requires anticoagulation with warfarin or equivalent vitamin K antagonists 
(eg, phenprocoumon ). 
16. Requires treatment with strong CYP3A4/5 inhibitors ( Appendix 7 ). 
17. Left ventricular ejection fraction (LVEF) ≥40%; 2 -d transthoracic echocardiogram (ECHO) 
is the preferred method of evaluation; multiple gated acquisition scan (MUGA) is acceptable 
if ECHO is not available. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
31 
Approved, Date: 5 September 2013  Proprietary and Confidential 18. Clinically significant cardiovascular disease such as uncontrolled or symptomatic 
arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to first 
administration of study treatment, or any Class 3 (moderate) or Class 4 (severe) cardiac 
disease as defined by the New York Heart Association Functional Classification.   
19. Known history of human immunodeficiency virus (HIV) or active infection with Hepatitis C 
Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active systemic infection. 
20. Any life-threatening illness, medical condition, or organ system dysfunction, which in the 
investigator’s opinion, could compromise the subject’s safety, or interfere with the 
absorption or metabolism of ibrutinib capsules. 
21. Women who are pregnant or breast-feeding.  
22. Any medical or psychiatric condition that, in opinion of investigator, could interfere with the 
subject’s ability to give informed consent, compliance, or treatment.  
5. TREATMENT OF SUBJECTS 
5.1. Phase 1 Dose Escalation  
Dose Escalation : A minimum of three subjects will be entered within each cohort with expansion 
as needed to determine the DLT. If one of three subjects experience study treatment (ibrutinib 
and/or carfilzomib) related DLT during the first treatment cycle, the same cohort will be 
expanded to six subjects. If one of six subjects experiences a study treatment related DLT during 
the first treatment cycle, the next cohort may be enrolled. If at any time during a cohort, 
≥2 subjects experience a study treatment related DLT, the MTD will have been exceeded, 
additional enrollment within the cohort will cease, and dose escalation will stop (Table 2) ie, 
if there are 2 DLTs in Dose Level 1, Dose Level -1 will be enroll ed. The MTD will be defined as 
the dose level below  which study treatment related DLT is observed in ≥33% (ie, ≥2 of 3 or 
≥2 of 6) subjects in a cohort. 
Table 2: Phase 1 Dosing Levels 
28-day Dosing Cycle  Ibrutiniba Carfilzomibb 
Dose Level -1 420 mg once daily  20 / 27 mg/m2 
Dose Level 1  
(starting dose)  560 mg once daily  20 / 27 mg/m2 
Dose Level 2  560 mg once daily  20 / 36 mg/m2 
Dose Level 3  840 mg once daily  20 / 36 mg/m2 
a. Ibrutinib will be administered orally daily on Days 8 -28 in Cycle 1 and thereafter on Days 1 -28 
b. Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 per cycle. Prior to carfilzomib 
administration  subject s will be given 4  mg dexamethasone (oral or IV)  during cycle 1 only with re -initiation 
as clinic ally appropriate  
 
Dose escalation guidelines for sequential cohorts are summarized in Table 3  below: 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
32 
Approved, Date: 5 September 2013  Proprietary and Confidential Table 3 : Dose Escalation Guidelines for Sequential Cohorts 
No. of Subjects  
with Drug -Related DLT  
at a Given Dose Level  Dose Escalation*  
0 of 3  Proceed to next dose cohort level  
1 of 3  3 more subjects are treated at the same dose level  
2 of 3  Dose escalation stops . MTD is next lower dose level.  
1 of 6  Proceed to next dose cohort level  
≥2 of 6  Dose escalation stops . MTD is next lower dose level.  
1 of 6 at the highest tested dose level  MTD  not identified use this dose in Phase  2b 
* The number of subjects within a cohort and dose groups may be expanded, to further establish safety, if 
needed .  
 
Before applying the dose escalation rules, 3  subjects in a given dose level must have completed 
28 days (1  cycle) of therapy and have been evaluated for toxicity (Cycle 2, Day 1). If the first 
3 subjects within a cohort tolerate the first 28-day cycle of treatment without experiencing a 
DLT, as defined below, the next cohort may enroll.  
Once the RP2D is identified, subjects enrolled in lower dose levels, with no dose reductions or 
DLTs, will be allowed to escalate to the RP2D .  
Missed doses of carfilzomib, and ibrutinib will not be made up. Doses of carfilzomib may be 
rescheduled by up to 1  day. Anticipated delays of a scheduled carfilzomib dose by >1 day may 
be approved at the discretion of the medical monitor after discussion with the investigator. 
Note :  In the Dose Escalation phase, if a subject ends treatment within the first cycle for reasons 
other than study treatment related toxicity, ie, withdraws consent, they will be replaced. 
5.2. Definition of Dose Limiting Toxicity  
DLT assessments will only be conducted during the Dose Escalation in Phase 1 for the first 
cycle. DLTs are defined as follows: 
Hematologic:  
 Grade 4 neutropenia (ANC <500/mm3) lasting for >10 days and/or the necessity for 
use of G-CSF, GM -CSF or pegylated G -CSF  
 Febrile neutropenia (ANC <1,000/mm3 with a fever ≥38.3ºC)  
 Grade 4 thrombocytopenia (<25,000/ mm3) that persists for 7 days, despite holding 
treatment 
 Grade 3-4 thrombocytopenia associated with bleeding requiring blood products  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
33 
Approved, Date: 5 September 2013  Proprietary and Confidential Non-Hematologic:  
 Grade ≥2 neuropathy with pain 
 Grade ≥3 unmanageable non-hematologic toxicity  
 Grade ≥3 nausea, vomiting, or diarrhea uncontrolled by maximal antiemetic / 
antidiarrheal therapy 
 Grade ≥4 fatigue persisting for >7 days 
Other : 
 Inability to administer most of the planned doses for both drugs during Cycle 1 
o More than one missed carfilzomib dose due to toxicity associated  with the 
study tre atment will be considered as a DLT 
o Three (3) or more days of missed ibrutinib treatment due to toxicity associated 
with the study treatment will be considered as a DLT. 
5.3. Randomization and Blinding  
Subjects who meet all the inclusion/exclusion criteria are eligible to enter the study. 
Phase 1 :  
 Is an open-label study, there will be no randomization or stratification of subjects. 
Phase 2b :  
 Eligible subjects will be randomized 1:1 to either ibrutinib or matching placebo capsules in 
combination with carfilzomib. 
 Subject s will be stratified at randomization by: 
1) Refractory status to the most recent line of therapy.  
2) Number of prior lines of therapy (2 -4 versus ≥5).  
The purpose of stratification is to maintain balance across treatment arms in regards to the 
allocation of subjects with different prognoses for progression and survival. 
5.4. Treatment Regimens 
All eligible subject s will be treated with carfilzomib.  
Phase 1 : 
Ibrutinib will be administered at 560 mg (4 capsules) or 840 mg (6 capsules) according to the 
designed treatment level ( Table 2 ).  
Phase 2b :  
During the conduct of the double-blinded portion of the study, subject s will be randomly 
assigned to treatment with either ibrutinib (Arm A) or matching ibrutinib/placebo (Arm B). 
Final dose level for conducting the Phase 2 b portion will be selected by the Sponsor.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
34 
Approved, Date: 5 September 2013  Proprietary and Confidential Missed doses of ibrutinib or matching ibrutinib/placebo and carfilzomib will not be made up . 
During the conduct of the Phase 2b , dose escalation for carfilzomib and/or ibrutinib at any time 
will not be allowed. 
Arm A  (28-day treatment cycles)  
Carfilzomib:  
 20 mg/m2 administered IV over 30 (+10)  minutes on Day 1 and Day 2 of Cycle 1 
 27 or 36 mg/m2 administered IV over 30 (+10) minutes on Day 8, 9, 15, and 16 in Cycle 1 
and from Cycle 2 onwards on Day 1, 2, 8, 9, 15, and 16.  
 4 mg dexamethasone premedication will be administered  orally or IV prior to each 
carfilzomib infusion during Cycle 1 only with reinitiation as clinically appropriate. 
Ibrutinib: 
 560 or 840 mg (4 or 6 capsules) orally administered daily beginning from Day 8 in Cycle 1 
Arm B  (28-day treatment cycles)  
Carfilzomib:    
 20 mg/m2 administered IV over 30 (+10)  minutes on Day 1 and Day 2 of the first cycle 
 27 or 36  mg/m2 administered IV over 30 (+10) minutes on Day 8, 9, 15, and 1 6 in Cycle 1 
and from Cycle 2 onwards on Day 1, 2, 8, 9, 15, and 16.  
 4 mg dexamethasone premedication will be administered orally or IV prior to each 
carfilzomib infusion during Cycle 1 only with reinitiation as clinically appropriate. 
Matching Ibrutinib/Placebo: 
 4 or 6 capsules of matching ibrutinib/placebo orally administered daily beginning from 
Day 8 in Cycle 1 
5.5. Ibrutinib or Ibrutinib/Placebo 
For the purposes of this study ibrutinib refers to open label study product used in Phase 1, 
ibrutinib/placebo refers to blinded study product used in Phase 2 b of the study. All subjects in 
both phases of the study will follow guidelines for ibrutinib dosing and toxicity management . 
Study drug refers to both ibrutinib and ibrutinib/placebo.  
5.5.1. Formulation, Packaging, and Storage of Ibrutinib  or Ibrutinib/Placebo 
Ibrutinib capsules are provided as a hard gelatin capsule containing 140 mg of ibrutinib . 
All formulation excipients are compendial and are commonly used in oral formulations. Refer to 
the ibrutinib Investigator's Brochure for a list of excipients.  
Matching placebo capsules are provided as a hard gelatin capsule and look identical to ibrutinib 
capsules. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
35 
Approved, Date: 5 September 2013  Proprietary and Confidential The study drug capsules will be packaged in opaque high-density polyethylene plastic bottles 
with labels bearing the appropriate label text as required by governing regulatory agencies. 
All study drug will be dispensed in child-resistant packaging .  
Refer to the pharmacy manual/site investigational product manual for additional guidance on 
study drug storage, preparation and handling. 
Study drug labels will contain information to meet the applicable regulatory requirements: 
 Phase 1 (open-label), each bottle will have a study specific label which will include ibrutinib 
140 mg.   
 Phase 2 b (double-blind), each bottle will have a study specific label with a unique 
identification number. 
5.5.2. Dosage and Administration of Ibrutinib  
The first dose of study drug will be administered orally on Day 8 of Cycle 1, of the Treatment 
Phase, after which study drug will be self -administered daily by the subjects on an outpatient 
basis. 
Study drug will be dosed 0 -60 minutes after the end of carfilzomib infusion by clinic staff on 
PK days.  
Study drug should be administered orally once daily with 8 ounces (approximately 240 mL) of 
water. The capsules should be swallowed intact and subjects should not attempt to open capsules 
or dissolve them in water. Each dose of study drug should be taken at least 2  hours after a meal 
or at least 30 minutes before the next meal, at approximately the same time each day. Ingestion 
of grapefruit and Seville oranges (see Appendix 7 ) should be avoided for the duration of study 
drug treatment due to CYP3A4/5 inhibition.  
If the subject misses a dose, it can be taken as soon as possible on the same day with a return to 
the normal schedule the following day. The subject should not take extra capsules to make up the 
missed dose. Study drug dosing is continuous (without interruption) throughout the Treatment 
Phase. If Day 1 carfilzomib dosing is delayed for toxicity that does not require study drug to be 
held for toxicity, dosing should continue at investigator discretion. If a Day 1 (of any Cycle) 
carfilzomib infusion is delayed due to scheduling delays, study drug dosing should continue. 
Treatment will continue until disease progression or other reason for treatment discontinuation as 
outlined in Section 5.7.  
Dose modifications for toxicity are outlined in Section 5.5.4 . 
Unused study drug capsules dispensed during previous visits must be returned and drug 
accountability records updated at the beginning of the next cycle. Returned capsules must not be 
re-dispensed to the same subject or to another subject. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
36 
Approved, Date: 5 September 2013  Proprietary and Confidential 5.5.3. Dose Delay of Ibrutinib 
Treatment with study drug should be withheld for any unmanageable, potentially study 
drug-related non-h ematological toxicity that is Grade 3 or higher in severity. Please see 
Section 6.3.3  for guidelines for management of study drug in subjects who require anticoagulant 
treatment. Any other clinically important events where dose delays may be considered 
appropriate by the Investigator must be discussed with the Medical Monitor. 
Study drug may be withheld for a maximum of 28 consecutive days for toxicity. Study treatment 
should be discontinued in the event of a toxicity lasting more than 28 days, unless reviewed and 
approved by the Medical Monitor. 
5.5.4. Dose Modification of Ibrutinib 
The dose of study drug should be modified according to the dose modification guidelines in 
Table 4 if any of the following toxicities occur: 
 Grade 4 ANC (<500/µL) for more than 7 days. See Section 6 for instructions regarding the 
use of growth factor support.  
 Grade 3 thrombocytopenia (<50,000/µL) in the presence of clinically significant bleeding 
events 
 Grade 4 thrombocytopenia (<25,000/µL) 
 Grade 3 or 4 nausea, vomiting, or diarrhea if persistent, despite optimal anti-emetic and/or 
anti-diarrheal therapy  
 Any other Grade 4 or unmanageable Grade 3 toxicity. 
Table 4: Ibrutinib Dose Modifications  
 Action to be taken - Hematologic Adverse Events  
 May resume therapy once ANC ≥750, follow dose modification guidelines below after first  
occurrence  
 May resume therapy once platelets >25,000 and no evidence of clinically significant bleeding, 
follow dose modification guidelines below after first occurrenc e 
 
Occurrence  Action to be Taken  - Non-hematologic  Adverse Events  
First Withhold study drug  until recovery to Grade ≤1 or baseline; may restart at original dose 
level  
Second  Withhold study drug  until recovery to Grade ≤1 or baseline; may restart at 1 do se level 
lower ( ie, Phase 1: 420 mg/day for 560 mg  /day cohort; or 700 mg /day f or 840 mg/day 
cohort  or Phase 2b: reduce daily dose by 1 capsule/day ) 
Third  Withhold study drug  until recovery to Grade ≤1 or baseline; may restart at 1 dose level 
lower ( ie, Phase 1: 280 mg/day for 560 mg/day cohort; or 560 mg/day for 840 mg/day 
cohort  or Phase 2b: reduce daily dose by 2 capsules/day ) 
Fourth  Discontinue study drug * 
 *If study drug is discontinued for toxicity, subject will end the Treatment Phase of the study. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
37 
Approved, Date: 5 September 2013  Proprietary and Confidential Dose changes must be recorded in the Dose Administration CRF. 
At the Investigator’s discretion, the dose of study drug may be re -escalated after 2 cycles of a 
dose reduction in the absence of a recurrence of the toxicity that led to the reduction. 
5.5.5. Overdose Instructions 
Any dose of study drug in excess of that specified in this protocol is considered to be an 
overdose. Signs and symptoms of an overdose that meet any Serious Adverse Event criterion 
must be reported as a Serious Adverse Event in the appropriate time frame and documented as 
clinical sequelae to an overdose. Treatment of adverse events associated with overdose should be 
supportive for the underlying symptoms. 
5.6. Carfilzomib 
5.6.1. Formulation, Packaging, and Storage of Carfilzomib 
Carfilzomib for injection is supplied as an individually cartoned single-use vial containing a dose 
of 60 mg of carfilzomib as a white to off-white lyophilized cake or powder. Refer to the 
pharmacy manual/site investigational product manual for detailed guidance on carfilzomib 
storage guidance.  
5.6.2.  Dosage, Preparation and Administration of Carfilzomib 
Carfilzomib vials contain no antimicrobial preservatives and are intended only for single use.  
The reconstituted solution contains carfilzomib at a concentration of 2 mg/mL. Read th e 
complete preparation instructions prior to reconstitution.  Refer to the pharmacy manual/site 
investigational product manual for detailed instructions for reconstitution.  
Carfilzomib is administered IV over 30  (+10) minutes,  on two consecutive days, each week for 
three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). 
Each 28-day period is considered one treatment cycle.  In Cycle 1, carfilzomib  is administered at 
a dose of 20 mg/m2. If tolerated in Cycle 1, the dose should be increased to 27 or 36 mg/m2/day 
on Day 8 Cycle 1 and stay at that level for subsequent cycles. See Section 5.6 for study treatment 
details. Treatment may be continued until disease progression  or until unacceptable 
toxicity  occurs  
The dose is calculated using the subject ’s actual body surface area  (BSA) at baseline. 
Subjects with a BSA >2. 2 m2 should receive a dose based upon a BSA of 2.2  m2. 
Dose  adjustments do not need to be made for weight changes of ≤20%.  
5.6.2.1. Administration Precautions of Carfilzomib 
The quantity of carfilzomib contained in one single-use vial (60 mg carfilzomib) may exceed the 
required dose. Caution should be used in calculating the quantity delivered to prevent 
overdosing. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
38 
Approved, Date: 5 September 2013  Proprietary and Confidential Do not mix carfilzomib with or administer as an infusion with other medicinal products.  
The IV administration line should be flushed with 0.9% Normal Saline (0.9% NS) or 
5% Dextrose Injection, USP immediately before and after carfilzomib administration. 
Carfilzomib should not be administered as a bolus.  
5.6.2.2. Hydration and Fluid Monitoring 
Hydration to reduce the risk of renal toxicity and of tumor lysis syndrome with carfilzomib 
treatment should be administered during Cycle 1 only . Maintain adequate fluid volume status 
throughout treatment and monitor blood chemistries closely. Prior to each dose in Cycle 1, 
give 250 mL to 500 mL of IV 0.9% NS or other appropriate IV fluid. Give an additional 250 mL 
to 500 mL of IV fluids if clinically appropriate following carfilzomib admi nistration. 
Monitor subjects during this period for fluid overload. Hydration following the completion of 
Cycle 1 should only occur as clinically appropriate on a per subject basis .  
5.6.2.3. Dexamethasone Premedication 
Pre-medicate with dexamethasone 4 mg orally o r IV prior to all doses of carfilzomib during 
Cycle 1 only to reduce the incidence and severity of infusion reactions. Dexamethasone 
premedication may be reinstated (4 mg orally or IV) if these symptoms develop or reappear 
during subsequent cycles. 
5.6.3. Dose Modification  of Carfilzomib 
Table 5 : Dose Modification for Carfilzomib Toxicity 
Hematologic Toxicitya Recommended Action  
 Grade 3 or 4 Neutropenia  
 Grade 4 Thrombocytopenia  
  Withhold dose.  
 If fully recovered before next scheduled dos e, continue at 
same dose level.  
 If recovered to Grade 2 neutropenia or Grade 3 
thrombocytopenia, reduce dose by one dose level ( Table 6). 
 If tolerated, the reduced dose may be escalated to the 
previous dose at the discretion of the physician.  
Non-Hematologic Toxicity  Recommended Action  
Cardiac Toxicity  
Grade 3 or 4, new onset or worsening 
of: 
 congestive heart failure;  
 decreased left ventricular function;  
 or myocardial ischemia   Withhold until resolved or returne d to baseline.  
 After resolution, consider if restarting carfilzomib  at a 
reduced dose is appropriate ( Table 6). 
 If tolerated, the reduced dose may be escalated to the 
previous dose at the discretion of the physici an. 
Pulmonary Hypertension   Withhold until resolved or returned to baseline.  
 Restart at the dose used prior to the event or reduced dose , 
(Table 6), at the discretion of the physician.  
 If tolerated, the reduced dos e may be escalated to the 
previous dose at the discretion of the physician.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
39 
Approved, Date: 5 September 2013  Proprietary and Confidential Pulmonary Complications  
 Grade 3 or 4   Withhold until resolved or returned to baseline.  
 Consider restarting at the next scheduled treatment with one 
dose level reduction (Table 6). 
 If tolerated, the reduced dose may be escalated to the 
previous dose at the discretion of the physician.  
Hepatic Toxicity  
 Grade 3 or 4 elevation of 
transaminases, bilirubin or other 
liver abnormalities   Withhold u ntil resolved or returned to baseline.  
 After resolution, consider if restarting carfilzomib  is 
appropriate; may be reinitiated at a reduced dose ( Table 6) 
with frequent monitoring of liver function.  
 If tolerated, t he reduced dose may be escalated to the 
previous dose at the discretion of the physician.  
Renal Toxicity  
 Serum creatinine equal to or greater 
than 2 × baseline   Withhold until renal function has recovered to Grade  1 or to 
baseline and monitor renal functio n. 
 If attributable to carfilzomib , restart at the next scheduled 
treatment at a reduced dose ( Table 6).  
 If not attributable to carfilzomib , restart at the dose used 
prior to the event.  
 If tolerated, the reduced do se may be escalated to the 
previous dose at the discretion of the physician.  
Peripheral Neuropathy  
 Grade 3 or 4   Withhold until resolved or returned to baseline.  
 Restart at the dose used prior to the event or reduced dose 
(Table 6), at the discretion of the physician.  
 If tolerated, the reduced dose may be escalated to the 
previous dose at the discretion of the physician.  
Other  
 Grade 3 or 4 non -hematological 
toxicities   Withhold until resolved or returned to baseli ne. 
 Consider restarting at the next scheduled treatment with one 
dose level reduction ( Table 6). 
 If tolerated, the reduced dose may be escalated to the 
previous dose at the discretion of the physician.  
a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) 
Version  3.0 
 
Table 6 : Dose Reduction of Carfilzomib 
Current Dose Level  20 mg/m2 27 mg/m2 36 mg/m2 
Dose Reduction 1  15 mg/m2 20 mg/m2 27 mg/m2 
Dose Reduct ion 2  Discontinue  15 mg/m2 20 mg/m2 
Dose Reduction 3   Discontinue  15 mg/m2 
Dose Reduction 4    Discontinue  
 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
40 
Approved, Date: 5 September 2013  Proprietary and Confidential 5.7. Criteria for Permanent Discontinuation of Study Drug 
Investigators are encouraged to keep a subject who is experiencing clinical benefit in the study 
unless significant toxicity puts the subject at risk or routine noncompliance puts the study 
outcomes at risk. If the subject meets any of the following criteria, then withdrawal from the 
study treatment is mandatory: 
 Confirmed PD. 
 Unacceptable toxicity: an intercurrent illness or adverse event that prevents further study 
drug capsule administration. 
 Withdrawal of consent for treatment by subject. 
 Investigator decision (such as chronic noncompliance, significant protocol deviation or best 
interest of subject). 
 Study termination by Sponsor. 
 Subject becomes pregnant. 
Subjects who withdraw for any reason after the Phase 1 Dose Expansion will not be replaced. 
An End of Treatment visit ( Section 8.3.5 ) is required for all subjects except for those subjects 
who have withdrawn full consent (see Section 9). 
6. Concomitant Therapy 
Concomitant therapy must be recorded throughout the study beginning 14 days prior to Cycle 1, 
Day 1 until 30 days after the last dose of study treatment.  
6.1. Permitted Concomitant Medications 
Supportive medications in accordance with standard practice (such as for emesis, diarrhea, etc.) 
are permitted.  
Erythropoietic growth factors (eg, erythropoietin) and hematopoietic growth factors filgrastim 
and pegfilgrastim are allowed. Transfusional support (packed red blood cells and platelets) 
may be given in accordance with institutional policy. 
In Phase 1, Dose Escalation:   Erythropoietic and hematopoietic growth factors (filgrastim and 
pegfilgrastim) as well as transfusional support (packed red blood cells and platelets) should not 
be given in Cycle 1 determination of DLT. If they are administered this will be an indication 
of DLT. 
6.2. Prohibited Concomitant Medications 
Any chemotherapy, anticancer immunotherapy, experimental therapy, or radiotherapy are 
prohibited while the subject is receiving study treatment.  
Short courses (<14 days) of corticosteroids (at dosages equivalent to prednisone ≤20  mg per day) 
for treatment of non-cancer-related medical reasons are permitted as is carfilzomib 
premedication as required.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
41 
Approved, Date: 5 September 2013  Proprietary and Confidential The use of sargramostim and platelet growth factors (eg, thrombopoietin) are prohibited. 
Erythropoietic growth factors (eg, erythropoietin) and hematopoietic growth factors 
(filgrastim and pegfilgrastim) are prohibited during Phase I Dose Escalation, Cycle 1, but are 
allowed as indicated in Section 6.1. 
The Sponsor should be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered. 
6.3. Medications to be Used With Caution 
6.3.1. CYP Inhibiting/Inducing Drugs 
Concomitant use of ibrutinib and drugs that strongly or moderately inhibit CYP3A4/5 can 
increase ibrutinib exposure. 
Co-administration of ketoconazole, a strong CYP3A4/5 inhibitor, in 18 healthy subjects, 
increased dose normalized exposure C max and AUC 0-last of ibrutinib by 29- and 24 -fold, 
respectively. However, in 38 patients treated with mild and/or moderate CYP3A4/5 inhibitors, 
the ibrutinib exposure (AUC) was ≤2 -fold the upper limit of the range of 76 patients not treated 
concomitantly with CYP3A4/5 inhibitors. Clinical safety data in patients treated with weak, 
moderate, or strong CYP3A4/5 inhibitors did not reveal meaningful increases in toxicities. Since 
no exposure data are available in subjects treated concomitantly with strong inhibitors of 
CYP3A4/5 (eg, ketoconazole, indinavir, nelfinavir, ritonavir, saquinavir, clarithromycin, 
telithromycin, itraconazole, and nefazadone), these inhibitors should be avoided. If a strong 
CYP3A4/5 inhibitor must be used, consider reducing the ibrutinib dose to 140 mg or withhold 
treatment temporarily. Subjects should be monitored for signs of ibrutinib toxicity. If the benefit 
outweighs the risk and a moderate CYP3A4/5 inhibitor must be used, monitor subject for 
toxicity and follow dose modification guidance as needed. Avoid grapefruit and Seville oranges 
during ibrutinib treatment, as these contain moderate inhibitors of CYP3A4/5 (see Section 5.5.2 ). 
Co-administration of ibrutinib with strong CYP3A4/5 inducers (such as carbamazepine and 
rifampin) may decrease ibrutinib plasma concentrations and should be avoided.  
For subjects who must take strong or moderate CYP3A4/5 inhibitors while on treatment with 
ibrutinib, additional PK blood samples during concomitant use of ibrutinib with strong or 
moderate CYP3A4/5 inhibitors will be requested for ibrutinib exposure confirmation 
(see Section 7.5.2 ). 
A list of common CYP3A4/5 inhibitors or inducers is provided in Appendix 7 ; a comprehensive 
list of inhibitors, inducers, and substrates may be found at http://medicine.iupui.edu/clinpharm/ 
ddis/table.aspx. This website is continually revised and should be checked frequently for 
updates. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
42 
Approved, Date: 5 September 2013  Proprietary and Confidential 6.3.2. Concomitant Use of QT Prolonging Agents 
Any medications known to cause QT prolongation should be used with caution; periodic 
monitoring with electrocardiograms and electrolytes should be considered and if needed, 
the Medical Monitor may be contacted. 
6.3.3. Concomitant Use of Antiplatelet Agents and Anticoagulants 
There have been reports of hemorrhagic events in subjects treated with ibrutinib. These include 
minor hemorrhagic events like contusion, epistaxis and petechiae; and major hemorrhagic events 
including gastrointestinal, intracranial hemorrhage and hematuria. It is not clear whether or not 
these events are attributable to ibrutinib, however, it is possible that treatment with the ibrutinib 
could increase the risk of bruising or bleeding. 
Warfarin or vitamin K antagonists should not be administered concomitantly with ibrutinib . 
Ibrutinib should be used with caution in subjects requiring other anticoagulants or medications 
that inhibit platelet function. Subjects receiving antiplatelet agents in conjunction with ibrutinib 
should be observed closely for any signs of bleeding or bruising, and ibrutinib  should be 
withheld in the event of any bleeding events. Supplements such as fish oil and vitamin E 
preparations should be avoided. Please refer to the current IB for additional information. 
6.4. Guidelines for Ibrutinib Management with Surgeries or Procedures 
Ibrutinib may increase risk of bleeding with invasive procedures or surgery. The following 
guidance should be applied during the perioperative period for subjects who require surgical 
intervention or an invasive procedure while receiving ibrutinib:   
 For any surgery or invasive procedure requiring sutures or staples for closure, ibrutinib 
should be held at least 7 days prior to the intervention and should be held at least 7 days 
after the procedure and restarted at the discretion of the investigator when the surgical site is 
reasonably healed without serosanguineous drainage or the need for drainage tubes.  
 For minor procedures (such as a central line placement, needle biopsy, thoracentesis, 
or paracentesis) ibrutinib should be held for at least 3 days prior to the procedure and should 
not be restarted for at least 3 days after the procedure. For bone marrow biopsies that are 
performed while the subject is on ibrutinib, it is not necessary to hold ibrutinib for these 
procedures.  
 For emergency procedures, ibrutinib should be held after the procedure until the surgical site 
is reasonably healed, for at least 7 days after the urgent surgical procedure.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
43 
Approved, Date: 5 September 2013  Proprietary and Confidential 7. STUDY EVALUATIONS 
7.1. Screening / Administrative 
All routine laboratory and clinical screening assessments must be performed within 28 days 
before the first administration of study drug (Cycle 1 , Day 1), unless otherwise indicated in 
Section 8.2 (longer windows allowed for baseline radiologic assessments). Screening tests may 
be used at baseline if done within 7 days of Cycle 1, Day 1. 
Some laboratory assessments may be performed at a Central Laboratory. Please review the 
Central Laboratory Manual for details. 
7.1.1. Informed Consent  
The subject must read, understand, and sign the Institutional Review Board/Research Ethics 
Board/Independent Ethics Committee (IRB/REB/IEC) approved informed consent form (ICF) 
confirming his or her willingness to participate in this study before any study-specific screening 
procedures are performed. Subjects must also grant permission to use protected health 
information per the Health Insurance Portability and Accountability Act (HIPAA). In addition, 
subjects must sign all approved ICF amendments per the site IRB/REB/IEC guidelines during 
the course of the study.  
7.1.2. Confirmation of Eligibility 
All necessary procedures and evaluations must be performed to document that the subject meets 
all of the inclusion criteria and none of the exclusion criteria ( Section 4). Measurable disease 
documented by SPEP, UPEP and/or SFLC is required prior to enrollment. Multiple myeloma 
diagnosis will be confirmed as well as the stage at original diagnosis and current disease status 
(relapsed or relapsed and refractory) will be documented if all requisite clinical results are 
available.  
7.1.3. Medical History and Demographics 
The subject’s complete history including concurr ent medical signs and symptoms will be 
collected and recorded.  
Disease history, including the date of initial diagnosis, documentation of relapsed/refractory 
disease, prior anticancer treatments with best responses and date of progression to these 
treatments will be collected and recorded.  
7.1.4. Prior and Concomitant Medications  
All medications from 14 days before Cycle 1, Day 1 through 30 days after the last dose of study 
treatment will be documented. After a subject discontinues study treatment, receipt of all 
subsequent anticancer therapies will be collected until death, subject withdrawal of full consent , 
loss to follow-up, or study termination by Sponsor, whichever comes first. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
44 
Approved, Date: 5 September 2013  Proprietary and Confidential 7.1.5. Adverse Events 
The accepted regulatory definition for an adverse event is provided in Section 11.1. All medical 
occurrences that meet the adverse event definition must be recorded from the time the ICF is 
signed until 30 days after the last dose of study treatment. Laboratory abnormalities designated 
clinically significant by the Investigator will also be recorded as adverse events. Additional 
important requirements for adverse event and serious adverse event reporting are explained in 
Section 11.2. 
7.2. Study Assessments 
7.2.1. Physical Examination, Height, and Weight 
The Screening and End of Treatment physical examination will include, at a minimum, 
the general appearance of the subject, height (screening only) and weight, and examination of the 
skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, 
nervous system, and lymphatic system. 
A limited symptom-directed physical examination is required at Day 1 of each cycle, 
Suspected Disease Progression visits and Follow-up visits.  
7.2.2. Eastern Cooperative Oncology Group (ECOG) Performance Status 
The ECOG performance index is provided in Appendix 2 . 
7.2.3. Vital Signs 
Vital signs will include blood pressure, heart rate, respiratory rate, and body temperature and will 
be assessed after the subject has been resting in the sitting position for at least 3 minutes.  
7.2.4. Electrocardiogram 
A 12-lead electrocardiogram (ECG) will be performed at Screening and Day 1 of Cycle 2 for all 
subjects. Subjects should rest in a supine position for at least 5 minutes before ECG collection 
and should refrain from talking or moving arms or legs. Abnormalities noted at Screening should 
be included in the medical history.  
Additional 12-lead ECGs may be performed at any time during the study, as determined 
necessary by the investigator.  
7.2.5. Echocardiogram  (ECHO) 
An ECHO will be performed at Screening on all subjects to assess cardiac function and confirm 
eligibility.  ECHO is the preferred method of evaluation; multiple gated acquisition scan 
(MUGA) is acceptable if ECHO is not available. Abnormalities noted at Screening should be 
included in the medical history. 
Additional evaluations may be performed at any time during the study, as determined necessary 
by the investigator.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
45 
Approved, Date: 5 September 2013  Proprietary and Confidential 7.3. Efficacy Assessmen ts 
Efficacy evaluations will be conducted at the beginning of each cycle. Response assessments will 
be made using the IMWG response criteria ( Appendix 3). In Phase 1 assessments will be 
performed at a Local Laboratory, in Phase 2b assessments will be sent to a Central Laboratory.  
All screening, Cycle 1 Day 1 and complete response (CR) efficacy assessments will be evaluated 
and will include quantitative immunoglobulins, serum and urine electrophoresis, serum and urine 
immunofixation, and serum free light chain assay.  
After the determination of measurable disease at Cycle 1 Day 1 assessment, only the parameters 
that qualify for response assessment will be measured; 
 If SPEP and UPEP both meet criteria both will be performed at each cycle 
 If only SPEP meets criteria only SPEP will be required at each cycle 
 If only UPEP meets criteria only UPEP will be required at each cycle 
 If neither SPEP or UPEP meet criteria, only S FLC assay  will be required at each cycle 
 At the investigators discretion additional evaluations may be performed but they are not 
to be used for response assessment. 
If at any time CR is suspected, all assessments including serum and urine must be performed as 
per the IMWG response assessment guidelines. 
7.3.1. Serum and Urine Protein Electrophoresis  
Samples will be collected at Screening, and prior to study drug administration on Day 1 of 
Cycle 1. Additional sample collection per Section 7.3 .  
7.3.2. Serum Free Light Chain Assay 
Samples will be collected at Screening, and prior to study drug administration on Day 1 of 
Cycle 1. Additional sample collection per Section 7.3 .  
7.3.3. Serum and Urine Immunofixation 
Samples will be collected at Screening. Repetitive serum and urine immunofixation on study is 
only required to confirm CR (conducted on the first observation that the subject has no 
detectable M-protein) and then repeated on Day 1 of each cycle until disease progression.  
7.3.4. Quantitative Serum Immunoglobulins (IgA, IgG and IgM) 
Samples will be collected at Screening, prior to study drug administration on Day 1 of each 
cycle, End of Treatment, Suspected Disease Progression and Follow-up visits.  
7.3.5. C- Reactive Protein and Serum β2 -microglobulin 
Samples will be collected at Cycle 1 , Day 1 only.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
46 
Approved, Date: 5 September 2013  Proprietary and Confidential 7.3.6. Bone Radiological Assessment 
A radiologic skeletal survey for evaluation of bone lesions is required. Bone radiological 
assessment includes a lateral radiograph of the skull, antero-posterior and lateral views of the 
spine, and antero-posterior views of the pelvis, ribs, femora, and humeri. Bone radiological 
assessments are to be done within 50 days prior to the first administration of study drug . 
Magnetic resonance imaging and computed tomography scans are to be performed as clinically 
indicated. If evidence of plasmacytoma noted on radiographic imaging at screening, subsequent 
response assessments must include follow-up studies as appropriate. 
Additional radiologic skeletal surveys may be performed at any time during the study, 
as determined necessary by the investigator.  
7.3.7. Bone Marrow Aspirate/Biopsy  
A unilateral bone marrow aspirate/biopsy will be obtained at Screening and submitted to a Local 
Laboratory to document bone marrow involvement and evaluate for morphology.  
Phase 1 :  Bone marrow aspirate is to be evaluated at a Local Laboratory by fluorescent in situ 
hybridization (FISH) to allow for identification of t(4;14), t(11;14) and del 17p. If the test has 
been performed within 90 days, it does not need to be repeated .  
Phase 2b :  Bone marrow aspirate to be submitted to a Central Laboratory for FISH. 
Phase 1 and selected Phase 2b sites : An additional 6  mL of bone marrow aspirate will be 
collected for biomarker assessments ( Section 7.6).  
If the subjec t’s physical examination findings, laboratory evaluations, and radiographic 
evaluations suggest that CR has been achieved, an additional bone marrow aspirate/biopsy 
should be obtained to confirm the CR. Bone marrow for confirmation of CR should include 
staining for CD138 and κ/λ mono -clonality by immunohistochemistry or immunofluorescence.  
7.3.8. Survival and Subsequent Anticancer Therapies 
Survival 
After disease progression, subjects will be contacted to assess survival status every 
12 weeks (± 14 days) from End of Treatment Visit until death, subject withdrawal of full 
consent, or loss to follow-up  until 2 years after the last subject is randomized or study 
termination by Sponsor, whichever comes first. At the time of the analysis and at study closure, 
a survival sweep will be conducted. All subjects who are not known to have died or withdrawn 
consent prior to survival sweep will be contacted at that time. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
47 
Approved, Date: 5 September 2013  Proprietary and Confidential Subsequent Anticancer Therapies 
After study treatment is complete, the following information on subsequent anticancer therapies 
will be collected every 12 weeks (± 14  days) from End of Treatment Visit until death, subject 
withdrawal of full consent, loss to follow-up  until 2 years after the last subject is randomized or 
study termination by Sponsor, whichever comes first: 
 Receipt of subsequent anticancer therapies 
 Indication for initiation of subsequent anticancer therapy  
 Response to subsequent anticancer therapies  
7.3.9. Patient-Reported Outcome (PRO) Assessment (Phase 2b only)  
The PRO instruments, EQ-5D and EORTC QLQ -MY20, will be administered in this study on 
Day 1 of Cycle 1 and every other cycle thereafter (eg, Cycle 3, Cycle 5, etc.), as well as at 
Suspected Disease Progression and Follow-up visits. It is preferable that questionnaires be 
administered at the beginning of each visit prior to any procedures or physician assessments 
according to the Schedule of Assessments ( Appendix 1 ).  
The EQ-5D is a standardized instrument for use as a measure of health outcome consisting of a 
5-item questio nnaire and a “thermometer” visual analogue scale ranging from  0 (worst 
imaginable health state) to 100 (best imaginable health state). The scores for the 5 separate 
questionnaires are categorical and should not be analyzed as cardinal numbers. The scores f or the 
5 dimensions are normalized to a single utility score ranging from 0 to 1, representing the 
general health status of the individual. The United Kingdom weights will be used to generate 
patient utilities from the 5 dimensions of the EQ-5D in this study  (Appendix 8 ).  
The EORTC QLQ-MY20 ( Appendix 9 ) is a 20-item questionnaire to assess the quality of life in 
multiple myeloma patients.  
7.4. Clinical Laboratory Assessments  
7.4.1. Hematology 
Hematology parameters will include a complete blood count : white blood cells, red blood cells, 
hemoglobin, hematocrit, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils 
and bands (if reported).  
7.4.2. Serum Chemistry 
Serum chemistry parameters will include sodium, potassium, chloride, blood urea nitrogen 
(BUN), creatinine, glucose, calcium, total protein, albumin, AST, ALT, alkaline phosphatase, 
total bilirubin, lactate dehydrogenase (LDH), phosphate, and uric acid.     
7.4.3. Coagulation Studies 
Measurement of prothrombin time (PT)/INR, and activated partial thromboplastin time (aPTT) 
will be performed at Screening using a local laboratory.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
48 
Approved, Date: 5 September 2013  Proprietary and Confidential 7.4.4. Pregnancy Test 
Pregnancy tests (urine or serum) are required at Screening only for women of childbearing 
potential. If positive, pregnancy must be ruled out by ultrasound to be eligible. This test may be 
performed more frequently if required by local regulatory authorities. 
7.4.5. Hepatitis Serologies 
Hepatitis serologies include Hepatitis C antibody, Hepatitis B surface antigen, Hepatitis B 
surface antibody, and Hepatitis B core antibody and will be evaluated by local laboratory at 
Screening. Hepatitis B surface antigen must be confirmed negative prior to enrollment (Phase 1) 
or randomization (Phase 2b). If Hepatitis B core antibody is positive, then Hepatitis B 
polymerase chain reaction (PCR) to quantitate Hepatitis B DNA must be performed. DNA PCR 
needs to be confirmed negative (<29 U) prior to enrollment (Phase 1) or randomization (Phase 
2b) in subjects who are Hepatitis B core antibody positive . Subjects who are hepatitis C PCR 
positive will be excluded. 
7.4.6. Thyroid-stimulating Hormone (TSH) 
Sample for TSH will be drawn prior to study drug administration on Day 1 of Cycle 1. If the 
TSH result is abnormal, samples for free T4, T3, anti-thyroid peroxidase antibodies and 
anti-thyroglobulin antibodies testing will be drawn and an endocrinology consult should be 
considered when appropriate. 
7.5. Pharmacokinetics and Pharmacodynamics (Phase 1 and Selected 
Phase 2b Sites) 
PK and pharmacodynamic sample collection will be conducted on all subjects in Phase 1 and 
may be continued at selected Phase 2b sites. If PK collection continues in Phase 2b, 
Pharmacyclics will inform selected sites when additional samples are no longer required.  
7.5.1. Pharmacokinetics and Pharmacodynamics Sample Collection 
During treatment with ibrutinib and carfilzomib, venous blood samples will be collected from all 
subjects for the determination of plasma concentrations of ibrutinib and its metabolite, PCI-452 27, 
at time points specified in Table 7  below : 
Table 7: Pharmacokinetics and Pharmacodynamics Sample Collection Schedule 
Cycle  Day Predoseb Time after ibrutinib dosing 
1 hour  
(1h ± 15 mi n) 2 hour  
(2 h ± 30 min) 4 hour  
(4 h ± 30 min)  6 hour  
(5 h to 8h)  
1 1 Y     
1 8 X,Y X X X,Y X 
1 9a  X,Y     
2  1  X,Y X X X,Y X 
2  2a X,Y     
X = Pharmacokinetics timepoint  
Y = Pharmacodynamics timepoint  
a  Samples should be collected approximately 2 4 (± 2 h) hour after previous study dose  of ibrutinib   
b  Samples should be collected approximately 30 -60 minutes before study dose  of ibrutinib  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
49 
Approved, Date: 5 September 2013  Proprietary and Confidential On the day of the sampling visit, the subject will not take a dose of ibrutinib before arrival at the 
clinic. Study drug intake will be observed by clinic staff. Ibrutinib will be administered 
0-60 minutes after the end of the carfilzomib infusion. The time of the PK sample and the time of 
the ibrutinib dose will be recorded in the medical record and CRF for Days 8 and 9 of Cycle 1, 
and for Days 1 and 2 of Cycle 2, plus time for dose of ibrutinib on Day 28 of Cycle 1. 
Additionally record the time meals are taken before and after the dose of ibrutinib on Day 8 of 
Cycle 1 and Day 1 of Cycle 2. 
Pharmacodynamics will continue to be collected on Day 1 of Cycles 4, 6, 8, 10 and 12, 
Suspected Disease Progression and End of Treatment visits. 
7.5.2. Pharmacokinetics Sample Collection for Subject Treated with 
Concomitant CYP3A4/5 Inhibitors on Ibrutinib Treatment 
For subjects who must take strong or moderate CYP3A4/5 inhibitors while on treatment 
with ibrutinib, additional PK blood samples for evaluation of ibrutinib exposure is requested 
at the following scheduled visit after concomitant CYP3A4/5 inhibitor/inducer has started  and is 
still in use. PK samples will be collected at:      
 Pre-dose (Sample should be obtained approximately 24 (± 2 h) hours post the previous 
study dose and approximately 30-60 minutes before study dose of ibrutinib 
 1 hour ± 15 min 
 2 hours ± 30 min 
 4 hours ± 30 min 
7.5.3. Pharmacokinetics Analytical Procedures 
Plasma samples will be analyzed to determine concentrations of ibrutinib and the PCI-45227 
metabolite using validated, specific, and sensitive liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) methods. Other potential ibrutinib metabolites may be explored . 
Carfilzomib concentrations will not be determined in this study. 
7.5.4. Pharmacokinetics Parameters 
Bioanalytical data from this study will be used in noncompartmental PK analysis and also may 
be combined with data from other studies performed with ibrutinib in subjects with hematologic 
malignancies as part of a population PK analysis using nonlinear mixed effects models to 
provide estimates of PK parameters (eg, oral clearance) or metrics of systemic exposure 
(eg, AUC) . Model-derived plasma concentrations or metrics of exposure parameters 
(eg, minimum concentration [C min] or AUC) may be further analyzed to explore PK correlation 
between ibrutinib exposure and relevant clinical or biomarker information. 
For subjects who received CYP3A4/5 inhibitors, as data permits, a comparison of ibrutinib and 
PCI-45227 plasma concentrations after ibrutinib administration alone and in combination with 
CYP3A4/5 inhibitors will be explored. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
50 
Approved, Date: 5 September 2013  Proprietary and Confidential 7.5.5. Pharmacodynamics Analytical Procedures 
Peripheral blood mononuclear cell (PBMC) cells will be isolated from whole blood samples 
before and after ibrutinib treatments. After the complete collection of PBMCs from the various 
time points, equal protein from each sample will be labeled with a biotinylated derivative of 
ibrutinib (probe), and subjected to probe enzyme-linked immuno-sorbent (ELISA) assays that 
determine the occupancy of probe in each sample. B TK occupancy is defined as (100% - probe 
occupancy %). 
7.5.6. Pharmacodynamics Parameters 
Baseline BTK by the ELISA assay described above will be determined prior to the first dose of 
carfilzomib (D1) and prior to the first dose of ibrutinib (D8) in order to detect any possible effect 
of carfilzomib on BTK baseline levels. BTK occupancy by ibrutinib after the first ibrutinib dose 
and at steady-state will be calculated as compared to both the D1 (pre-carfilzomib) and D8 
(pre-dose of ibrutinib) BTK occupancy will be compared to that achieved in other studies of 
ibrutinib and is expected to be ≥90%. 
7.6. Biomarkers (Phase 1 and Selected Phase 2b Sites) 
7.6.1. Genetic and Molecular Prognostic Markers  
Cytokines, chemokines, bone metabolism biomarkers, and exploratory investigations of 
predictive biomarkers and mechanisms of resistance will be tested in both blood and urine . 
Samples will be collected at the same time as pharmacodynamic samples (see Section 7.5.1 ) on 
Days 1, 8 and 9 of Cycle 1, Days 1 and 2 of Cycle 2 and on Day 1 of Cycles 4, 6, 8, 10 and 12, 
Suspected Disease Progression and End of Treatment visits. Testing will include IL-6, SDF-1, 
RANKL,  MIP -1α and other secreted proteins. Testing will be performed at a central laboratory . 
Samples will be collected from all Phase 1 subjects. Sample collection(s) may continue at 
selected sites in Phase 2b. 
Bone marrow aspirate/biopsy will be collected at Screening, Cycle 2 , Day 15  (± 2 weeks) and at 
disease progression. Additional bone marrow aspirate/biopsy are required at any time to confirm 
a CR if the subject has no detectable monoclonal protein and if clinical indicated (eg,  prolonged 
cytopenia or progression). These samples will be utilized or maintained to evaluate potential 
biomarkers related to disease response and to investigate potential mechanisms of treatment 
resistance. These samples may later be characterized by technologies such as gene expression 
profiling, mutational analysis by sequencing, and intracellular signaling pathway analysis. 
Inhibition of B TK and other related kinases may also be explored. These efforts may identify 
genes and pathways associated with primary or later development of resistance to ibrutinib and 
potentially identify biomarkers that could assist with future development of this compound.  
7.7. Sample Collection and Handling 
The actual dates and times of sample collection must be recorded in source documents for 
transcription to the CRF or laboratory requisition form. Refer to the Schedule of Assessments 
(Appendix 1 ) for the timing and frequency of all sample collections.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
51 
Approved, Date: 5 September 2013  Proprietary and Confidential Instructions for the collection, handling, and shipment of samples are found in the laboratory 
manual that will be provided for sample collection and handling. 
8. Study Procedures 
8.1. Overview 
The study is divided into a Screening Phase, a Treatment Phase, and a Follow-up Phase. 
The Schedule of Assessments Table ( Appendix 1 ) summarizes the frequency and timing of 
efficacy, PRO, PK, biomarker, and safety measurements applicable to this study. The PK 
assessments are detailed in the PK Sample Collection Schedule ( Table 7 ). 
It is preferable that all visit-specific PRO assessments (Phase 2b only) during a visit should be 
conducted before any tests, procedures, or other consultations for that visit to prevent influencing 
subject perceptions. Adverse event information will be collected using the NCI CTCAE 
Version 4.03.  
8.2. Screening Phase 
Screening procedures will be performed up to 28 days before Cycle 1, Day 1, unless otherwise 
specified.  All subjects must first read, understand, and sign the IRB/REB/IEC-approved ICF 
before any study-specific screening procedures are performed. All study tests and procedures 
should be performed at the study center at which the subject was enrolled and will be receiving 
treatment. After signing the ICF, screening, and being deemed eligible for entry, subjects will be 
enrolled in the study.  
Screening Visit 
The following procedures will be performed at the Screening Visit within 28 days prior to 
treatment unless otherwise noted: 
 Informed consent 
 Review of eligibility criteria 
 Medical history and demographics 
 Prior medications (including over-the-counter drugs, vitamins and herbs) 
 Physical examination, including weight and height  
 Evaluation of ECOG performance status 
 Vital signs 
 12-lead ECG 
 Echocardiogram 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
52 
Approved, Date: 5 September 2013  Proprietary and Confidential  Laboratory Tests (Section 7.4): 
o Hematology within 7 days prior to enrollment (Phase 1) or randomization (Phase 2b) 
o Serum chemistry within 7 days prior to  enrollment (Phase 1) or randomization (Phase 2b)  
o Coagulation studies 
o Hepatitis serologies 
o Pregnancy test for women of childbearing potential (urine or serum), within 3 days prior 
to enrollment (Phase 1) or randomization (Phase 2b) 
o Serum and urine protein electrophoresis (SPEP and UPEP) 
o Serum free light chain assay (SFLC) 
o Serum imm unofixation 
o Quantitative serum immunoglobulins (IgA, IgG, and IgM) 
 X-ray skeletal survey (may be performed within 50 days prior to C1D1) 
 Bone marrow aspirate/biopsy (Section 7.3.7 ) 
 Magnetic resonance imaging ( MRI), computed tomography ( CT) or p ositron emission 
tomography ( PET)/CT in those with known or suspected plasmacytoma  
8.3. Treatment Phase 
The Treatment Phase must begin within 7 days of enrollment (Phase 1) or randomization 
(Phase 2b). If laboratory tests are required to be collected on Day 1  of Cycle 1, subject must 
continue to meet all eligibility criteria to begin treatment. 
After Cycle 1, pre-dose assessments may be performed up to 2 days prior to Day 1 of a cycle . 
Pre-dose assessments for Days 8 and 15 may be performed 1 day prior to day of treatment.  
If Carfilzomib dosing requires a schedule adjustment for administrative reasons of more than 
±1 day contact the Medical Monitor to discuss. 
Day 1 administration of carfilzomib must be at least 11 days from the last cycle carfilzomib 
administration. 
8.3.1. Cycle 1 
8.3.1.1. Cycle 1, Day 1 
Pre-Dose  
The following procedures will be performed prior to dosing Cycle 1 Day 1 v isit unless otherwise 
noted. Screening tests may be used at baseline  if done within 7  days of Cycle 1, Day 1 where 
indicated.   
 PRO assessments (Phase 2b only) – preferable to be performed prior to any assessments 
 Laboratory Tests:  
o Hematology and chemistry to be redrawn if not collected within 7 days of C1D1 
o TSH, C-Reactive protein, and β2-microglobulin 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
53 
Approved, Date: 5 September 2013  Proprietary and Confidential o SPEP, UPEP, SFLC, quantitative serum immunoglobulins 
 Phase 1, and selected Phase 2b sites - Central Laboratory Manual for Details:  
o Blood sample collection for pharmacodynamics 
o Serum and Urine Biomarkers (requires 12 hours fasting)  
 Adverse events and concomitant medications (if applicable) 
 Symptom-directed physical examination, including weight  
 ECOG 
 Vital signs 
Dosing and Post-Dose   
 Hydration with 250 mL to 500 mL 0.9% NS or other appropriate fluid  
 Administration of dexamethasone pre-medication and carfilzomib  
 Additional 250 mL to 500 mL of IV fluids if clinically indicated 
8.3.1.2. Cycle 1, Day 2  
Pre-Dose  
 Laboratory Test : chemistry 
 Adverse events and concomitant medications 
Dosing and Post-Dose 
 Hydration with 250 mL to 500 mL 0.9% NS or other appropriate fluid  
 Administration of dexamethasone pre-medication and carfilzomib  
 Additional 250 mL to 500 mL of IV fluids if clinically indicated 
8.3.1.3. Cycle 1, Day 8 
Pre-Dose  
 Laboratory Tests: hematology and chemistry 
 Adverse events and concomitant medications 
 Symptom-directed physical examination, including weight 
 Vital signs 
 Phase 1, selected Phase 2b sites :  
o Record time of last meal prior to administration of study drug  
o Central Laboratory Tests: Blood sample collection for PK and pharmacodynamics 
30-60 minutes before study drug  dose 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
54 
Approved, Date: 5 September 2013  Proprietary and Confidential Dosing and Post-Dose 
 Hydration with 250 mL to 500 mL 0.9% NS or other appropriate fluid  
 Administration of dexamethasone pre-medication and carfilzomib  
 Additional 250 mL to 500 mL of IV fluids if clinically indicated 
 Phase 1, selected Phase 2b sites :  
o Administration of study drug 0-60 minutes post the end of carfilzomib infusion   
o Record time of meal following administration of study drug  
o Central Laboratory Tests : Blood sample collection for PK / pharmacodynamics 
(times from study drug dose): 
1 hour (window 45 to 75 minutes) after dosing (for PK only) 
2 hours (window 1.5 to 2.5 hours) after dosing (for PK only) 
4 hours (window 3.5 to 4.5 hours) after dosing (for PK and pharmacodynamics) 
6 hours (window 5 to 8 hours) after dosing (for PK only) 
 Phase 2 b non-PK only: Administration of study drug.  
Subject will self-administer once daily beginning Cycle 1 Day 8 . A dose diary will be 
provided and subject is to return any unused study drug and diary at day 1 of the next cycle. 
8.3.1.4. Cycle 1, Day 9 
Pre-Dose  
 Laboratory Test : chemistry 
 Adverse events and concomitant medications 
Dosing and Post-Dose 
 Hydration with 250 mL to 500 mL 0.9% NS or other appropriate fluid  
 Administration of dexamethasone pre-medication and carfilzomib  
 Additional 250 mL to 500 mL of IV fluids if clinically indicated 
 Phase 1 PK, selected Phase 2b sites :  
o Blood sample collection for PK and pharmacodynamics 24 hours (±2 hours) after the first 
dose of study drug and 30 -60 minutes prior to second dose  
o Administration of study drug 0-60 minutes post the end of carfilzomib infusion   
o A dose diary will be provided and subject is to return any unused study drug and diary at 
day 1 of the next cycle  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
55 
Approved, Date: 5 September 2013  Proprietary and Confidential 8.3.1.5. Cycle 1, Day 15 
Pre-Dose  
 Laboratory Tests: hematology and chemistry 
 Adverse events and concomitant medications  
 Symptom-directed physical examination, including weight 
 Vital signs 
Dosing and Post-Dose 
 Hydration with 250 mL to 500 mL 0.9% NS or other appropriate fluid  
 Administration of dexamethasone pre-medication and carfilzomib  
 Additional 250 mL to 500 mL of IV fluids if clinically indicated 
8.3.1.6. Cycle 1, Day 16 
Pre-Dose  
 Adverse events and concomitant medications 
Dosing and Post-Dose 
 Hydration with 250 mL to 500 mL 0.9% NS or other appropriate fluid  
 Administration of dexamethasone pre-medication and carfilzomib  
 Additional 250 mL to 500 mL of IV fluids if clinically indicated 
8.3.2. Cycles 2 -3  
8.3.2.1. Cycles 2 -3, Day 1 
Pre-Dose  
 PRO assessments (Phase 2b only) – Cycle 3 preferable to be performed prior to any 
assessments 
 Laboratory Tests: hematology and chemis try 
 Efficacy Assessments:  
o SPEP, UPEP, SFLC, and quantitative serum immunoglobulins (Section 7.3)  
o Only to confirm CR: serum and urine immunofixation, then repeated every cycle until 
disease progression 
 Adverse events and concomitant medications 
 Collect subject diary and any remaining study drug from last cycle 
 Symptom-directed physical examination, including weight 
 ECOG 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
56 
Approved, Date: 5 September 2013  Proprietary and Confidential  Vital signs 
 ECG (Cycle 2 only) 
 Phase 1, selected Phase 2b sites : (Cycle 2) 
o Record time of last study drug  dose (C ycle 1  Day 28)  
o Record time of last meal prior to administration of study drug  
o Central Laboratory Tests:   
- Blood sample collection for PK / pharmacodynamics 30-60 minutes before study 
drug dose and 24 hours (±2 hours) after the previous dose (Cycle 1  Day 28)   
- Serum and Urine Biomarkers (requires 12 hours fasting)   
Dosing and Post-Dose 
 Administration carfilzomib  
 Phase 1 , selected Phase 2b sites : (Cycle 2)  
o Administration of study drug 0-60 minutes post the end of carfilzomib infusion   
o Record time of meal following administration of study drug  
o Central Laboratory Tests: Blood sample collection for PK / pharmacodynamics 
(times from study drug dose): 
- 1 hours (window 45 to 75 minutes) after dosing (for PK only) 
- 2 hours (window 1.5 to 2.5 hours) after dosing (for PK only) 
- 4 hours (window 3.5 to 4.5 hours) after dosing (for PK and pharmacodynamics) 
- 6 hours (window 5 to 8 hours) after dosing (for PK only) 
8.3.2.2. Cycles 2-3, Day 2 
Pre-Dose  
 Adverse events and concomitant medications 
Dosing and Post-Dose 
 Administration of carfilzomib  
 Phase 1, selected Phase 2b sites: (Cycle 2)  
o Blood sample collection for PK and pharmacodynamics 24 hours (±2 hours) after the first 
dose of study drug and 30 -60 minutes prior to second dose.  
8.3.2.3. Cycles 2-3, Day 8 
Pre-Dose  
 Laboratory Test: hematology  
 Adverse events and concomitant medications 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
57 
Approved, Date: 5 September 2013  Proprietary and Confidential Dosing and Post-Dose 
 Administration of carfilzomib  
8.3.2.4. Cycles 2- 3, Day 15 
Pre-Dose  
 Laboratory Test: hematology  
 Adverse events and concomitant medications 
 Symptom-directed physical examination, including weight 
 Vital signs 
 Phase 1, selected Phase 2b sites : Cycle 2 Day 15 (±2 weeks) Bone Marrow Aspirate 
Biomarker see Central Laboratory Manual for details  
Dosing and Post-Dose 
 Administration of carfilzomib  
8.3.2.5. Cycles 2-3, Days 9  and 16 
Pre-Dose  
 Adverse events and concomitant medications 
Dosing and Post-Dose 
 Administration of carfilzomib  
8.3.3. Cycle 4 (and subsequent cycles) 
8.3.3.1. Cycle 4 (and subsequent cycles), Day 1 
Pre-Dose  
 PRO assessments (Phase 2b only) – Cycles 5, 7, and every other Cycle preferable to be 
performed prior to any assessments 
 Laboratory Tests: hematology and chemis try 
 Efficacy Assessments:  
o SPEP, UPEP, SFLC, and quantitative serum immunoglobulins ( Section 7.3)    
o Only to confirm CR: serum and urine immunofixation, then repeated every cycle until 
disease progression 
 Central Laboratory Tests (Phase 1, selected Phase 2b sites ) – Cycles 4, 6, 9 and 12:  
o Blood sample collection for pharmacodynamics  
o Serum and Urine Biomarkers (requires 12 hours fasting)   
 Adverse events and concomitant medications 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
58 
Approved, Date: 5 September 2013  Proprietary and Confidential  Collect subject diary and any remaining study drug from last cycle 
 Symptom-directed physical examination, including weight 
 ECOG 
 Vital signs 
Dosing and Post-Dose 
 Administration of carfilzomib  
8.3.3.2. Cycle 4 (and  subsequent cycles), Days 2, 8, 9 and 16  
Pre-Dose  
 Laboratory Test: hematology (Day 8 only) 
 Adverse events and concomitant medications 
Dosing and Post-Dose 
 Administration of carfilzomib  
8.3.3.3. Cycle 4 (and subsequent cycles), Day 15  
Pre-Dose  
 Laboratory Test: hematology  
 Adverse events and concomitant medications 
Dosing and Post-Dose 
 Administration of carfilzomib  
8.3.4. Suspected Disease Progression Visit 
If, at any time, there is suspected disease progression, the following assessments should be 
performed to confirm progression if not already performed within 7 days: 
 PRO assessments (Phase 2b only) – preferable to be performed prior to any assessments 
 Laboratory Tests : hematology, chemistry  
 Efficacy Assessments:  
o SPEP, UPEP, SFLC, and quantitative serum immunoglobulins (Section 7.3) 
o Only to confirm CR: serum and urine immunofixation, then repeated every cycle until 
disease progression 
 Central Laboratory Tests (Phase 1, selected Phase 2b sites):  
o Blood sample collection pharmacodynamics 
o Serum and Urine Biomarkers (requires 12 hours fasting)   
o Bone Marrow Aspirate 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
59 
Approved, Date: 5 September 2013  Proprietary and Confidential  Adverse events and concomitant medications 
 Symptom-directed physical examination, including weight 
 ECOG 
 Vital signs 
8.3.5. End of Treatment Visit  
The End of Treatment Visit will be performed 30 days (±3 days) after the last administration of 
study drug. The following procedures will be performed: 
 PRO assessments (Phase 2b only) – preferable to be performed prior to any assessments 
 Laboratory Tests : hematology, chemistry  
 Efficacy Assessments:  
o SPEP, UPEP, SFLC, and quantitative serum immunoglobulins (Section 7.3) 
o Only to confirm CR: serum and urine immunofixation 
 Central Laboratory Tests (Phase 1, selected Phase 2b sites):  
o Blood sample collection pharmacodynamics 
o Serum and Urine Biomarkers (requires 12 hours fasting)   
 Adverse events and concomitant medications 
 Collect subject diary and any remaining study drug from last cycle 
 Symptom-directed physical examination, including weight 
 ECOG performance status 
 Vital signs 
8.4. Follow- Up Phase  
8.4.1. Follow-up Procedures (Until Disease Progression) 
For subjects who discontinue treatment for reasons other than disease progression, the following 
assessments will be performed every 12 weeks (±14 days) until disease progression or study 
closure, whichever is earlier: 
 PRO assessments (Phase 2b only) preferable to be performed prior to any assessments 
 Laboratory Tests : hematology, chemistry  
 Efficacy Assessments:  
o SPEP, UPEP, SFLC, and quantitative serum immunoglobulins (see Section 7.3).  
o Only to confirm CR: serum and urine immunofixation, then repeated every cycle until 
disease progression 
 Symptom-directed physical examination, including weight 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
60 
Approved, Date: 5 September 2013  Proprietary and Confidential  ECOG performance status 
 Vital signs and weight 
 Survival status and new anticancer therapy 
8.4.2. Survival Follow- up 
Once a subject progresses, receipt of subsequent anticancer therapy and survival status will be 
assessed every 12 weeks (± 14 days) until death, withdrawal of full consent by subject, lost to 
follow-up, or study terminated by Sponsor, whichever comes first.  
 Survival status and new anticancer therapy 
 PRO assessments (Phase 2b only) for the first 2 Survival Follow-Up assessments 
9. SUBJECT COMPLETION/WITHDRAWAL 
9.1. Discontinuation of Treatment  
Study drug and carfilzomib treatment will be discontinued in the event of any of the 
following events: 
 Confirmed progressive disease  
 Unacceptable toxicity  
 Withdrawal of consent for treatment by subject 
 Investigator decision (such as chronic noncompliance, significant protocol deviation, or best 
interest of the subject ) 
 Study termination by Sponsor 
 Subject becomes pregnant 
A subject who discontinues study treatment for reasons other than disease progression 
(eg, adverse event, Investigator decision) will undergo an  End of Treatment Visit and be 
followed for progression and survival.  
The Investigator should notify the Sponsor within 24 hours if a subject discontinues study 
treatment due to disease progression and should provide documentation of disease progression 
for review by the Sponsor ’s Medical Monitor . If a subject shows signs of disease progression on 
physical examination or laboratory assessment, the subject may continue study treatment until 
disease progression is confirmed. These subjects should stay in the study to be followed for 
survival.  
9.2. Withdrawal From the Study 
Withdrawal from study (including all follow-up) will occur under the following circumstances: 
 Withdrawal of consent for follow-up observation by the subject 
 Lost to follow-up  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
61 
Approved, Date: 5 September 2013  Proprietary and Confidential  Study termination by Sponsor 
 Death 
If a subject withdraws consent, it should be defined in the medical record whether the subject 
withdraws full consent to treatment and all further contact or if the subject withdraws partial 
consent, ie, they no longer wish to receive treatment, but will participate in the End of Treatment 
Visit and/or Long-term Follow -up. 
If a subject is lost to follow-up, every reasonable effort should be made by the study site 
personnel to contact the subject. The measures taken to follow up should be documented. 
10. STATISTICAL METHODS 
Statistical analysis will be performed by the Sponsor or under the authority of the Sponsor. 
A general description of the statistical methods for the analysis of the efficacy and safety data i s 
outlined below. Specific details will be provided in the Statistical Analysis Plan (SAP). 
10.1. Analysis Populations 
10.1.1. Intent- to-Treat Population  
Phase 2b:  The Intent- to-Treat (ITT) population is defined as all eligible subjects who are 
randomized into the Phase 2b study. Eligible subjects are defined as all subjects who signed the 
ICF, with a confirmed diagnosis of M M who had received  at least two prior lines of therapy and 
had documented relapse/refractory disease according to IMWG consensus criteria ( Appendix 3 ), 
and a baseline assessment. All efficacy analyses will be based on the ITT population.  
10.1.2. Response-evaluable Population 
Phase 1: The Response-evaluable population is defined as all eligible subjects who received at 
least 1 dose of study treatment,  regardless of whether there is a post-baseline disease assessment.  
10.1.3. Safety Population 
The safety population will consist of all enrolled subjects who received at least one dose of study 
treatment. The safety population will be used for the analysis of safety data and for the summary 
of subject disposition. 
10.1.4. Additional Analysis Populations 
Additional analysis population, which may be used in sensitivity analyses for primary and 
secondary efficacy objectives or analyses for exploratory objectives, will be defined in the 
statistical analysis plan. 
10.2. Sample Size Determination  
Phase 1: This is a standard 3+3 design to determine the maximally tolerated dose and toxicity 
profile of ibrutinib. Dose escalation will follow the 3+3 principles and up to 2 cohorts in the 
absence of dose-limiting toxicity will be expand up to 18 subjects per cohort. Expansion beyond 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
62 
Approved, Date: 5 September 2013  Proprietary and Confidential the 3+3 principles will allow a more accurate evaluation of the RP2D and preliminary efficacy 
results. This study is not powered for comparison of treatment arms. 
Phase 2b : A sample size of approximately 134  eligible subjects will be enrolled to observe 
101 PFS events in this study. For the calculation, the median PFS of 4 months for carfilzomib 
and placebo arm and the enrollment rate of 10 subjects per month were assumed. Assuming 
exponential survival distribution and 75% improvement in median PFS of the carfilzomib in 
combination with ibrutinib arm over carfilzomib and placebo arm (hazard ratio of 0.57), 
the study has at least 80% power to achieve a statistical significance level of 2.5% (1-sided). 
10.3. Subject Information 
The distribution of subjects for each of the analysis populations will be provided. The number of 
subjects enrolled by each investigative site and country, dosed, and discontinued will be 
summarized. Treatment discontinuation will be summarized according to the reasons for 
discontinuation. Demographic and baseline vital sign variables will be summarized. Baseline 
disease characteristics (documented in the source documents and CRF) will also be summarized.  
10.4. Efficacy Analyses 
10.4.1. Primary Endpoint 
The primary efficacy endpoint of Phase 2 b part of this study is PFS. A set of written rules and 
formulae will be developed based on the IMWG Response Criteria ( Appendix 3 ) to evaluate 
laboratory and other data for response and progression. Progression-free survival will be 
assessed on  all subjects in the ITT population. Subjects who had the event (ie, PD or death) after 
the start of subsequent anti-cancer therapy, or are progression-free and alive at the time of 
clinical cutoff, or have unknown status will be censored on the date of the last adequate disease 
assessment that is on or before the start of subsequent anti-cancer therapy. Sensitivity analysis 
will be performed for PFS without censoring at subsequent therapy if initiated prior to 
documented PD. 
10.4.2. Secondary Endpoints 
 The ORR will be asses sed according to the IMWG criteria and is defined as the proportion 
of subjects who achieve a PR or better over the course of the study. 
 The DOR is defined as the interval between the date of initial documentation of a response 
and the date of first documented evidence of progressive disease, death, or date of censoring 
if applicable, for responders only. Subjects who start new anticancer treatment before 
documentation of disease progression will be censored on the date of the last adequate 
disease assessment that is on or before the start date of new anticancer therapy. Responders 
are subjects in the ITT population who achieve PR or better according to the IMWG 
response criteria. Non responders (≤MR)  will be excluded from the analysis for DOR. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
63 
Approved, Date: 5 September 2013  Proprietary and Confidential  OS is defined as the time from date of randomization until date of death due to any cause. 
Subjects who are known to be alive or whose survival status is unknown will be censored at 
the date last known to be alive. Subjects  who are completely lost to follow-up for survival 
will be censored at randomization date. 
 TTP is defined as the time from the start of treatment until date of disease progression, 
with deaths from other causes than progression censored.  
10.4.3. Exploratory Endpoints 
Exploratory endpoints may include the following: 
 Duration of the clinical benefit rate including subjects with minimal response (MR) or better 
according to the IMWG. 
 Prognostic and predictive biomarkers and genetics relative to treatment outcomes.  
Phase 1:  
 PK and pharmacodynamics of ibrutinib (eg, BTK occupancy of drug, levels of secreted 
protein or bone biomarkers) in subjects with MM.  
Phase 2b:  
 TTNT  
 PROs and disease-related symptoms according to EORTC QLQ -MY20 and EQ-5D  
10.5. Analysis Methods 
10.5.1. Analysis for Phase 1 
The Phase 1 part of this study is an algorithm-based dose-escalation trial to find the MTD of 
ibrutinib in combination with carfilzomib and to characterize the most frequent adverse events 
and the DLTs. Dose-limiting toxicities will be evaluated and will include all adverse events 
experienced through Phase 1.  
The Phase 1 secondary efficacy endpoints are the ORR and DOR according to the IMWG 
response criteria. The point estimate of the rate and the corresponding exact binomial 95% 
confidence interval (CI) will be calculated. For DOR, the distribution of DOR as assessed will be 
provided using Kaplan-Meier estimates for responders. 
10.5.2. Primary Efficacy Analyses 
Progression free survival is defined as the time from the date of randomization to confirmed 
disease progression or death from any cause, whichever occurs first. Subjects who withdraw 
from the study or are considered lost to follow-up without prior documentation of disease 
progression will be censored on the date of the last adequate disease assessment. Subjects who 
had the event (ie, PD or death) after the start of a subsequent anti -cancer therapy, or are 
progression-free and alive at the time of clinical cut-off, or have unknown status will be censored 
on the date of the last adequate disease assessment that is on or before the start date of the 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
64 
Approved, Date: 5 September 2013  Proprietary and Confidential subsequent anti-cancer therapy. For subjects without an adequate post-baseline disease 
assessment, PFS will be censored on the date of randomization. Subjects who have 2 or more 
consecutive missing disease assessments immediately before PD or death will be censored for 
analysis of PFS at the time of last adequate disease assessment. Adequate disease assessment is 
defined according to the IMWG criteria. 
The analysis of PFS will be performed on Phase 2b subjects in the ITT  population to compare 
PFS for the 2 treatment arms using a stratified log-rank test stratified by BTZ refractory and 
double refractory. Distribution of PFS will be summarized for each treatment arm using the 
Kaplan-Meier estimate of median and its corresponding 95% CI. The estimate of the hazard ratio 
and its corresponding 95% CI will be computed using a Cox proportional hazards model 
stratified by the randomization stratification factors. A sensitivity analysis of PFS will be 
conducted without censoring at subsequent therapy if initiated prior to documented PD.  
10.5.3. Secondary Efficacy Analysis 
The secondary efficacy analyses for Phase 2b will based on the ITT  population . Overall response 
rate PR or better), and its 95% CI will be calculated using normal approximation to the binomial 
distribution.  
DOR will be analyzed for subjects who achieve response (PR or better) during the study, defined 
as the interval between the date of initial documentation of a response and the date of first 
documented evidence of progressive disease, death, or date of censoring if applicable. Subjects 
who had the event (ie, PD or death) after the start of subsequent therapy, are progression-free and 
alive at the time of clinical cutoff, or have unknown status will be censored at the last adequate 
disease assessment before the start of subsequent therapy. The distribution (median and 
Kaplan-Meier curves) of duration of response will be estimated using the Kaplan Meier method.  
The clinical response rate including MR or better will be analyzed similar to the analysis 
of ORR. 
OS will be analyzed in the ITT  population to compare OS for the 2 treatment arms using a 
stratified log -rank test, stratified by the refractory status to the last treatment regimen and the 
number of prior regimens. Distribution of OS will be summarized for each treatment arm using 
the Kaplan-Meier estimate of median and its corresponding 95% CI.  
10.5.4. Exploratory Efficacy Analysis 
The distribution of TTNT will be estimated using the Kaplan-Meier method. Analysis method 
will be detailed in the statistical analysis plan. 
Descriptive statistics for change in scores from baseline to each assessment time point will be 
summarized for the PROs and disease-related symptoms according to EORTC QLQ-MY20 and 
EQ-5D (Phase 2b only) 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
65 
Approved, Date: 5 September 2013  Proprietary and Confidential 10.5.5. Pharmacokinetic Analyses 
The plasma concentration data for ibrutinib and PCI-45227 at each timepoint will be summarized 
using descriptive statistics.  
Non-compartmental analysis of ibrutinib and PCI-45227 plasma concentration-time data will be 
performed using WinNonlin.  
Ibrutinib and PCI-45227 data will be listed for all subjects with available plasma concentrations. 
Subjects will be excluded from the PK analysis if their data do not allow for accurate assessment 
of the PK (eg, incomplete administration of the study agent; concentration data not sufficient for 
PK parameter calculation due to missing PK draws at multiple visits; or early discontinuation 
from the study). 
All concentrations below the lowest quantifiable concentration or missing data will be labeled as 
such in the concentration data presentation. Concentrations below the lowest quantifiable 
concentration will be treated as zero in the summary statistics and for the calculation of PK 
parameters. All subjects and samples excluded from the analysis will be clearly documented in 
the study report. 
Derived PK parameters may be subjected to further explore PK/pharmacodynamic correlation 
between exposure with relevant clinical or biomarker information. 
Bioanalytical data from this study may also be combined with data from other studies performed 
with ibrutinib in subjects with hematologic malignancies as part of a population PK analysis 
using nonlinear mixed effects models using NONMEM. Available subject characteristi cs 
(demographics, laboratory variables, genotypes, etc) will be tested as potential covariates 
affecting PK parameters. The results of the population PK analyses will be presented in a 
separate report. 
10.5.6. Pharmacodynamics  Analysis Plan 
The pharmacodynamics of ibrutinib binding to patient's cells is determined by a competitive 
probe assay which measures the amount of BTK that is not bound by ibrutinib. PCI-41025 is the 
“probe” that consists of ibrutinib linked to biotin via a long chain linker . Labeled probe wi ll 
produce a signal which allows for the detection of BTK not occupied by drug. PBMC of patients 
is isolated pre- and  post-treatment. Protein lysate is extracted from the PBMC and is 
subsequently analyzed on an ELISA platform by using MSD Electrochemiluminescent Detection 
Technology . Lysate is analyzed to achieve a signal for probe and total BTK. Total BTK is 
determined with an anti Human BTK antibody to capture all BTK, bound and unbound, in the 
lysate. The percentage of BTK occupied by ibrutinib can be determined by comparing signal of 
probe before and after treatments normalized to total BTK. BTK occupancy is further derived by 
subtracting normalized probe occupancy from 100 (BTK occupancy= 100- probe occupancy). 
 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
66 
Approved, Date: 5 September 2013  Proprietary and Confidential BTK occupancy will be listed for all subjects with samples that can be evaluated. Subjects will 
be excluded from the PD analysis if samples were not received within 36 hrs of shipment, or if 
samples are hemolysed, degraded, clotted or compromised during the shipments. In general, 
BTK occupancy will be summarized for each cohort using descriptive statistics (mean, median, 
standard error and range). 
10.5.7. Safety Analyses 
Analysis of safety data will be conducted on the safety population , which includes enrolled 
subjects who receive at least 1 dose of study drugs. The baseline value for safety assessment s 
will be defined as the last value on or before the day of the first dose of study drugs  if we do not 
specify . The safety analyses will be based on the monitoring of adverse events, survival status, 
ECOG performance status, vital signs measurements, and clinical laboratory results. 
The safety variables to be analyzed include adverse events, clinical laboratory test results 
(hematology and chemistry), physical examination findings, and vital signs measurements . 
Exposure to ibrutinib first do se and reasons for discontinuation from study treatment will be 
tabulated. In general, continuous variables will be summarized using descriptive statistics 
(n, mean, median, standard deviation, standard error and range). Categorical variables will be 
summarized using frequencies and percentages. No formal statistical testing is planned.  
Adverse Events 
Adverse event parameters to be evaluated are the type, incidence, and intensity of adverse 
events; the relationship of adverse events to ibrutinib; and the action taken with respect to 
ibrutinib treatment due to adverse events. 
The verbatim terms used in the CRF by Investigators to identify non-hematological adverse 
events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). 
Treatment-emergent adverse events are those adverse events occurring after the first dose of 
study drugs and within 30 days following the last dose of study drug; any adverse event that is 
considered study drug-related regardless of the start date of the event; or any adverse event that 
is present at baseline but worsens after the first administration of study drug in severity or is 
subsequently considered drug-related by the Investigator . All treatment-emergent adverse events 
will be included in the analysis. For each adverse event, the percentage of subjects who 
experience at least 1 occurrence of the given event will be summarized. The number and percent 
of subjects with treatment-emergent adverse events will be summarized according to intensity 
(NCI CTCAE, Version 4.03) and drug relationship as well as categorized by system organ class 
and preferred term. Summaries, listings, datasets, or subject narratives may be provided, 
as appropriate, for those subjects who die, who discontinue treatment due to an adverse event, 
or who experience a severe or a serious adverse event. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
67 
Approved, Date: 5 September 2013  Proprietary and Confidential Clinical Laboratory Tests 
Laboratory tests will be summarized separately for hematology and serum chemistry. 
Local laboratory results will be converted based on the normal ranges and standardized using the 
SI unit. Selected hematologic and chemistry laboratory parameters are detailed in Section 7.4. 
Descriptive statistics will be provided for the values of selected clinical laboratory tests at each 
scheduled on-treatment evaluation including the final value. Percent change from baseline to 
each scheduled on-treatment evaluation and to the final value will also be summarized. 
For selected variables, the mean value and mean percent change over time will be presented 
graphically. 
A summary of the shifts in selected laboratory hematology and serum chemistry parameters from 
baseline to the worst toxicity grade during the study will be provided. The worst toxicity grade 
during the study will be tabulated. 
All laboratory values will be converted to standard international units. and will be graded using 
the NCI CTCAE Version 4.03. Standard methods for summarizing laboratory variables will be 
used, including the use of summary statistics and shift tables. 
10.5.8. Data Monitoring Committee 
The safety of this study will be monitored by an independent DMC. In Phase 1 the DMC will 
review safety and efficacy data and advise on the RP2D. In Phase 2b th e DMC will review the 
safety data on an ongoing basis. 
The independent DMC will be chaired by a physician with expertise in MM. The DMC will 
review data and provide recommendations regarding stopping or continuing the trial in 
accordance with the DMC charter.  
11. ADVERSE EVENT REPORTING 
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects, Investigators, and the Sponsor, and are mandated by 
regulatory agencies worldwide. The Sponsor has established Standard Operating Procedures in 
conformity with regulatory requirements worldwide to ensure appropriate reporting of safety 
information; all clinical studies conducted by the Sponsor or its affiliates will be conducted in 
accordance with those procedures. 
11.1. Adverse Event Definitions and Classifications 
11.1.1. Adverse Event 
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical 
product and which does not necessarily have a causal relationship with this treatment. 
An adverse event can therefore be any unfavorable and unintended sign (including a clinically 
significant abnormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of an investigational study drug, whether or not considered related to the 
study drug. [ICH-E2A] 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
68 
Approved, Date: 5 September 2013  Proprietary and Confidential For the purposes of this clinical study, adverse events include events which are either new or 
represent detectable exacerbations of pre-existing conditions. 
Disease progression is not an adverse event; rather it may be the cause of an adverse event. 
The clinical diagnosis that is associated with disease progression must be reported as all other 
adverse events. Disease progression should never be used as an adverse event term. 
Adverse events may include, but are not limited to: 
 Subjective or objective symptoms spontaneously offered by the subject and/or observed by 
the Investigator or study staff including laboratory abnormalities of clinical significance. 
 Any adverse events experienced by the subject through the completion of final study 
procedures.  
 Adverse events not previously observed in the subject that emerge during the 
protocol-specified adverse event reporting period, including signs or symptoms associated 
with MM that were not present before the adverse event reporting period. 
 Complications that occur as a result of protocol-mandated interventions (eg, invasive 
procedures such as biopsies). 
The following are NOT considered adverse events: 
 Pre-existing condition:  A pre-existing condition (documented on the medical history CRF) 
is not considered an adverse event unless the severity, frequency, or character of the event 
worsens during the study period. 
 Pre-planned or elective hospitalization:  A hospitalization planned before signing the 
informed consent form is not considered a serious adverse event, but rather a therapeutic 
intervention. However, if during the pre-planned hospitalization an event occurs, which 
prolongs the hospitalization or meets any other serious adverse event criteria, the event will 
be considered a serious adverse event. Surgeries or interventions that were under 
consideration, but not performed before enrollment in the study, will not be considered 
serious if they are performed after enrollment in the study for a condition that has not 
changed from its baseline level. Elective hospitalizations for social reasons, solely for the 
administration of chemotherapy, or due to long travel distances are also not serious adverse 
event s. 
 Diagnostic Testing and Procedures:  Testing and procedures should not to be reported as 
adverse events or serious adverse events, but rather the cause for the test or procedure 
should be reported. 
 Asymptomatic treatment -related lymphocytosis: This event should also not be considered 
an adverse event.  Patients with treatment -related lymphocytosis should r emain on study 
treatment and continue with all study -related procedures.  Treatment -related lymphocytosis , 
for the purposes of this protocol, is defined as an elevation in blood lymphocyte count of 
≥50% compared to baseline and ≥5,000/µL that occurs in the setting of improvement in at 
least one other disease -related parameter including lymph node size, spleen size, 
hematologic parameters (hemoglobin or platelet count), or disease -related symptoms .  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
69 
Approved, Date: 5 September 2013  Proprietary and Confidential 11.1.2. Serious Adverse Event 
Note: The terms “severe” and “serious”  are not synonymous. Severity (or intensity) refers to the 
grade of an adverse event (see below). Serious is a regulatory definition. 
A serious adverse event (experience) or reaction is any untoward medical occurrence that: 
 Results in death (ie, the actually causes or leads to death). 
 Is life-threatening. Life-threatening is defined as an adverse event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically 
might have caused death if it were more severe. If either the Investigator or the Sponsor 
believes that an adverse event meets the definition of life-threatening, it will be considered 
life-threatening. 
 Requires in-patient hospitalization for more than 24 hours or prolongation of existing 
hospitalization. 
 Results in persistent or significant disability/incapacity (ie, the adverse event results in 
substantial disruption of the subject’s ability to conduct normal life functions).  
 Is a congenital anomaly/birth defect. 
 Is an important medical event that may not result in death, be immediately life-threatening 
or require hospitalization, but may be considered a serious adverse event when, based upon 
appropriate medical judgment, the event may jeopardize the subject or subject may require 
medical or surgical intervention to prevent one of the other outcomes listed in this definition. 
Examples of such events are intensive treatment in an emergency department or at home for 
allergic bronchospasm, blood dyscrasias, or convulsion that does not result in 
hospitalization; or development of drug dependency or drug abuse. 
Given that the Investigator’s perspective may be informed by having actually observed the event, 
and the Sponsor is likely to have broader knowledge of the drug and its effects to inform its 
evaluation of the significance of the event, if either the Sponsor or the Investigator believes that 
the event is serious, the event will be considered serious. 
11.1.3. Unexpected Adverse Events 
An “unexpected” adverse event is an adverse event that is not listed i n the Ibrutinib 
Investigator’s Brochure  and carfilzomib package insert or is not listed at the specificity or 
severity that has been observed. For example, hepatic necrosis would be unexpected (by virtue of 
greater severity) if the Investigator’s Brochure referred only to elevated hepatic enzymes or 
hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected 
(by virtue of greater specificity) if the Investigator’s Brochure/package insert listed only cerebral 
vascular accidents . Unexpected also refers to adverse events mentioned in the Investigator’s 
Brochure as occurring with a class of drugs or as anticipated from the pharmacological properties 
of the drug, but are not specifically mentioned as occurring with the study drug under 
investigation. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
70 
Approved, Date: 5 September 2013  Proprietary and Confidential 11.1.4. Causality 
The Investigator is to assess the causal relation (ie, whether there is a reasonable possibility that 
the study drug caused the event) using the following definitions: 
Not Related:  Another cause of the adverse event  is more pla usible; a temporal 
sequence cannot be established with the onset of the adverse event  
and administration of the investigational product; or, a causal 
relationship is considered biologically implausible.  
Unlikely:  The current knowledge or information about  the adverse event  
indicates that a relationship to the investigational product is 
unlikely.  
Possibly Related:  There is a clinically plausible time sequence between onset of the 
adverse event  and administration of the investigational product, but 
the adve rse event  could also be attributed to concurrent or 
underlying disease, or the use of other drugs or procedures . Possibly 
related should be used when the investigational product is one of 
several biologically plausible adverse event  causes.  
Related:  The adverse event  is clearly related to use of the investigational 
product.  
11.1.5. Severity Criteria 
Definitions found in the NCI CTCAE version 4.03 will be used for grading the severity 
(intensity) of non-hematologic adverse events. The NCI CTCAE Version 4.03 categorizes 
Grades 1 through Grade 5 with unique clinical descriptions of severity for each referenced 
adverse event. Should a subject experience any adverse event not listed in the NCI CTCAE 
Version 4.03, the following grading system should be used to assess severity: 
 Grade 1 (mild adverse event) – experiences which are usually transient, requiring no special 
treatment, and not interfering with the subject’s daily activities  
 Grade 2 (moderate adverse event) – experiences which introduce some level of 
inconvenience or concern to the subject, and which may interfere with daily activities, 
but are usually ameliorated by simple therapeutic measures 
 Grade 3 (severe adverse event) – experiences which are unacceptable or intolerable, 
significantly interrupt the subject’ s usual daily activity, and require systemic drug therapy or 
other treatment 
 Grade 4 (life-threatening or disabling adverse event) – experiences which cause the subject 
to be in imminent danger of death 
 Grade 5 (death related to an adverse event) – experiences which result in death  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
71 
Approved, Date: 5 September 2013  Proprietary and Confidential 11.2. Documenting and Reporting of Adverse Events and Serious Adverse 
Events by Investigators 
The Investigator is responsible for ensuring that all adverse events and serious adverse events 
observed or reported during the study, as outlined in the prior sections, are recorded on the CRF. 
All serious adverse events must also be reported on the Serious Adverse Event Worksheet and to 
the Sponsor (see Section 11.2.3 ). 
11.2.1. Adverse Event Reporting Peri od 
All adverse events whether serious or non-serious, will be documented in the source documents 
from the time signed and dated informed consent is obtained until 30 days following the last dose 
of study drug. Only serious adverse events will be reported to the Sponsor during this time. 
From the first dose of study drug adverse events and serious adverse events will be recorded in 
the CRFs and will continue until 30 days after the last dose of study drug. At the End of 
Treatment visit, the Investigator should instruct each subject to report to the Investigator any 
subsequent adverse events that the subject’s personal physician believes could be related to prior 
study drug treatment or study procedures. 
If a serious adverse event is present at the End of Treatment Visit, the serious adverse event 
should be followed to resolution, until the Investigator assesses the subject  as stable, or the 
subject is lost to follow-up or withdraws consent. Resolution/stable means the subject has 
returned to his or her baseline state of health or the Investigator does not expect any further 
improvement or worsening of the event. Any SAE occurring more than 30 days after the last 
dose of study treatment and is deemed related to study treatment, must be reported to the 
Sponsor.   
If a death occurs within 30 days after the last dose of study treatment, the death must be reported 
to the Sponsor as a serious adverse event . Furthermore, the Investigator should notify the 
Sponsor of any death, serious adverse event, or other adverse event of concern occurring at any 
time after a subject has discontinued study treatment or study participation,  if the event is believe 
to be related to prior study drug treatment or study procedures. The Sponsor should also be 
notified if the Investigator becomes aware of the development of cancer or a congenital 
abnormality/birth defect in a subsequently conceived offspring of a subject that participated in 
this study. 
11.2.2. Assessment of Adverse Events 
Investigators will assess the occurrence of adverse events and serious adverse events at all 
subject evaluation timepoints during the study . All adverse events and serious adverse events 
whether volunteered by the subject, discovered by study personnel during questioning, detected 
through physical examination, clinically significant laboratory test, or other means, will be 
recorded in the subject’s medical record and on the Adverse Eve nt CRF and, when applicable, 
on the Serious Adverse Event Worksheet. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
72 
Approved, Date: 5 September 2013  Proprietary and Confidential Each recorded adverse event or serious adverse event will be described by its duration 
(ie, start and end dates), severity, regulatory seriousness criteria (if applicable), suspected 
relationship to study drug or carfilzomib and any actions taken. 
11.2.3. Expediting Reporting Requirements for Serious Adverse Events 
All serious adverse events (initial and follow-up information) will be reported on the Serious 
Adverse Event Worksheet and faxed to Pharmacyclics Drug Safety, or designee, within 24 hours 
of the discovery of the event or information. Pharmacyclics may request follow-up and other 
additional information from the Investigator (eg, hospital admission/discharge notes and 
laboratory results). The contact information (phone, fax and email) for Drug Safety can be found 
on the Serious Adverse Event Worksheet form and instructions. 
All deaths should be reported with the primary cause of death as the adverse event term, as death 
is typically the outcome of the event, not the event itself. The primary cause of death on the 
autopsy report or the adverse event/serious adverse event most proximal to death should be the 
term reported. Autopsy and postmortem reports must be forwarded to Pharmacyclics Drug 
Safety, or designee, as outlined above. 
If study treatment is discontinued because of an serious adverse event, this information must be 
included in the serious adverse event report. 
11.2.4. Other Malignancies 
In addition to all routine adverse event reporting, all new malignant tumors including solid 
tumors, skin malignancies and hematologic malignancies are to be reported for the duration of 
study treatment and during any protocol-specified follow-up periods including post-progression 
follow-up for overall survival.  
11.2.5. Events of Special Interest 
Specific adverse events, or groups of adverse events, will be followed as part of standard safety 
monitoring activities by the Sponsor. These events will be reported to the Sponsor within 
24 hours of awareness (irrespective of seriousness, even if non-serious) following the procedure 
described above for serious adverse events and will require enhanced data collection.  
11.2.5.1. Major Hemorrhage 
Major hemorrhage is defined as any hemorrhagic event that is Grade 3 or greater in severity or 
that results in 1 of the following: intraocular bleeding causing loss of vision, any hemorrhagic 
event which results in the need for a transfusion of 2 or more units of red cells or an equivalent 
amount of whole blood, hospitalization, or prolongation of hospitalization. 
Events meeting the definition of major hemorrhage will be captured as an event of special 
interest according to Section  11.2.5  above. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
73 
Approved, Date: 5 September 2013  Proprietary and Confidential 11.2.5.2. Intracranial Hemorrhage 
Any intracranial hemorrhage adverse event, including subdural hematoma/hemorrhage, epidural 
hematoma/hemorrhage, and intracerebral hemorrhage, of any grade severity, will be captured as 
an event of special interest according to Section  11.2.5  above.  
11.2.6. Pregnancy  
Before study enrollment, subjects must agree to take appropriate measures to avoid pregnancy. 
However, should a pregnancy occur in a female study subject, consent to provide follow- up 
information regarding the outcome of the pregnancy and the health of the infant until 30 days old 
will be requested. 
A female subject must immediately inform the Investigator if she becomes pregnant from the 
time of consent to 30 days after the last dose of study drug . A male subject must immediately 
inform the Investigator if his partner becomes pregnant from the time of consent to 3 months 
after the last dose of study drug. Any female subjects receiving ibrutinib capsules who become 
pregnant must immediately discontinue study drug. The Investigator should counsel the subject, 
discussing any risks of continuing the pregnancy and any possible effects on the fetus .  
Although pregnancy itself is not regarded as an adverse event, the outcome will need to be 
documented. Any pregnancy occurring in a subject or subject’s partner from the time of consent 
to 30 days after the last dose of study drug will be reported. Any occurrence of pregnancy will be 
recorded on the Pregnancy Report Form Part I and faxed to Pharmacyclics Drug Safety, or 
designee, within 24 hours of learning of the event. With consent, the pregnant woman will be 
followed for outcome, which is defined as elective termination of the pregnancy, miscarriage, or 
delivery of the fetus. For pregnancies with an outcome of live birth, the newborn infant will be 
followed until 30 days old by completing the Pregnancy Report Form Part II. Any congenital 
anomaly/birth defect noted in the infant must be reported as a serious adverse event. 
12. ETHICAL ASPECTS 
This clinical study was designed and will be implemented in accordance with the protocol, the 
International Conference on Harmonization Harmonized Tripartite Guidelines for Good Clinical 
Practices, with applicable local regulations (including US Code of Federal Regulations [CFR] 
Title 21 and European Directive 2001/20/EC), and with the ethical principles laid down in the 
Declaration of Helsinki. 
12.1. Study-Specific Design Considerations 
In addition to receiving study treatment, all participating subjects will receive full supportive 
care and will be followed closely for safety and efficacy throughout the study. Efficacy 
assessments will occur according to the internationally accepted response criteria from the 
IMWG. Safety assessments will occur through regular clinic visits including laboratory analyses. 
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and may 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
74 
Approved, Date: 5 September 2013  Proprietary and Confidential be withdrawn at any time with no reason given and without penalty or loss of benefits to which 
they would otherwise be entitled. Only subjects who are fully able to understand the risks, 
benefits, and potential adverse events of the study, and provide their consent voluntarily will be 
enrolled.  
12.2. Regulatory Ethics Compliance 
12.2.1. Investigator Responsibilities 
A complete list of Investigator responsibilities are outlined in the clinical trial research 
agreement and the Statement of Investigator Form Food and Drug Administration (FDA) 1572, 
both of which are signed by the Investigator before commencement of the study. In summary, 
the Investigator will conduct the study according to the current protocol; will read and 
understand the I nvestigator’s Brochure; will obtain IRB/REB/IEC approval to conduct the study; 
will obtain informed consent from each study participant; will maintain and supply to the 
Sponsor or designee, auditors and regulatory agencies adequate and accurate records of study 
activity and drug accountability for study-related monitoring, audits, IRB/REB/IEC reviews and 
regulatory inspections; will report serious adverse events to the Sponsor or designee and 
IRB/REB/IEC according to the specifics outlined in this protocol; will personally conduct or 
supervise the study; and will ensure that colleagues participating in the study are informed about 
their obligations in meeting the above commitments. 
12.2.2. Institutional Review Board, Research Ethics Board, and Independent 
Ethics Committee Approval  
The Investigator will submit this protocol, the ICF, Investigator’s Brochure , and any other 
relevant supporting information (eg, all advertising materials or materials given to the subject 
during the study) to the appropriate IRB/REB/IEC for review and approval before study 
initiation. Amendments to the protocol and ICF must also be approved by the IRB/REB/IEC 
before the implementation of changes in this study. The Investigator is also responsible for 
providing the IRB/REB/IEC with any required information before or during the study, such as 
serious adverse event expedited reports or study progress reports. 
The IRB/REB/IEC must comply with current US regulations (§21 CFR 56) as well as 
country-specific national regulations and/or local laws. 
The following documents must be provided to Pharmacyclics or its authorized representative 
before entering subjects in this study: 1) a copy of the IRB/REB/IEC letter that grants formal 
approval; and 2) a copy of the IRB/REB/IEC -approved ICF. 
12.2.3. Informed Consent 
The ICF and process must comply with the US regulations (§ 21  CFR Part 50) as well as country 
specific national regulations and/or local laws. The ICF will document the study-specific 
information the Investigator or his/her designee provides to the subject and the subject’s 
agreement to participate.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
75 
Approved, Date: 5 September 2013  Proprietary and Confidential The Investigator or designee (designee must be listed on the Delegation of Authority log), 
must  explain in terms understandable to the subject the purpose and nature of the study, 
study procedures, anticipated benefits, potential risks, possible adverse events, and any 
discomfort participation in the study may entail. This process must be documented in the 
subject’s source record . Each subject must provide a signed and dated ICF before any 
study-related (nonstandard of care) activities are performed. The original and any amended 
signed and dated consent forms must remain in each subject’s study file at the study site and be 
available for verification by study monitors at any time. A copy of each signed consent form 
must be given to the subject at the time that it is signed by the subject. 
12.2.4. Protected Subject Health Information Authorization 
Information on maintaining subject  confidentiality in accordance to individual local and national 
subject  privacy regulations must be provided to each subject as part of the informed consent 
process, either as part of the ICF or as a separate signed document (for example, in the US, 
a site-specific HIPAA consent may be used). The Investigator or designee must explain to each 
subject that for the evaluation of study results, the subject’s protected health information 
obtained during the study may be shared with Pharmacyclics and its designees, regulatory 
agencies, and IRBs/REBs/IECs. As the study Sponsor, Pharmacyclics will not use the subject’s 
protected health information or disclose it to a third party without applicable subject 
authorization. It is the Investigator’s or designee’s responsibility to o btain written permission to 
use protected health information from each subject . If a subject withdraws permission to use 
protected health information, it is the Investigator’s responsibility to obtain the withdrawal 
request in writing from the subject and to ensure that no further data will be collected from the 
subject . Any data collected on the subject before withdrawal will be used in the analysis of study 
results. 
During the review of source documents by the monitors or auditors, the confidentiality of the 
subject will be respected with strict adherence to professional standards and regulations. 
12.2.5. Financial Disclosure 
A separate financial agreement will be made between each Principal Investigator and 
Pharmacyclics or its authorized representative before the study drug is delivered. 
For this study, each Investigator and Subinvestigator (as designated on the Form FDA 1572) 
will provide a signed Financial Disclosure Form in accordance with §21 CFR Part 54. 
Each Investigator will notify Pharmacyclics or its authorized representative of any relevant 
changes during the conduct of the study and for 1 year after the study has been completed. 
12.2.6. Liability and Clinical Trial Insurance 
In the event of a side effect or injury, appropriate medical care as determined by the 
Investigator/designee will be provided. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
76 
Approved, Date: 5 September 2013  Proprietary and Confidential If a bodily injury is sustained, resulting directly from the use of the study drug, Pharmacyclics 
will reimburse for reasonable physician fees and medical expenses necessary for treatment of 
only the bodily injury which is not covered by the subject ’s medical or hospital insurance, 
provided that the injury is not due to a negligent or wrongful act or omission by the 
Investigator/study staff. The ICF will include a description of this reimbursement policy, 
incorporating country-specific national regulations and/or local laws. Financial compensation for 
lost wages, disability or discomfort due to the study is not available. 
Clinical trial insurance will be undertaken according to the laws of the countries where the study 
will be conducted. An insurance certificate will be made available to the participating sites at the 
time of study initiation. 
13. ADMINISTRATIVE REQUIREMENTS 
13.1. Protocol Amendments  
Pharmacyclics will initiate any change to the protocol in a protocol amendment document . 
The amendment will be submitted to the IRB/REB/IEC together with, if applicable, a revised 
model ICF. Written documentation of IRB/REB/IEC and required site approval must be received 
by Pharmacyclics before the amendment may take effect at each site. Additionally under this 
circumstance, information on the increased risk and/or change in scope must be provided to 
subjects already actively participating in the study, and they must read, understand and sign any 
revised ICF confirming willingness to remain in the study. 
No other significant or consistent change in the study procedures, except to eliminate an 
immediate hazard, shall be effected without the mutual agreement of the Investigator and 
Pharmacyclics. 
13.2. Regulatory Documentation 
13.2.1. Regulatory Approval/Notification 
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities 
in each respective country, if applicable. A study may not be initiated until all local regulatory 
requirements are met. 
13.2.2. Required Prestudy Docume ntation 
The following documents must be provided to the Sponsor before shipment of study drug to the 
investigational site: 
 Protocol and amendment(s), if any, signed and dated by the principal Investigator 
 A copy of the dated and signed, written IEC/IRB approval of the protocol, amendments, 
informed consent form, any recruiting materials, and if applicable, subject compensation 
programs. This approval must clearly identify the specific protocol by title and number and 
must be signed by the chairman or authorized designee. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
77 
Approved, Date: 5 September 2013  Proprietary and Confidential  Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to Good Clinical 
Practices ( GCP ) and the applicable laws and regulations. If accompanied by a letter of 
explanation, or equivalent, from the IEC/IRB, then a general statement may be substituted 
for this list. If an Investigator or a member of the investigational staff is a member of the 
IEC/IRB, then documentation must be obtained to state that this person did not participate in 
the deliberations or in the vote/opinion of the study. 
 Regulatory authority approval or notification, if applicable 
 Signed and dated statement of Investigator (eg, Form FDA 1572) 
 Documentation of Investigator qualifications (eg, curriculum vitae) 
 Completed Investigator financial disclosure form from the principal Investigator, 
where required 
 Signed and dated clinical trial agreement, which includes the financial agreement 
 Any other documentation required by local regulations 
The following documents must be provided to the Sponsor before enrollment of the first subject: 
 Completed Investigator financial disclosure forms from all clinical subinvestigators 
 Documentation of subinvestigator qualifications (eg, curriculum vitae)  
 Name and address of any local laboratory conducting tests for the study, and a dated copy of 
current laboratory normal ranges for these tests, if applicable 
 Local laboratory documentation demonstrating competence and test reliability 
(eg, accreditation/license), if applicable 
13.3. Subject Identification, Enrollment, and Screening Logs 
The Investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
Sponsor study site contact for completeness. 
The subject identification and enrollment log will be treated as confidential and will be filed by 
the Investigator in the study file. To ensure subject confidentiality, no copy will be made . 
All reports and communications relating to the study will identify subjects by subject 
identification number and date of birth. In cases where the subject is not randomized into the 
study, the date seen and date of birth will be used. 
The Investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study. 
13.4. Treatment Compliance  
The Investigator or designated study personnel will maintain a log of all study drug dispensed 
and returned. Drug supplies for each subject will be inventoried and accounted for throughout 
the study. On PK sampling days for ibrutinib only, the timing of meals in relation to the ibrutinib 
intake will also be recorded.  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
78 
Approved, Date: 5 September 2013  Proprietary and Confidential The study drug is to be prescribed only by the principal Investigator or a qualified physician 
listed as a sub-investigator on required forms. Records should be kept on the study drug 
accountability form provided by the Sponsor or its designee (any alternative forms must be 
preapproved by the Sponsor). Further instructions regarding accountability for study drug are 
provided in the Pharmacy Manual. Administration of the study drug must be recorded in the 
subject’s source documentation . The study drug may not be used for any purpose other than that 
outlined in this protocol, including other human studies, animal investigations, or in vitro testing. 
13.5. Drug Accountability 
The Investigator is responsible for ensuring that all study drug and carfilzomib received at the 
site is inventoried and accounted for throughout the study. Accountability records must be 
maintained and readily available for inspection by Sponsor’s site monitor during on -site 
monitoring visits. All study drug and carfilzomib will be stored in a limited access area 
according to the Sponsor's instructions.  
Study drug or carfilzomib should be dispensed under the supervision of the Investigator or a 
qualified member of the investigational staff, or by a hospital/clinic pharmacist, and will be 
supplied only to subjects participating in the study. The Investigator agrees neither to dispense 
the study drug or carfilzomib from, nor store it at, any site other than the study sites agreed upon 
with the Sponsor. 
At study initiation, the Sponsor or delegate will evaluate and approve the s ite’s procedure for 
investigational product disposal/destruction to ensure that it complies with Pharmacyclics’  
requirements. If the site cannot meet Pharmacyclics’  requirements for disposal/destruction, 
arrangements will be made between the site and Pharmacyclics or its representative, for return of 
unused investigational product . Before disposal/destruction, final drug accountability and 
reconciliation must be performed by the monitor. 
13.6. Source Documentation 
At a minimum, source documentation must be available for the following to confirm data 
collected in the CRF: subject identification, eligibility, and study identification; study discussion 
and date of informed consent; dates of visits; results of safety and efficacy parameters as 
required by the protocol; record of all adverse events and follow-up of adverse events; 
concomitant medication; drug receipt/dispensing/return records; study drug administration 
information; and date of study completion and reason for early discontinuation of study drug or 
withdrawal from the study, if applicable. 
In addition, the author of an entry in the source documents should be identifiable. 
At a minimum, the type and level of detail of source data available for a study subject should be 
consistent with that commonly recorded at the site as a basis for standard medical care. Specific 
details required as source data for the study will be reviewed with the Investigator before the 
study and will be described in the monitoring guidelines (or other equivalent document). 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
79 
Approved, Date: 5 September 2013  Proprietary and Confidential 13.7. Case Report Form Completion 
Case report forms (CRF) will be used to collect the clinical study data and must be completed for 
each enrolled subject with all required study data accurately recorded such that the information 
matches the data contained in medical record s (eg, physicians’ notes, nurses’ notes, clinic charts 
and other study-specific source documents). Authorized study site personnel (ie, listed on the 
Delegation of Authority log) will complete CRFs designed for this study according to the 
completion guidelines provided. The Investigator will ensure that the CRFs are accurate, 
complete, legible, and completed as soon as reasonable possible. At all times, the Investigator 
has final responsibility for the accuracy and authenticity of all clinical data. 
The CRFs exists within an electronic data capture (EDC) system with controlled access managed 
by Pharmacyclics or its authorized representative for this study. Study staff will be appropriately 
trained in the use of the CRFs and application of electronic signatures before the start of the 
study and before being given access to the EDC system. Any changes of data will be recorded 
using the EDC system, with all changes tracked by the system and recorded in an electronic audit 
trail. The Investigator attests that the information contained in the CRFs is true by providing 
electronic signature within the EDC system. After database lock, the Investigator will receive a 
copy of the subject data (eg, paper, CD, or other appropriate media) for archiving at the study 
site. 
13.8. Data Quality Assurance/Quality Control 
The Sponsor shall implement and maintain quality control and quality assurance procedures to 
ensure that the study is conducted and data are generated, documented and reported in 
compliance with the protocol, GCP, and applicable regulatory requirements. This study shall be 
conducted in accordance with the provisions of the Declaration of Helsinki (October 2008) and 
all revisions thereof, and in accordance with FDA regulations (§ 21 CFR Parts 11, 50, 54, 56, and 
312, Subpart D – Responsibilities of Sponsors and Investigators) and with the ICH guidelines on 
GCP (ICH E6). 
13.9. Record Retention 
The Investigator must keep a record that lists all subjects considered for enrollment 
(including those who did not undergo screening) in the study. For those subjects subsequently 
excluded from enrollment, the reason(s) for exclusion is to be recorded. 
The Investigator/study staff must maintain adequate and accurate records to enable the conduct 
of the study to be fully documented and the study data to be subsequently verified. Essential 
documentation includes, but is not limited to, the I nvestigator’s Brochure, signed protocols and 
amendments, IRB/REB/IEC approval letters (dated), signed Form FDA 1572 and Financial 
Disclosures, signed ICFs (including subject confidentiality information), drug dispensing and 
accountability records, shipping records of investigational product and study-related materials, 
signed, dated and completed CRFs, and documentation of CRF corrections, serious adverse 
event forms transmitted to Pharmacyclics and notification of serious adverse events and related 
reports, source documentation, normal laboratory values, decoding procedures for blinded 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
80 
Approved, Date: 5 September 2013  Proprietary and Confidential studies, curricula vitae for study staff, and all relevant correspondence and other documents 
pertaining to the conduct of the study. 
All essential documentation will be retained by the Investigator for at least 2 years after the date 
the last marketing application is approved for the drug for the indication for which it is bein g 
investigated and until there are no pending or contemplated marketing applications; or, if no 
application is to be filed or if the application is not approved for such indication, until 2 years 
after formal discontinuation of clinical development of the drug.  
The Investigator must notify Pharmacyclics and obtain written approval from Pharmacyclics 
before destroying any clinical study documents or images (eg, scan, radiograph, ECG tracing) at 
any time. Should an Investigator wish to assign the study records to another party or move them 
to another location, advance written notice will be given to Pharmacyclics. Pharmacyclics will 
inform the Investigator of the date that study records may be destroyed or returned to 
Pharmacyclics. 
Pharmacyclics must be notified in advance of, and Pharmacyclics must provide express written 
approval of, any change in the maintenance of the foregoing documents if the Investigator 
wishes to move study records to another location or assign responsibility for record retention to 
another party. If the Investigator cannot guarantee the archiving requirements set forth herein at 
his or her study site for all such documents, special arrangements must be made between the 
Investigator and Pharmacyclics to store such documents in sealed containers away from the 
study site so that they can be returned sealed to the Investigator for audit purposes. 
13.10.  Study Monitoring and Audits  
Representatives of Pharmacyclics or its designee will monitor this study until completion. 
Monitoring will be conducted through personal visits with the Investigator and site staff, remote 
monitoring, as well as any appropriate communications by mail, fax, email, or telephone. 
The purpose of monitoring is to ensure that the study is conducted in compliance with the 
protocol, Standard Operating Procedures, and other written instructions and regulatory 
guidelines, and to ensure the quality and integrity of the data. This study is also subject to 
reviews or audits. 
To assure the accuracy of data collected in the CRFs, it is mandatory that the monitor/auditor 
have access to all original source documents, including all electronic medical records (EMR) at 
reasonable times and upon reasonable notice. During the review of source documents, every 
effort will be made to maintain the anonymity and confidentiality of all subjects during this 
clinical study. However, because of the experimental nature of this treatment, the Investigator 
agrees to allow the IRB/REB/IEC, representatives of Pharmacyclics, its designated agents and 
authorized employees of the appropriate Regulatory Authority to inspect the facilities used in 
this study and, for purposes of verification, allow direct access to the hospital or clinic records of 
all subjects enrolled into this study . A statement to this effect will be included in the informed 
consent and permission form authorizing the use of protected health information. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
81 
Approved, Date: 5 September 2013  Proprietary and Confidential Pharmacyclics or its authorized representative may perform an audit at any time during or after 
completion of this study. All study-related documentation must be made available to the 
designated auditor . In addition, a representative of the FDA or other Regulatory Agencies may 
choose to inspect a study site at any time before, during, or after completion of the clinical study. 
In the event of such an inspection, Pharmacyclics will be available to assist in the preparation. 
All pertinent study data should be made available as requested to the Regulatory Authority for 
verification, audit, or inspection purposes. 
13.11.  Study Completion/Termination 
13.11.1. Study Completion 
The end of the study will occur 2 years after the last subject is randomized, or the Sponsor 
terminates the study, whichever comes first. The study is considered complete when the last 
subject completes the last study assessment.  
13.11.2. Study Terminati on 
The Sponsor reserves the right to close the investigational site or terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Investigational sites will be closed upon 
study completion. An investigational site is considered closed when all required documents and 
study supplies have been collected and a site closure visit has been performed. 
The Investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of an investigational site by the Sponsor or Investigator may 
include but are not limited to: 
 Failure of the Investigator to comply with the protocol, the requirements of the IEC/IRB or 
local health authorities, the Sponsor's procedures, or GCP guidelines 
 Inadequate recruitment of subjects by the Investigator 
 Discontinuation of further drug development 
13.12.  Use of Information and Publication 
Pharmacyclics may use the results of this clinical study in registration documents for Regulatory 
Authorities in the US or abroad . The results may also be used for papers, abstracts, posters, 
or other material presented at scientific meetings or published in professional journals or as part 
of an academic thesis by an Investigator. In all cases, to avoid disclosures that could jeopardize 
proprietary rights and to ensure accuracy of the data, Pharmacyclics reserves the right to preview 
all manuscripts and abstracts related to this study, allowing Pharmacyclics sufficient time to 
make appropriate comments before submission for publication. 
In most cases, the Investigators at the sites with the highest accruals of eligible subjects shall be 
listed as lead authors on manuscripts and reports of study results . The Medical Monitor, study 
director and/or lead statistician may also be included in the list of authors. This custom can be 
adjusted upon mutual agreement of the authors and Pharmacyclics. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
82 
Approved, Date: 5 September 2013  Proprietary and Confidential 14. REFERENCES 
Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 
2006;34:1289 -1295.  
Alsina M, Trudel S, Furman RR, et al . A phase 1 single-agent study of twice-weekly consecutive-day 
dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or 
lymphoma . Clinical Cancer Research 2012; 18:4830-4840. 
Arastu-Kapur S, Anderl JL, Kraus M, et al . Nonproteasomal targets of the proteasome inhibitors 
bortezomib and carfilzomib: a link to clinical adverse events . Clin Cancer Res 2011; 17:2734- 43. 
Badros A, Papadopoulos K, Zojwalla N, et al. A Phase Ib Study of 30-minute Infusion Carfilzomib 20/45 
and 20/56 mg/m2 plus 40mg weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) 
Multiple Myeloma. Blood 2012;120:Abstract 4036. 
Bishop GA, Haxhinasto SA, Stunz LL, et al. Antigen-specific B-lymphocyte activation . Crit Rev 
Immunol 2003;23:165 –197.  
Dasmahapatra, G, Patel H, Dent P, et al . The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 
synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and 
mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib . British Journal of Haematology 
2013;161:43- 56. 
Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the 
proteasome. Cancer Res. 2007;67:6383- 91. 
Hájek R, Bryce R, Ro S, et al. Design and rationale of FOCUS (PX- 171-011): A randomized, open-label, 
phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory 
multiple myeloma (R/R MM) BMC Cancer. 2012;12:415. 
Jagannath S, Vij R, Stewart AK, et al. An open-label single-arm pilot phase II study (PX-171- 003-A0) of 
low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin 
Lymphoma Myeloma Leuk. 2012;12:310-8.  
Kawano M, Hirano T, Matsuda T, et al . Autocrine generation and requirement of BSF -2/IL -6 for human 
multiple myelomas. Nature 1988;332:83 -85. 
Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the 
ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110:3281 –3290.  
KYPROLIS™ [carfilzomib package insert]. South San Francisco, CA: Onyx Pharmaceuticals, Inc.; 2012. 
Lendvai N, Landau H, Lesokhin A , et al.  Phase II Study of Infusional Carfilzomib in Patients with 
Relapsed or Refractory Multiple Myeloma . ASH Annual Meeting Abstracts 2012; 120: 947 .  
NCI. SEER Cancer Statistics Review 1978-2008. 2009 [cited 21 August 2011]; Available from: 
http://seer.cancer.gov/csr/1975_2008/results_merged/sect_19_nhl.pdf. 
O’Connor OA, Stewart AK, Vallone M, et al. A phase 1 dose escalation  study of the safety and 
pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic 
malignancies. Clin Cancer Res. 2009;15 :7085 –7091. 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
83 
Approved, Date: 5 September 2013  Proprietary and Confidential Ou Z, Zhang L, Newberry K , et al.  The bruton’s tyrosine kinase inhibitor ibrutin ib synergized with the 
proteasome inhibitor carfilzomib and overcame immunoproteasome-mediated carfilzomib resistance in 
mantle cell lymphoma. AACR 2013 Abstract 2432. 
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-1060. 
Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of 
clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691-5.  
Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res 2004;118:83-100. 
Roodman GD. Osteoblast function in myeloma. Bone 2011;48:135-140. 
Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem 2010a;109:283-291. 
Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 
2010 b;28:244-250.  
Rushworth SA, Bowles KM, Barrera LN, et al . BTK inhibitor ibrutinib is cytotoxic to myeloma and 
potently enhances bortezomib and lenalidomide activities through NF-κB. Cell Signal 2013:106 -12. 
Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B cell development and function: 
a genetic perspective. Immunol Rev 2000;175:120-127. 
Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: The dark side of B-cell differentiation . 
Nat Rev Immunol 2002;2:920 –932.  
Siegel D, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PC-171-0031-A1) 
in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-2825  
Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. 
Blood 2011;118: 4313 –4320. 
Suzuki E, Demo S, Deu E, et al. Molecular mechanisms of bortezomib-resistant adenocarcinoma cells. 
PLoS One. 2011;6:e27996. 
Tai Y, Chang B, Kong S, et al . Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting 
tumor in the bone marrow microenvironment in multiple myeloma . Blood 2012;120:1877-1887. 
Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib 
in patients with relapsed and/or refractory multiple myeloma who have been previously treated with 
bortezomib . British Journal of Haematology 2012a;158:739-748. 
Vij R, Wang M, Kaufman JL, et al . An open-label, single-arm phase 2 (PX-171 -004) study of 
single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma . 
Blood 2012b;119:5661-5670. 
Yang J, Wang Z, Fang Y, et al . Jiang J, et al. Pharmacokinetics, pharmacodynamics, metabolism, 
distribution, and excretion of carfilzomib in rats . Drug Metabolism and Disposition 2011;39:1873-1882. 
Zangari M, Terpos E, Zhan F, et al. Impact of bortezomib on bone health in myeloma: a review of current 
evidence. Cancer Treat Rev. 2012;38:968-80.  
Zangari M, Yaccoby S, Pappas L, et al. A prospective evaluation of the biochemical, metabolic, hormonal 
and structural bone changes associated with bortezomib response in multiple myeloma patients. 
Haematologica. 2011;96:333-6.   
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
84 
Approved, Date: 5 September 2013  Proprietary and Confidential 15. Appendices  
 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
85 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 1:  Schedule of Assessments 
Phase  Screening  
Phase  Treatment Phase (28 days/cycle)  Follow -Up Phase  
Study Cycle    Cycle 1  Cycle 2 -3 Cycle 4 and Subsequent 
Cycles  Suspected 
PD Visit  EOT  Follow -up 
Procedures  Survival 
Follow -up  30-day (Until PD)  
Study Day    1 2 8 9 15 16 1t 2 8u 9 15u 16 1t 2 8u 9 15u 16 anytime    q12 weeks   q12 weeks  
Visit Window  -28 days                                    ± 3 days  ± 14 days ± 14 days 
Study Procedure s 
Screening/Administrative  
Informed co nsent  X                                             
Confirm eligibility  X X                                           
Medical history and demographics  X                                            
Study Assessments   
Physical exam  (Height at screening only)a  X X   X   X   X      X   X          X X X   
ECOG status  X X         X         X          X X X   
Vital signsb X X   X   X   X      X   X          X X X   
12-lead ECGc X             X Additional tests may be performed, as determined necessary, at  any time during participation in the study  
Echocardiogram  X Additional tests may be performed, as determined necessary, at any time during participation in the study  
PRO assessments  (Ph 2b only) d   X            X           X           X  X X X d 
Conc omitant medications  Continuous from  14 days prior to C1D1  to 30 days after last dose of study drug    
Adverse events e Continuous from informed consent to 30 days after last dose of study drug    
Study Drug Administration  
Ibrutinib or Ibrutinib/Placebo f     X Continuous daily self administration      
Ibrutinib in-clinic administration (Ph 1 
only) g       X X     X X                          
Carfilzomib infusion h    X X X X X X X X X X X X X X X X X X         
Dexamethasone (po or IV) i  X X X X X X                 
Hydration j   X X X X X X                 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
86 
Approved, Date: 5 September 2013  Proprietary and Confidential Phase  Screening  
Phase  Treatment Phase (28 days/cycle)  Follow -Up Phase  
Study Cycle    Cycle 1  Cycle 2 -3 Cycle 4 and Subsequent 
Cycles  Suspected 
PD Visit  EOT  Follow -up 
Procedures  Survival 
Follow -up  30-day (Until PD)  
Study Day    1 2 8 9 15 16 1t 2 8u 9 15u 16 1t 2 8u 9 15u 16 anytime    q12 weeks   q12 weeks  
Visit Window  -28 days                                    ± 3 days  ± 14 days ± 14 days 
Efficacy Assessmen t 
Serum/Urine protein electrophoresis  
(SPEP/UPEP) and Serum free light chain 
assay  (SFLC) k X X           X           X           X X X   
Serum /Urine  immunofixationl X Additional t ests may be performed to confirm CR  
Quantitative immunoglobulin  X X           X           X           X X X   
C-reactive protein  and β2-microglobulin    X                                           
Bone radiological asssessmentm X Additional tests may be performed, as determined necessary, at any time during participation in the study  
Bone marrow aspirate/ biopsyn X Additional test  may be performed to confirm CR  
Survival status and new anticancer 
therapyo                                           X X 
Clinical Laboratory Assessments  
Hematologyp X X   X   X   X   X   X   X    X   X   X X X   
Serum chemistryq X X X  X  X X   X      X   X          X  X  X   
Coagulation  (PT, PTT, INR)  X                                             
Pregnancy testr X                                             
Hepatitis serologiess X                                             
TSH v   X                      
Biomarkers and Pharmacokinetic Assessments - Phase 1 and Selected Phase 2b Sites  
PK (See separate schedule) w    X    X X     X X                
Bone marrow aspirate  Biomarker x  X           X        X    
Pharmacodynamics and B iomarkers & 
mechanis ms of resistance blood , serum 
and urine sample collectiony  X X X X   X X     Day 1 of Cycles 4, 6, 9, 
and 12  X X   
EOT=End of Treatment Visit  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
87 
Approved, Date: 5 September 2013  Proprietary and Confidential a. At Screening PE should include: skin, eyes and fundi, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, nervous system and weight . 
During study conduct a symptom-directed PE, including weight, is required. 
b. Vital signs (blood pressure, heart rate, respiratory rate, and body temperature) will be assessed after the subject has been resting in the sitting position for at least 3 minutes.  
c. Performed at Screening and C2D1 after subject has been supine for 5 minutes . Not required at subsequent cycles unless medically indicated. 
d. Collected at C1D1, and Day 1 of every other cycle (eg, C3D1, C5D1, etc) . It is preferable that the questionnaires be administered at the beginning of each visit prior to any 
procedures or physician interactions . Collected until PD and for the 1st two Survival Follow-up contacts. 
e. Adverse events are reported from the time the subject signs the Informed Consent Form until 30 days following last dose of study drug. In addition to all routine adverse event 
reporting, all new malignant tumors including solid tumors, skin malignancies and hematologic malignancies are to be reported as adverse events for the duration of the study 
treatment and during any protocol-specified follow-up periods including post-progression follow-up for overall survival. 
f. Starting C1D8 subjects will be provided a dosing diary and dispensed ibrutinib to self-administer daily . Subject is to return unused ibrutinib and completed diary at day 1 of each 
subsequent cycle. 
g. Ibrutinib will be administered in the treatment center on C1D8, C1D9 and C2D1 and C2D2 . Time of dose is to be recorded in the medical record for PK and pharmacodynamic 
evaluation as well as C1D28 dose self administered at home. For C1D8 and C2D1 record time of last meal prior to administration of ibrutinib and time of meal following ibrutinib 
administration. 
h. Carfilzomib is to be administered intravenously over 30 (+10) minutes . If dosing requires a schedule adjustment for administrative reasons of >± 1 day contact the medical monitor 
to discuss . Day 1 administration of carfilzomib must be at least 11 days from the last cycle carfilzomib administration. 
i. Pre-medicate with dexamethasone 4 mg orally or IV, prior to carfilzomib . Reinstate in subsequent cycles if symptoms of infusion reaction develop or reappear .  
j. Administer 250 mL to 500 mL of IV hydration with 0.9%NS (or other appropriate fluid) prior to each dose of carfilzomib in Cycle 1 . Give additional 250 to 500mL of IV hydration 
if clinically appropriate following carfilzomib . Monitor subjects during this period for fluid overload . Hydration following the completion of Cycle 1 should only occur as clinically 
appropriate on a per subject basis.  
k. SPEP, UPEP and SFLC will be collected at Screening and C1D1 . Phase 1 tests will be submitted to a Local Laboratory, Phase 2b test will be submitted to a Central Laboratory . 
Subsequent on treatment assessments as follows ( Section 7.3): 
 If SPEP and UPEP both meet criteria both will be performed at each cycle 
 If only SPEP meets criteria only SPEP will be required at each cycle  
 If only UPEP meets criteria only UPEP will be required at each cycle 
 If neither SPEP nor UPEP meet criteria, only SFLC will be required at each cycle.  
If at any time CR is suspected, all assessments must be performed per IMWG guidelines. 
l. Additional test required to confirm CR, conducted at first observation of CR and then repeated at Day 1 of each cycle until progression.  
m. Radiologic skeletal bone survey for evaluation of bone lesions, includes; skull, antero-posterier and lateral views of the spine, and antero-posterier views of the pelvis, ribs, femora 
and humeri. Assessments to be done within 50 days of C1D1 . MRI or CT scans are to be performed if clinically indicated. If evidence of plasmacytoma on imaging at screening, 
subsequent response assessments must include follow-up assessments. 
n. To be submitted at screening to a local laboratory to document bone marrow involvement and evaluate for morphology . Bone marrow aspirate will be evaluated for FISH, in Phase 1 
locally, in Phase 2b at Central Laboratory. Additional bone marrow biopsy procedure should be obtained to confirm CR. 
o. After disease progression, subjects will be contacted to assess survival status approximately every 12 weeks (±14 days) to assess survival status . . 
After ibrutinib treatment is discontinued all information on subsequent anticancer therapies will be collected approximately every 12 weeks (±14  days) until death, subject withdrawal, 
loss to follow up, or study termination by Sponsor, whichever comes first, to include: Receipt of subsequent anticancer therapies, indication for initiation of subsequent anticancer 
therapy and response to subsequent anticancer therapies. 
p. Hematology (WBC, RBC, hgb, hct, platelet count, neutrophils, lymphocytes, monocytes, eosinophils, basophils and bands if reported), to be collected within 7 days of Screening . 
C1D1 testing not required IF Screening test is within 7 days . While in treatment phase may be drawn up to 1 day prior to treatment, results to be reviewed prior to carfilzomib 
administration .  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
88 
Approved, Date: 5 September 2013  Proprietary and Confidential q. Chemistry (sodium, potassium, chloride, BUN, creatinine, glucose, calcium, total protein, albumin, AST, ALT, alkaline phosphatase, total bilirubin, LDH, phosphate, and uric acid ) 
to be collected within 7 days of Screening. C1D1 testing not required IF Screening test is within 7 days . While in treatment phase may be drawn up to 1 day prior to treatment .  
r. Pregnancy tests (urine or serum) are required at Screening only for women of childbearing potential and required within 3 days of enrollment (Phase 1) or randomization (Phase 2b) . 
If positive, pregnancy must be ruled out by ultrasound to be eligible. This test may be performed more frequently if required by local regulatory authorities .  
s. Hepatitis C antibody, Hepatitis B surface antigen, Hepatitis B surface antibody, and Hepatitis B core antibody and will be evaluated . Hepatitis B surface antigen must be confirmed 
negative prior to enrollment . If Hepatitis B core antibody is positive, then Hepatitis B PCR to quantitate Hepatitis B DNA must be performed . DNA PCR needs to be confirmed 
negative (<29 U) prior to randomization in subjects who are Hepatitis B core antibody positive . Subjects who are hepatitis C PCR positive will be excluded .  
t. Cycle 2 and beyond, Day 1 pre-dose assessments may be performed up to 2 days prior to Day 1 of a cycle. 
u. Cycle 2 and beyond, Day 8 and 15 pre-dose assessments may be performed 1 day prior to treatment. 
v. Sample for TSH will be drawn prior to study drug administration on Day 1 of Cycle 1. If the TSH result is abnormal, samples for free T4, T3, anti-thyroid peroxidase antibodies and 
anti-thyroglobulin antibodies testing will be drawn and an endocrinology consult should be considered when appropriate. 
w. Assessments pre- and post-dose ibrutinib, see Table 7  in Section 7.5.2  
x.  Bone marrow aspirate (6 mL) to be submitted to Central Laboratory for biomarker testing . Additional bone marrow biopsy procedures at Cycle 2 Day 15 (± 2 weeks), and disease 
progression.  
y. Biomarker serum and urine collections require 12 hour fasting prior to collection. Cytokines, chemokines, bone metabolism biomarkers, exploratory investigations of predictive 
biomarkers and mechanisms of resistance. 
z. A 2-d thoracic ECHO is the preferred method of evaluation; MUGA is acceptable if ECHO is not available.    
 
 
 
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
89 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 2 :  Eastern Cooperative Oncology Group Performance Status Scale 
 
Grade  Eastern Cooperative Oncology Group Performance Status  
0 Fully active, abl e to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. 
Up and about more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined  to bed or chair  
5 Dead  
 
Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair 
 
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
90 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 3:  Definitions of Response  
 
IMWG Response Criteria  
CATEGORY  RESPONSE CRITERIA a 
Stringent complete 
response (sCR)   CR a s defined below plus all of the following:  
 Normal serum FLC ratio  
 Absence of clonal cells in bone marrow by immunohistochemistry or 
immunofluorescence b 
Complete response 
(CR)   Negative immunofixation of the serum and urine  
 <5% plasma cells in bone marro w  
 Disappearance of any soft tissue plasmacytomas  
 If at on study, the only measurable non -bone marrow parameter was FLC, 
normalization of FLC ratio  
Very good partial 
response (VGPR)e  PR as defined below plus all of the following:  
 Serum and urine M -compon ent detectable by immunofixation but not on 
electrophoresis or  
 If at on study, serum measurable, ≥90% or greater reduction in serum 
M-component  plus urine M -component <100  mg per 24  h  
 If at on study, the only measurable non -bone marrow parameter was FLC, 
≥90% or greater reduction in the difference between involved and 
uninvolved free light chain levels  
Partial Response 
(PR)   One of the following:  
 If at on study, serum and urine measurable, a ≥50% reduction of serum 
M-protein and reduction in 24 -h urinary M -protein by ≥90% or to 
<200  mg per 24  h  
 If at on study, only seru m measurable (but urine not), a ≥ 50% 
reduction of serum M -protein  
 If at on study, urine measurable (but serum not), a reduction in 24 -h 
urinary M -protein by ≥90% or to <200  mg per 24  h  
 If at on study, the only measurable non -bone marrow parameter was 
FLC, a ≥50% decrease in the difference between involved and 
uninvolved FLC levels   
 If at on study, the bone marrow was only measurable parameter, ≥50% 
reduction in bone marrow plasma cells is required in place of M -
protein, provided baseline percentage was ≥30%  
 In addition to the above criteria, if  a plasmacytoma present at baseline, 
≥50% reduction in the size of soft tissue plasmacytomas is also required  
Minimal Response 
(MR)   ≥25% but ≤49% reduction of serum M -protein and reduction in 24h urine 
M-protein by 50 -89%,  
 In addition to the above criteria, if  a plasmacytoma present at baseline,  
25-49% reduction in the size of soft tissue plasmacytomas is also required  
 No increase in size or number of lytic bone lesions (development of 
compression fracture does  not exclude response)  
Stable disease (SD)  Not meeting criteria for CR, VGPR, PR, MR or progressive disease  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
91 
Approved, Date: 5 September 2013  Proprietary and Confidential Progressive disease 
(PD)  Any one or more of the following:  
 Increase of 25% from lowest value in g: 
 Serum M -component (absolute increase must be ≥0.5  g/dL)c  
 Serum M -component increase ≥1 g/ dL, if starting  M component 
was ≥5  g/dL 
 Urine M -compone nt (absolute increase must be ≥ 200 mg/24  h) c 
 If at on study, the only measurable non -bone marrow parameter 
was FLC, the difference between involved and uninvolved FLC 
levels (absolute increase must be >10  mg/dL) c  
 Bone marrow plasma cell percentage (absolute % must be ≥10%)c 
Or any one or more of the following felt related to the underlying clonal 
plasma cell pro liferative disorder  
 Development of new soft tissue plasmacytomas or bone lesions  
 Hypercalcemia (≥11.5 mg/ dL) 
Relapse from CR or 
sCR d Subject who has achieved confirmed CR  who has any one or more of 
the following:  
 Reappearance of serum or urine M -protein by immunofixation or 
electrophoresis  
 Development of ≥5% plasma cells in the bone marrow f 
 Appearance of any other sign of progression (i.e., new plasmacytoma, 
lytic bone lesion, or hypercalcemia)  
a All response categories require two consecutive assessmen ts made at any time  before the institution of any new 
therapy; complete and PR, MR and SD categories also require no known evidence of progressive or new bone 
lesions if radiographic studies were performed. Radiographic studies are not required to satisfy these response 
requirements. Bone marrow assessments need not be confirmed. Each category, except for stable disease, 
will have a working subcategory of “unconfirmed” [prefix ‘u”] to designate first time point at which response 
category MAY have been achie ved if confirmed.  
b Presence/absence of clonal cells is based upon the k/  ratio. An abnormal k/  ratio by immunohistochemistry 
and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting 
presence of an abnor mal clone is k/  of >4:1 or <1;2.  
c Positive immunofixation alone in a subject previously classified as CR will not be considered progression.  
d This category will ONLY be used to analyze disease free survival  
e This response category is not available for  those subjects being followed by bone marrow only.  
f  Relapse from CR has the 5% cutoff versus 10% for other categories of relapse.  
g In the case where a value is felt to be a spurious result per physician discretion (for example, a possible lab 
error), t hat value will not be considered when determining the lowest value. 
Confirmation of Response Categories  
In order to be classified as a hematologic response, confirmation of serum monoclonal protein, serum 
immunoglobulin free light chain (when primary determinant of response) and urine monoclonal protein 
(when primary determinant of response) results must be made by verification on two consecutive 
determinations .  
 Bone marrow aspirate/biopsy is only required to document CR or sCR, except for subjects with bone 
marrow plasmacytosis evaluable disease only, where a bone marrow is required to document all 
response categories including progression. However, a second confirmatory bone marrow is not 
required to confirm response in any case 
 Radiographic studies are not required to satisfy these response requirements; however, if radiographic 
studies were performed there should be no evidence of progressive or new bone lesions. 

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
92 
Approved, Date: 5 September 2013  Proprietary and Confidential Measurable disease  
o Serum M-protein ≥1 g/dL  
o Urine M-protein ≥ 200 mg/24 h  
o Serum FLC assay : Involved FLC level ≥10 mg/dL provided serum FLC ratio is abnormal  
 
The serum free light chain (FLC) assay is of particular use in monitoring response to therapy in subjects 
who have oligo-secretory or non-secretory disease and should be used in assessing response only if the 
baseline serum and/or urine M proteins are not “measurable” as above, and the baseline level of the 
involved FLC is “measurable.”  When using this assay, it is important to note that the FLC levels vary 
considerably with changes in renal function and in subjects with renal insufficiency, the levels of both the  
kappa and lambda may remain elevated, but the ratio normalizes with achievement of CR . Thus, both the 
level of the involved and the uninvolved FLC isotype (i.e., the involved/uninvolved ratio or involved-
uninvolved difference) should be considered in assessing response . Subjects included on the study on the 
basis of FLC alone (i.e., no measurable serum/urine m-spike) should be the only ones who are 
evaluated using FLC response criteria . The others should follow usual criteria and ignore FLC results 
with the exception of defining stringent complete response. 
 
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
93 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 4:  International Staging System (ISS) for Myeloma Criteria  
 
Stage  Criteria  
Stage 1  β2-microglobulin <3.5 mg/ dL 
Albumin ≥3.5g/ dL 
Stage 2  Neither 1 or 3  
Stage 3  β2-microglobulin ≥5.5 mg/ dL 
 
 
 
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
94 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 5:  Lines of Therapy 
 
According to the IMWG Consensus panel on uniform reporting criteria in clinical trials 
(Rajkumar 20 11), a line of therapy consists of at least 1 or more cycles of a planned treatment 
regimen. This may consist of single-agent or combination therapy or a sequence of treatments 
administered in a planned manner. For example, a planned induction, followed by autologous 
stem cell transplant (ASCT) followed by maintenance is considered one line of therapy. A new 
line of therapy starts when a planned course is modified as a result of progression, relapse or 
toxicity or when a planned period of observation is interrupted by the need for additional 
treatment of the disease.  
 
Modification of drug doses or resuming therapy after holding will not be considered a new line 
of therapy provided that there was no evidence of progression of disease as defined in the 
“Response Criteria” section of this document.  
 
 
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
95 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 6:  Disease Classification (Study Population) 
 
The definitions to define the patient populations studied are based on the ASH-FDA panel on endpoints in 
myeloma (Rajkumar 20 11). 
 
Classification  Definition  
Relapsed Myeloma  Relapsed myeloma is defined as previously treated myeloma patients 
who after a period o f being off -therapy require salvage therapy but do 
not meet criteria for “primary refractory myeloma” or “re lapsed -and-
refractory” categories.  
Refractory Myeloma  Refractory myeloma is defined as disease that is non -responsive while 
on primary or salvage therapy or progresses within 60 days of last 
therapy . Non-responsive disease is either failure to achieve minor 
response or development of progressive disease whil e on therapy . 
There  are 2 categories of refractory myeloma  
Primary Refractory 
Myeloma*  Primary Refractory myeloma is defined as disease that is no n-responsive 
in patients that have never achieved a minor response or better with any 
therapy. It includes: 1) non -responding, non -progressing; patients who 
never achieve MR or better in whom ther e is no significant change in 
M protein and no evidence of c linical progression; and 2) progressive; 
primary refractory, progressive disease where patients meet criteria for 
true progressive disease1.  
Relapsed AND Refractory 
Myeloma*  Relapsed and refractory myeloma is defined as disease that is non -
responsive whi le on salvage therapy, or within 60 days of last therapy in 
patients who have achieved minimal response (MR) or better at some 
point previously prior to then progressing in their disease course.  
 
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
96 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 7 :  Inhibitors and Inducers of CYP3A4/5  
 
Inhibitors of CYP3A4/5 are defined as follows. A comprehensive list of inhibitors can be found 
at the following website: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. The general 
categorization into strong, moderate, and weak inhibitors according to the website is displayed 
below. Refer to Section 6.3.1  on instructions for concomitant use of CYP3A4/5 inhibitors or 
inducers with ibrutinib. 
 
Inhibitors of CYP3A4/5  Inducers of CYP3A4/5  
Strong inhibitors:  Carbamazepine  
INDINAVIR  Efavirenz  
NELFINAVIR  Nevirapine  
RITONAVIR  Barbiturates  
CLARITHROMYCIN  Glucocorticoids   
ITRACONAZOLE  Modafinil  
KETOCONAZOLE  Oxcarbarzepine  
NEFAZODONE  Phenobarbital  
SAQUINAVIR  Phenytoin  
TELITHROMYCIN  Piogli tazone  
Moderate inhibitors:  Rifabutin  
Aprepitant  Rifampin  
Erythromycin  St. John’s Wort  
Diltiazem  Troglitazone  
Fluconazole   
grapefruit juice   
Seville orange juice   
Verapamil   
Weak inhibitors:   
Cimetidine   
All other inhibitors:   
Amiodarone   
NOT azithromycin   
Chloramphenicol   
Boceprevir   
Ciprofloxacin   
Delaviridine   
diethyl -dithiocarbamate   
Fluvoxamine   
Gestodene   
Imatinib   
Mibefradil   
Mifepristone   
Norfloxacin   
Norfluoxetine   
star fruit   
Telaprevir   
Troleandomycin   
Voriconazole   
Source:  http://medicine.iupui.edu/clinpharm/ddis/table.aspx  
 
 
  
Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
97 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 8 :  EQ-5D 
 
 
 

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
98 
Approved, Date: 5 September 2013  Proprietary and Confidential  

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
99 
Approved, Date: 5 September 2013  Proprietary and Confidential  

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
100 
Approved, Date: 5 September 2013  Proprietary and Confidential  
  

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
101 
Approved, Date: 5 September 2013  Proprietary and Confidential Appendix 9:  EORTC QLQ-MY20  
 
 
 

Ibrutinib (PCI-32765)  Pharmacyclics, Inc. 
  Clinical Protocol PCYC-1119- CA  
 
102 
Approved, Date: 5 September 2013  Proprietary and Confidential  
 
 
